var title_f22_33_23056="Continent ileostomy";
var content_f22_33_23056=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The continent ileostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 374px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ileal pouch is formed from a loop of ileum, folded on itself as a U, and sutured along with antimesenteric borders. The limbs are then incised, exposing the mucosa, and the nipple valve is fashioned. The pouch is closed and positioned as shown underneath the abdominal wall. Note that the stoma is flush with the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Pemberton, JH, Phillips, SF. Ileostomy and its alternatives. In: Gastrointestinal and Liver Disease, 6th ed, vol 2, Feldman, M, Sleisenger, MH, Scharschmidt, BF (Eds), WB Saunders Company, Philadelphia 1998. p. 1764.",
"     <br>",
"      Reproduced with permission from Mayo Foundation, Copyright &copy;1999. Mayo does not endorse any organizations or non-Mayo products that may appear in this Website. Materials copyrighted by Mayo may be reprinted for personal use only. Permission to reprint or electronically reproduce any document in part or in its entirety for any other reason is expressly prohibited, unless prior written consent is obtained from Mayo.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_33_23056=[""].join("\n");
var outline_f22_33_23056=null;
var title_f22_33_23057="Paraphimosis";
var content_f22_33_23057=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76100&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paraphimosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 434px; height: 184px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Paraphimosis caused by excessive retraction of a physiologic phimosis in a male infant. Note the marked swelling at the coronal sulcus and the flaccid penile shaft.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Waseem, M, Devas, G. Photo Quiz: Pediatrics. Resident &amp; Staff Physician, 2007; 53(6). Copyright &copy;2007 Ascend Media Healthcare.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_33_23057=[""].join("\n");
var outline_f22_33_23057=null;
var title_f22_33_23058="Splitting of a long arm cast";
var content_f22_33_23058=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68520&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Splitting of a long arm cast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 697px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The long arm cast should be split as shown and then wrapped with an elastic bandage to permit swelling at the fracture site.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_33_23058=[""].join("\n");
var outline_f22_33_23058=null;
var title_f22_33_23059="Defibulation 5";
var content_f22_33_23059=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F69034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F69034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Defibulation (reversal of female genital infibulation)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Step 5: Place (4.0) absorbable subcuticular sutures on each side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_33_23059=[""].join("\n");
var outline_f22_33_23059=null;
var title_f22_33_23060="NSCLC RUL mass";
var content_f22_33_23060=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chest CT of lung cancer with paratracheal adenopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 350px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFeAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5XZm3Hk9fWm7m9T+dDfeP1pKAF3N6n86Nzep/OkooAXc3qfzo3N6n86SigBdzep/Ojc3qfzpKKAF3N6n86Nzep/OkooAXc3qfzo3N6n86SigBdzep/Ojc3qfzpKKAF3N6n86Nzep/Okqe1tbi7kEdrBLM5ONsalj+lAEO5vU/nRub1P5111v8OfEsiB7ixWyQ8Zu5ViP5E5/Sry/D+3tyq6r4l02BzglYFabAPcngUAcHub1P50bm9T+dehr4X8IxzSRPruoTsM7DHbqm/wBxknAqMaL4J3lTf60QF+Y7I+GPQdKAOA3N6n86Nzep/Ou7m0PwkZNkN5q6sx+TeIyMY6nill8LeGXiT7P4guYpmxxNbAjp7GgDg9zep/Ojc3qfzrr7rwSQFNjrOnXAYfddjG2fTBH9apXHgrxDAGb+zJZlUAloCJQAfXaTQBzu5vU/nRub1P51NdWlzaSmO6glhkU4KyIVI/OoKAF3N6n86Nzep/OkpQCSABkmgA3N6n86Nzep/OtOw8P6xqDYstMvJj/sQsR+db6/DrWoiv8AaclhpwK7h9puVzj6LuI/HFAHG7m9T+dG5vU/nXfp4T8NWsBmv/ENxcqByLS228+xY8/lVlZfBmmJvh0Se+dmCxm7uTgj12rigDzfc3qfzpyiRvuhj9K9H/4SiKKJo9O8P6PA2d6sLcMBj03ZzRF461p3P2P7NHKvDGK3QBRnpwKAPOSso6q/5GmksOpYV6l/wmus27qbiaJ2YEbnhQj3HTpUUvj/AFO8KxvYabdSQfMvm2iMGX0JxQB5jub1P50bm9T+deowaz4fuWB1XwzYTk8v9nDQtk9R8pwPaku9H8A6rCpspNT0a4OQFLC4jPoTnB+uDQB5fub1P50bm9T+dd1L8NdSudjeHr2w1lXBISCXZJx1+V8foTXH6lp17plwYNRtZ7WYdUmQof1oAq7m9T+dG5vU/nSUUALub1P50bm9T+dJRQAu5vU/nRub1P50lFAC7m9T+dG5vU/nSUUALub1P50bm9T+dJRQAu5vU/nRub1P50lFAC7m9T+dOVm3Dk9fWmUq/eH1oAG+8frSUrfeP1pKACiiigAooooAKKKKACiiigAoorrvDXgm61OBb3U7iPStLJGJ7gHdICf+WadW+vT3oA5NQWICgkngAd667RPAGr38Aur/AMrSdPHLXF6dnHsv3j+VdMuq6B4W3p4Yst95GMNeXqh5d3baOi/hWJcapdak0hvbl7h3HzszE4PqKANSLT/BegwuWjutcvlXcrTfuoMjttBzz7mppPGt79mKaUtto8K4VUtkCAA9cnqce9cnGu47A20E/KG5PHeoWUNEOjyPMWYZ6L2/OgDS1G+mlKz3N/JeOzZZnbsPuj8aph/Om/eDduPzY6Env9BSSESJsiQcHOey/wCNNVvIwQQsa8k5zyeMn8egoAcoDXJKAlYyUdu5Ht6VGIi0wCKxhU8BuCSav2Vhe6hcrBaQy5cFGIXp3Gfc11um+AbqYRQ3tyirHIrS7DymaAOFkYxgAgb153HpjuKXy3g2s4d2cnDkcgEevsa9etvAGnb5I5PMmEfJboG9AtWH8GWsbLFEz+W2HkhXAAPpnsM0AeMLEyeXKhZplYgf7P8A9erNve3kVuIbeeSMqMGQPjec9APSvXbrwRbTqGg2bwzM28HKDHQetee+LfDraZcTps2orADaMkcdPagBk3iHVozGJpzcoBj98obOfr2qSTVkdofP0vTZl8sli0K5kOfasQynaglBbBCBeoP41OxRJAVYBQhzgd/QUAdEur6aITJBoGmecPlANuD09M1CPElwkkf2WzsbdE5/d26DJ9zisV3Cx5VtjYIVF6fU/wCFRR7wkasfm+8SB0NAGxe+I9b1ESGe+umxxy/GD2AHArGv1Z5SZbg4Tl9zbifrW/4Z0WbU5UVovKh35LsOpx/Ku8s/hjp9wymS4aR/vEoMKOf50AeN4D3QUKdq7VwTxjr07UjYO2ZISyqD8pGSPevc7LwRosF0RLF5j84UNnPue1W/+Ec0vSr6NzZxPbvhXUDcd3Y/SgDwBX3AmYEOBux0wKie7ZZVMOYzGMiNOoz3PrX0bNoOlyh5n022eKRiVwAOB69/wrCvvh3oN8pktoZbSWUlhs6H8+lAHh0LCWMu5Mkp4MfXA9c09GK7Vif90BlcA9fT3r0TVfhRdshl0u7R9oyUIwWx2+lc3P4L1yGPa1hMUHcfwH6dqAMAeeo8oSZOcrjoGp4wQvVZT949ceoApsiT27mGeIxzp8zGRSPxFR27jzGJO1ZCA0meQe1AFt3mtJM28reeAJFKNggDvx/KunsfG93c26WviCGHWLIDH2e5jDbfo3VT+NckYvsxdI/9aDuHr7g0qGQu0YxlvmjA+6PrQB0U3g/RPEqhvCVy1jqWSp0y9kyrkdPLk9+OG/OuD1nSb/Rb+Sy1W0ltblDgpIuPxHqPcVsQ+bCUkhcmZW2l1ONh7V1ln4jfUoo9N8WQjU9Oz1Y/vYOMZR+oIP4UAeWUV1/inwf/AGfaNqmh3Q1LRMgGUDEkBP8ADIvb6jg+1chQAUUUUAFFFFABRRRQAUUUUAFKv3h9aSlX7w+tAA33j9aSlb7x+tJQAUUUUAFFFFABRRRQAVYsLO41C8htbKF57iVgiRoMliataFo9xrF35MG1I1wZZ34SJc4yx/p3rtZtQj0S1l0nREKWpG24nxiW5zxk+gH92gCbTdM0bwcxbUUg1fxEoBW3PzW9qT/e/vsPyHvWXr2tXmsXS3VzOXuFYoAe309qzWimumdAxG3LeZjqvYVceXbCkK/JNGnyt3P1NAFcs8kphnk3zOwG7/Zx3pk8sZhCxswDnaXPVSP6UwNIxYgB52PzqOwHf6CnpKm4GbafLX5G/hegB24u/mLxO52rkdB/hiojCkKliNykbWC9evStLR9MvtflkSxti8m3ajAYCe5r0vwr4H0/TIkbUSJ5Yl5XbkE9aAPONK8O6hq8ifY4GW2lYRliCqrjvXf6F8PtPSJTeyefck8Y+6G9cd+nFdXcXu2Fld0inBKmJTjZF2B9B/jWfaSTX4lWzAkihGwzDjG7qR+XSgDdtILGz07ybCMwg8lwAXX1Yn1qRoIpIxG7iGCEbiuclyehY03SfB15qEYOoSeXDGw8xe7kcj8Oldpb6LZ29vEgAAQhvNfnzG6GgDhPtrwFY1BTzBjnjacdT71Vn1m1QrG8eyFAHUE8sQedx785ruNaufD+mz3Mc4hMoUmRlbcVP+PtXlfiTX2v7YTWdokNsgIVtnRc9/yoA6+LbfW7SW4Id0A8zdgJzjpUdzpmns7LPbLPPIo5fOHPQ5rzK+12/wBHmWOG8UR8Fvm3FgecY7V6R8F9CvfiI11rOs6gbPStPk8sRxAbnOMkbj0AHf3oAxfEHgrTGs4zBstZiwJRecL3wa8/8ReE7vSJI8SQ7SufLVst04r6rNx8NdKtZYmEM6K3zO25ycc9T9e1T2GpfDW+uJBHDYh3wzNJEcH060AfG0Gn3qlDNa3KIT85KkBR6CvSPC/hCyRFuZJobjK7tpP3R7+hr32fUvhlqNw9pMlpvgyGHluoXb34q5e+C/D2seHL3/hHGCSyRHy5EYnkDgc84oA8PvrrTbTWLe11UGKFE3AhNqEnoBjg12BNg8ER0xppl27QsZwB9T7185DXr2a5urCe7kaANgxsC2ME8ZPSvZfhl41sItLii1J9iCUR7gMBePzP1oA6210LUk+fykQNgeTGeo/2ielWx4YvJw0lvcw28395xlVB7D1resr2zvYFltrmEwOScl+WPtSXFmkrB5pCE5IjQ4/E0AcTqnhPVwhiW8DKM4ZRsGP6VyxvbvQpzb3NjNCoO4uTvST8+/vXrqSw2+PNPlqo3EswwR7k1w3xC8SaFJpkkMur2QL8qsky5B+goA5638V6VJJ5qTT7YzlgvDfketbsWpWeqp52n3CSMSAUJwPqfcV5Bp/i7Tba+ki1B7e9tycfKcAj2NdmPDNhrNr/AGh4eulgL4MabsqD6cd6AOp1fRdN1mHyb2zjZweJFT5ie3P9a8+8QfCrzAw0a42/xNDIMAj0z6j1ol1XxR4ebyb5Jrm1U8SEdPUGuhtfEgvLVbe5TbbynKuDyD7+lAHi+raRd6Jc/Y9TgkiP3TIxzvHY56VXB2ELnbk7T6Zr6QshBqEMmnXyGSPbh0kAO9T0/EV5z4t+HX7lp9DjaROVMB7Y6Y/woA84YPFdrLuVS4wcjAJHf9Knul3xrN98o3TOA4PUGoAtxaArdR7ZojhoyAOnB/pSxSCR2jRQTnDBRnPoKANHStQuNGuvNtQCHBVonUMjr3DA8EYpnibwzb3mmTa74eQRxRn/AEywz80BP8SdzH/L6VTUMYCsi+S8Z+WMHLEDqD+dOgnksr3z9PR42UB1c9cjrQBx9Fdv4l0631uwk1rSkRL2PLX9tEMKf+mqD0/vD8a4igAooooAKKKKACiiigApV+8PrSUq/eH1oAG+8frSUrfeP1pKACiiigAooooAK1fD2iXOuXbxW+1IokMs8z/diQdSf6DvUWh6Vc6zqKWdmuXILMx+6iDqzHsBXU3MkNrYNpulFxbCPdJI3ytK/Qk+3oO1AFy81KOz8PpommQotqJd5mx+8lbH3mPf2HasbyQIHlnlPlqAqt3zjoPeoVjWYGMnaqOpLPzn0Gfyqxczl3aNoQxGMjHH1z60AIZXHmEORBsUsccDHb8TUJKeVHJIfKaUEjcM5AOM+xqxcMi+YvLDZ90nG7vT9P0u41q6ijs4XljO0ByPlVumDQBWZv3KqsbK5QEhR82O3vya6zw/4Jubzy5NU/dWbANsXG8KehHoDXbeGfCNv4eRJ7nyp77cQ0jjKjGBt578mn3ut2ukzzxXEhMRy3zDGGxwB7AcUAaFvaWmlxQafZqtvbsd74JJBz6+uRWNqfiMREIqebqEpJVF79sEfrWfBfav4qvYrPRbWWa7kOFjQbtkfTJbsPU16fo3hXTfA2nT6jGo1nxD5eHlZS6W7jqi+v1oAi8LfDCfWPDV3qHiC4ns7zekoHHzx443en/1q66w0jTNJtY7aziVI1z9omUdcc5zWR4e1KW2glPii/YXOtMHSNQSUIxhWUdBTviBrkHgq2jiu7m1a4nQssHmDIA/iPpQBr6xrdpawMZT5bSYQZPPr07k15L4y8eNcPcwwztZW0fCQR/6x+erHtXnvi7x+HnZrYm4uX581jwPce9ec3Wp3d1O8sszF2zmgD0mx8RX02s2VnbpFFDLMgLuAxLE/eOa9P8AHvg7TdBvLm3j1UtGbcTMuRtDE5JP1r5e86XcGEj7gcg7jkGrUurahMzNNe3EjNjJeQtnHrmgD1bX/Cs9lYDU0lSWVgCS7ckEdcdAK9Y/Zdu9Nj8K61oUt+La/v7jKM5B3ErjCgnk8Hivl+016+kkihurh5Ydw+Vj3zwT64rfh1NdKljutPlkSaOUSqUOG3Dng9hQB9HeJfhnrCTG0srMzwh1Jn4249scn6UWXwl1ySG9nu0jW4iUmEZA8zA4G0dzXPeEv2k76xsJ017TG1KUHMLJJ5bEHsflOa0Yv2qrOB50v/DkpZfuLBcD8iSKALOn/DPXbSSS6n09JIjlnViCzd+ldnbak/hX4bax4h1GE2cotjBbxBjkvyFwDwPmx+Rrg7P9rLSy5F74YvUXPBiuEY/kQP51wnxj/aDbxpoK6Noekvp9qziSWWd1d2x0AAGB+dAHme+GOIy6jdEb2LExnDPxXbeGfG/gfQ/A13DNpU914h8z/R8Z2f7zMen4ZNeNzSvNIXlYs56k1HQB0dx4x1hr2S4s7qS03MWCxMfl+map3XiTW7tg1xq185HQmdv8ayKKALc2pX0/+vvLmT/flY/zNVTSUUAFaOka1qOjzibTbya3cf3G4P1HSs6igD1/QPjDJJth8UWYuExtMsAAz/vL3+oNdDewadrdl/anhe8i+zJ80iqNpiY9mB5FfP8AWhoesX2h36XemXDQzL1xyGHow6EexoA9outT1WJbdpoHaHbtEvRSfY/rXQeHPFFxOyJNOjkjB2jB3g9cds1R+F/jnR/EL/2XrMENvJONrRsMqG/vxk9Pcda7Pxl8JFMMd54bnEEhXMi5wrMOhz7igDlPG3hfT9etxOrRw3pHyEcfNno59+leO6rp1xo2oPZ6hA0U4ODt4zjvmvXdIu3kSTSdfQQXCEjeTgNj+IHvV7xBoVv4h0tYr7EU8aeSt0eq4+6aAPDZJl81pGVUmV9r85BFWj+9nMcg3bh8rZwDnjGadr+iXej6hcQX0Z3ADDsflb3+hqr5iLBJHMS3loCgXjgnjFAEmnXstnIZEJURvyFHUdMH1rP8SaQLeOPULRQLSY4ZB1hf+6fQHqKvyNMXJUbWU5CjuO4PvVnRp4lL2t8BNZ3S7ZF6EEng59QRQBxFFX9a06TStRltZSG2nKOOjqejD6iqFABRRRQAUUUUAFKv3h9aSlX7w+tAA33j9aSlb7x+tJQAUUUUAFT2drNe3UVtaxtLPKwVEUZJNRIjSOqRqWdiAqqMkn0FegWNkPCFlKLkIdduEwQG5tEI6cfxkdfQcetAC6l9m8PaXBpujSI93tL6hc9VnfqIx/sr+p5rCtN89sYwCsjuRhj93v19KJIJcMS7bXwVAGdob1q3MosdsIQFxudzJ644oAjUmLdaxOCA4aRuu7vxTYmBRmjBlY7tpzjjPf8AWmghZWK48gqFJPUD29jXQ+DvDbazdbiwgtgN29hgHnH5UAL4T8J3OrxfaZisNpuBctyXzjp6V6ci2FjNZ6LpUUjxR5kmIGN2OR/LrU0c8MBsraOAIDgAR9MAdAP1rnde1NUmubSyDsjALIQMMeeFoAqa/wCLAl6YbeQvaxMJJNx5c46D0Oan+Gvgi8+I+sRvcO0Nju3uMfMFz1z+lX/Dfw9fVZ4bd4ftWpXGFKR8pbAnkv8AQV9EaTb6X8PNMstF0oJc6reOqHtuPTJ9AOwoAju9C0fwHogi8Owx2twybJJs5Yp3JP1rN8PaHNf6ZBfa1ILLTomeSRmbBnHY4+n4102v3Wn6H4ffUvFpjBDkrADuMjHOEH94n06V4P4v8V634wv5GJe2sYcG2tlO1Y+2CB94kGgDd8afEfTbG8Fj4O0pDLHD5QvpF/eYPGFzyPr1rxPxX4H13W70TRz/AGmbbvczMQ2PfP8AWvTNG0WGFZJ3aNp4yNrEZC56n1p15fhZi8eSfvOynJOO59B9aAPDLz4beJoLKO5isTdI24FYDuZcdeOv5Vy13p19Zkfa7O5gycDzYmXn8RX05FqW50EbFXxtQA9Tn74J7VJ4w8VX+m6FcTSSRuygBAR8oz3Ge9AHyz5E24r5Um4dRtORVqHSryZiqxYb0YgV0F5qN1eNLeXcsjs5w4bue3FIs7SPFJMPnZunb60AVRoM+mBJbxQzsuQqnIXPqelO8pY4/wB8FL90U52/U/SrO9rhPJWU7FbbhhkZ5p+u6d9j8PtdqZCrSCDkcZxuPP4UAYNzqjqWW1OwY27++PasykooAKKKKACiiigAooooAKKKKACiiigAooooAfHI8UiyRsyOpyrKcEH1r67/AGc/iUPGOmP4X1qcReILaLNpOf8Al5jHVcdNw6/T8a+Qau6Nqd5o2q2mpaZO9ve2siyxSoeVYHI//VQB9qeOPAp1ewk1Ozh8y+gJWa2YfMPcCvMo76awvLeynffFJgIz916bSPUV674P8cjxV4YsvGmnFUKoINTtV58mdcZP+6QQRnsRVD4l+DLHxDpQ8SaEEWCWMyXSxYGxhzvHuDwRQB5brel22vWZsZpDIAjJDOTgo3YNXkGq6VPpOpTWeoJtdFO3uCO4B/GvWYp1t8HVtwtrhd6zD7rnGD9CcCnazZaZ4l0mGCUFLlARbSheXBHT6g4oA8eEgZASGCsMBl5x9aVYtsWM5yueDn60upWN3pt1Jb3gXegIZexGetLC5lgWCUgMo3hQP4cfyoAmuoP7a8PbD82pWKl41Ubmliz8wJ9uo/GuLrrtLuJtPktLmFdksLhwc8MPpVPxpYxw6j9us4wllelpERTxG2fmT8M5HsRQBztFFFABRRRQAUq/eH1pKVfvD60ADfeP1pKVvvH60lABTkRpHVI1LOxwFAySataXpt5qtz9nsIHmkxk46KB1JPQD3NdlpkVr4dhLWIF5qrphrkD5YCeoQHrj+9+WKAGeHLSbwy09zNbqdb2EQK/IteOXP+1jp6fWqcpknje6bE8jEb3PJz7fnTJLkGQOZ8yNHg5zye/HY1PeW0sWnWtyC/lTbtrKcYIOMGgBlpcKxeRX+SPGFbuQTmoJXL+YWzlzkibp/wDqoj2PYkoqGOOT5mPHXt+dWLPTJdf1SGwhkIkuHCqw6AUAb/g/wo2parHJMvlafFHudm4DH0Br0ZYNLsBcXSSJFbonlojniUjtj2pL6W00CxTT2VdkYEawqcmQgdSO/NZWn6c15bB7sBLULujth7nGT9TQBW/tHVdd1kQ6bGbK1gXZFPjaSuPvc/Wut8O6TFZvaWsMJ+3TTD944+eVz0wPTIqle3UNvbKjoElyQiREMUHAGe3J7V6LZTxeBvD1rq2q7f7f1VfKsxOf+PaPaOQOx7/pQBc1O/tfA1gvh/Q2jk8Q3uDczK21o89gfX/9fpWv4Z08eHdPfxJ4vBWeFCtvC/zup5yQe5P/ANesL4XeFbS3tZ/FniBmktoN00E1zyzjqznPPXpnrXP+JNdv/GOuR3FwskNghYQorZCAjAyPUjk0AZPi7WdS8W+KRe3mxYYkItrcPuWJT3AH8R75qqzC0LxTx7rdpAERiMpIOd5x1Fa0VtELKeCECCKEsiXI65/iJP8AKqIto4Y4IWK3AQDMrDO0Z+U4oAZLKxb7XJvjZGweOoxyoFUbyP8A4lxClJYlcLJgYOepyevA/CrWrLOloS4ZIseTIGbIVz0PqKz5QbazCyMZJHTYuw8L/vDoM0AV0fypEdJAYVcDdJ19xn0qt8WnB8LWaLGVaR9xLddoGRirYSZX6IIi+wADIA9/881kfF6ZIG0yJQfKZNoz91WAxkfh2oA82t4Hlt/NAy0WBIG4B9DTUgkmASAAAnLFug5zipvM2ISquEICs+efY0Q+bCSImBAJUH1NABAi7pMBnk7j+H8fpU17ctf6EbJyDllZX/2hkce3aobmfzJ1Kx/Z/OxviB74qu4cznd8qLkYXoPQfnQBzlxbyQMBIpAPQ9jUNdLIDyly2YWDKEY8545FZt7pUkFit4jBoGcrtJw6fUf1oAzKKKKACpZ4vKYASRyBlDBkOevY+hqKigAoqybOYWC3mFMBcx5DAkNjPI6iq1ABRRRQAUUUUAFFOIIAJBAPQ+tNoAKKKKAPUf2f/H6+CvF32bVGDeHNWAtr+NhkKDkLJ/wEk59ie+MfQWk67c/Dv4iXWianK1x4evP3scjfMqxt0I7Y7Gviyvp/4VazF8Rvhs+makktz4l8MoDbFGHmXFqeg567cYPtt9aAO5+JPgqDTLGa605El0G7YOqqNwhLen+yScg15pFaSaLqEYkXzLCZSE3H/VvjtXuvw31eJ9Pn8O60EeDaPJLHKtGw+6fTBz9K4jxl4cGlajPp06GVGXfASOHXJwMnoccfUUAebeNtCsdd0eS/08KuoWsYle3xguvRs/jXllu6yWpUEIwUop7g9wa9l82TQ9TiXUIQ9q/7uOU9drDo/vXAeP8AQ5tK8RNJB8ttdASoQAA2R0oA5WCPz45lCtI8S8kLggd/1rRtQdUsrrSJVRnmjRrbH8M69B/wIZH403S7j7NfSFBvM0ZR4mPbH+SKoRzD94VYqAwdSvUMtAHLyI0cjJIpV1JDKRggjtTK7DxjbLqduNftl/eMRHfqBjbKRw/0YDn3z61x9ABRRRQAUq/eH1pKVfvD60AO2lpMKCSTgAd66fT/AAq0JSXxC8ljCy7kiUAzP6fL/CPc/lWpbXdp4aaUaXErzEmJ7yVAzkHoUB4QfTn3ql5jT3Md2HaS5YHO98nnr1oAmiv1W0uLawj+y2hXDxwk7pB2LHuaoKZHlVRFsXAXcx5A71J8m+OTJ2sAjvjAA9SKrXEuyVCzGRfvfIMHHTk0AWVit2kdstlgRkd+3TtVi6vXewtrd2xDbs2xeuQf/wBVRzxlSGVduecMcfl+dQT2yx7Y52J2KG3Y5z6cdqACFSbSby4syzkeXH33dOe1dmulweGoS8Fwz62VMHlqfljZlB4PfrXP6Rdtplz9sSBTLExZFYg854H9a1fCgk1TXTcXpDeUTIecZY8A0AdtoGlFsal4inzcAARg8c4xxntVm+1CCGSOMIYJd/7/AJ/h5xzVF9ZluNbj8nbMYUMQklXIBGfmA9u1Y2tyW7omnabbSy6neOpl5LMMnAAPck4/OgD0L4M6baa1rWp6xqEX/FPaUBK7SDh5xyoB7nvj3HrXQaJBcfEv4hC81SzJso2ZlLZIhjXouOxPH51b8QaePCPgLQ/AmmIxvrvD3bQn5mlPzOc9+cD6AV0esunw48AW9jZlBqt7gTSn72SOW9yOgoAzPiv4i+2StpFhJ5NhZuqsFwEmcfw59BwK49HhSIrbKqmQqXjUnAx1Kn164zWfblmuY2nV5I2Vn3bsDg5ztPcn1qOaVG8xrRpI0xulDcnk9B70AaF3ewWtqZbdXdMjfAWyT/tf41DI1vczL5vCKpLSQkqZM9Vx6DimKEkliUotusYyzbvlC9lf3xVGC4tlWSN0cXJYiMb/ALwz09AP1oA1o2e6lngaQIRhSuMlx0zmsNtlrNLbB8SJlsD5gR7Huc81dcmQxyWp2qybXBODxx3q3JBHFBgJECBkOww3TBBXuKAMYRT3F7bnaRISElQ9PbOOv1rC+KmmvI+m20e+TlgrMcKG69O3bmun0+52XUF04dkVkEu1eDtPA+hFZfxSb+0LBr2C3WFvPOIC+TH6D6EUAeTrmOOZVKxFTgoQSC3XGPf1qwyCSNZYwyuoywxke1bGuNDqNhbXFnaxWzJF5bpv+8wHO41R0KW0Fy2ds0c8eTE2QAcfw+hzQBnL/r8ynlsguwyo9gfWq8ivbyZUoFaPaOrDIPXH0rqtG8L3+snyLCD/AFUnDdRg8/Su6svgnqt4TKCo2/e7Dp0IoA8QVFRZGR9sqjIx83GeCPep2ZEZ1lQz55woySCM8169q3wJ1u03y28SyxscK0bEDHXpXmutaVcaLetaSpIhAz5siEb6AOZ1TTgiG6tATbk/MP7h9PpWVXUQs0QWNFVEIxluQQc5xWNqlmltJuty72543sMfNjkUAUKKKKALOnzxwXcbXEfm2+4eZH/eXv8Aj6H1rqviL4MHhl7C/wBMuxqPh3VI/Osb1RjI/ijcdnXoR/8AXA4yvRPA3iS0u/Cep+CfERUWF0Tc6ddSc/YrsDjHor9Dj1PqTQB53X0/8Ufhp4Xv/g3onjy1k/se8XTbeS4WGPelyzooClcjDbiBuHbOQeMfMTAqxUjkHBr6i8N6n/wmH7IGt6a77rvRAY2z1KJIsqH6bTt/4DQB8t0UUUAOZ2ZVVmJCjABPSm0UUAFFFFABXYfCXxdL4I8e6VrKSOltHKI7pV/jhY4cY78c/UCuPooA+7LvT1/4TK5httQSJJ4xd2zYwjRMN24Hv6Ve8Y48S/D9NStlD3WnOUcn+6Dgt+gP515V8Ldfl8UfBmKJWU6v4alFm7kgE2kn3Gz2C8r9E969D+Cl2sN5qugX00cySjcoDbwc8MM/nQB5xrF3Y32nyWt4hkkkVRxyUIHJHuOtee+JL+6hsk0rUkM8MbloLgjG1e34V6X4005NK1i605Y/LliuSVbPoMjHsRXDfESPztK067XaskZZMKM/L1waAODRMyFBGdxOFfvnt+FRvHJA5VghJc5UHt604qzbngcBlAYk+mf/AK9SvbxXNtDKsxeZFKkqMDDev8qAJtPLxQ3qSvD9juYTFMCM7umGHuDg/hXH6xplxpV41vdLzjcjj7sinoynuDXRwtwACVUA5B7YrUljh1Sxt7PUG2WxU+TK3LwN9PT1FAHnVFWtSsZ9Ou5Le5XDqeD2YdiD3BqrQAUq/eH1pKVfvD60AdTDHK0IQ4kDAhd3YZ7UyKBVYSMNzRAD5W5z6+1T28i7giYMiuxOTwM+gpWVEkZkAzKTg4+ZueRQAhgVXR2kbdjO0nkD6U9rgxxDKqgj5QMvbPpTGf8AeT4RURgFUAZxn1NJEqR4gGHdDubac/KRgEnvQAwlmUTzKzJg7ff147dabI+4L5ZLBsbmbjn6+mMVaS1ecK8rxqyOQqYGCvv+FRkNG88TBWAYO6/jjj+dACAGdtz7maJDjzOPbJrS0fUjpYmEVuHuHKqGJ+VOefxrLbynASFjKAS7SMccjnmrdtNI4d4csWDENIOp7UAdn4V1OytprsXib5IkMkaFuGPOea7n9n3w1b6j4h1LxhfRO1ppRL25kzgzEcD3Cjn6kV47pENzdLFbWUZknMoUBV79AM+hJr6+/wCEdbw74C0zwnpzxjUZ0D3TLwWJ++358D2FAFbwJYyz6rqnjPxIUPlM5t8dl6ZA7ZrgtX1mbxNqtzf6h5ivLIRbW5b7idgPcD8812vj27W2srbw3Yv/AKJBConfO0lh2z6dK82tmaacK8KBFdgSD1OeMDt+FAEk7M0krrFKFRRuwOjYxwKzbeNpbmKNHMfkgM7t0YVsahdGO3dSZFeQZ+Y4Cn0HrnNZjwXSRR7vLSd4jHG0bAg8ZPFAF26mEcEHkR7LWYncsbfPuHYZ6CqL26W168tpGHiKB/Lb7yg9Dn9aXSJLeVliv5XdkCnEIz0Gcc9DRfJFNve3kZ3RgEViFLA84PrigAikdsJOojd8uk2eDz/EKuWybZ43maOfdH87bipyOfmP6Vn2AEpmwpMg+8gfhT1yD3Faun3unM7F5lkldgisoKqW6benGKAMNgx1OS1jOyRn3ES8pntgf40/xZEz+F3BjM00jKiPGvAbPKkdSR2NReKreW11SRjF5Ue0BXzhCR2z/Wt74d2EfjRodMnlmgkkm8ySaMA7GQZBH1HHNAHm0/hO7/sJL+WaKG2ZnRkxyjL/AFOelZ9pb2Vw1lBpLTPKrbXDgDDHsPxr6KufBNhe+I5/C93FvgVBM2XOWJziT2NcFqHgBfDvimS40d/NitHXzIrjnBzyB60AeqfDjwdBYabAxOPNVf3iLgbhzgj8a9RSyhjZsRhWKj585Jx6is3wagbSYJo3cpIgPI2/ht7VtzTRRMglYAtwMigBSViLMVCpjls/pXEeP/h5o3jGyMd5EsVwkbKsqcNjqAc118piuEaNGVhs+7k8D1xUSyP56yDDxvtBZRkk+hHbrQB8KfEbwDe+DtS+xy53IGaOUj5SOwB71ysbG9gS1u0JikHyMg+43rz9K+8/HfhLT/GOmPZXMcS3exhG7HLRn1z3r4d8eaBqnhfxPd2F/guiYRjkCQdsetAHDXML29xJDKMOhwairofENrEbOGeEfvI8JL3BzyPy6c1z1ABRRSgkEEHBoA2P7HhHhebVX1O1S8jvBbHTXJE5Upu80D+7nj610vw38cnwxoPi7R5t32XW9PaEY/hlAIU/QhmFcJLI8sjSSuzyMclmOST7mrOlT29vfxS3kC3EC5LRMSA3BwDj3xQBTorQmsETRrfUEu7Z2kmeJ7YN+9jIAIYr/dIPB9QRWfQAUUUUAFFFFABRRRQB6l+ztrQsfHZ0a4INhr9u+mzKx43MMofruAGfc16boH9p+EPFjBIXM1ndCJjj5Qp7fpXzTp15Np+oW17atsuLaVZo29GUgg/mK+vvilrXnXuh6tYRRtY6zYRXYxgBiRnr64IoA6n4z6cb6wtNWshGhuYdjSAZIOMj9Mj8K+avEOpmSyi05ixngJBYjBcdj9a+o7Uy+IfhEG3B7i12z44OQpyR/wB87q+bPH2lj7Ol7CPLmScneFJwG7HHGOKAOGSRUldjwkmdwAxjjqPyp8HyRv5ffBV89qSdk3ebGQAFAYHoD0yPrUZKlHErN9zDIoz9PpQApUNcM0cY2lck9gCf8aklaQHIYCQrjn09aj2+bEEjDqjKuMnkAUrFGLRr8zEgK2Oo9qAL8MVnrNkLLVJTG6FvIuMf6r/EH0rjNY0u60m7NveJtJG5GHKuvZge4rpLhXZC3mKJFX7qrk/WrsWpRXVgNP1eLzrZm3hf+WkZxjcrdvp0NAHAUq/eH1roPEPhmfS0W6tpFu9PcArMnVcjOHXsf0rn1+8PrQB1ETss0bqqiRn+fPXH0p3kRuHkdgQrkYzzg+1TOynyh3UlSWXGB65qpb8ncsiuuT8vf1oAnl2NEYlYIrAAAVArRhVOATk7gDjGO1TeZHEzq+4seQuOgxxUqTW+6VSrb3wW2jIHGRQBFPclkieFU2EhWA6nuKdHeZMhlhBcsdzMM7geABThJDlVjTjcOOpAxTorndh/KLKnyjK/MxPQ+1AEU8KRyKkpZJCVPK8Y9yPSiFmuJgkQk3buABgn6Cur0nSY4r6ziu5UH20NGd395vun8BzWl4K0W3t5JLl4hN9mDFTLwA2etAHbfs4+Ho5dRGo3sbeTpublz0JccKpHfk/pXt0Qjvtf1O8vZNrW9uWeUcBVIwE/SuQ8FJHoHwqW4s4la51e+CRA8b1DYB+gwx/GtnxTqi6H4PkbD7LpvLXnHmOe4z260AcJeXouT58ybGmlO4DkLEDgHn1xn8KxZJ4oLdWKZt1kJAwd4B9a14lR0RbWIeegIRXfknPJx0x1p12sVxDch7UsVXJkB4Uge3UYFAGbdRfbEdShn+UfOw/1aY4B/nVCBpGtAGtmMcG7ZMOSx6cDtWnPbrJZW5t5JImnG5lZhkKP6VUmWXzJWmlLL5BG0DCnuBx6YoApWwlt5Gm2ohydzlhtzjjnqatvdxNAlx5W6M9XXgsRzhR2qqjEmK2KRShlwFY8epb0qaGR2uVjaMM0i7UPKoieo45/D0oAxp1n8yW5Z4ba0+9GuQzlScduhqOy1CCKQ8bQcBH2DIJGMY+tbUWnFZWtyIxE3DvtzvbsQO49ap3dpGLxrGBfkU9ZABucL93jPB7UAJqHiQ6hYnT9T2vdk7VnXADY+6D2HpXZfsxSW2seIfEPnRzW97ZeQXjzgE5bn9K8on8M3V1ESjyiXaSqxqSFI6A47165+ytp7aTrWvLrETWur30EUsSOeZYUZgWHuCwz9RQB7zPo9v8A222sJCGvUg8pSpwXHJwfxxiqd14YtdTjgOoIvmgEzbQP3jHHOfY10VUNe1O30XRL/U7x1jtrOB55GY4ACgn+lAGB4a1/RY0m0fSpxNNp7+TOueUOT1Pc+wq/JfRvNF5xz5X+sGVK9cdfwr4O+HfjrUdL8bG7MxEV/cFrgZyfmbJwfXmvsfQ57m6so72N4lhOH3QpuPPfpjqOaAOqE7GdRFIH2ktDIBnK91Pt0p6S7rxwhlB8sY2n7pHr2x9aoQmRdrL5U0Ux3j5QpBPB+WraXMIeWOeGUtG+3cAP3g+npQBciYrsW7j2OGGHjXgg9ia84+O/w4g8a+Gp57aJG1S3AeNlPzEAfdz1xXoYuUMYXLAY2kOe4/ukVMtynJCOPNQBe4Y/40AfnfLZXIsr+3MXzg7HXoykdMg8nkVx9fTH7QvhdfDvjKLX9MtQtrdLtlTBwH75FfOmshBqdwYV2xs29R9eaAKNFFFABWg+k3SaEmruoWzkuDbIT1Zgu449hXUfB/wBc/EbxjFo0FwtrbohnuZyMlIgQDtHdiSAPrX0T+1H4M0/Q/gpoltpEXl2ui3UcUe7BZlZSpLHuScE+9AHx9RXReCdU0XSL++uPEGkf2tG9jNFbQs21UnYAI7cjIHP44I5Fc7QAUVIkm2KRNiHfj5iORj0NR0AFTRyIsEqNCju+NshJBTB5wAcHPvmoaKACiiigAr6x8Mw/wDCT/syaLexFZL/AEKSSEsRkqoc4X/vlkr5Or6w/ZBuzqXw/wDGGhzbHjjlWZEY/wDPRCCf/IYoA9T+DU63eiNbsFkt7iAFwMbVYfKy49DmvKNSjWN7vTrtMeXMYioXJJXKnP8AOvSPg/BJYahJayYUK7gDv71y/wAQWNp8SdQjJzCzJKAOoZlHb65oA+ari2e0uZ0ZHZEmMYMkZAK56CqEuyGS4Ee9gCHD9MqDwPrmux8fRCLxDck7tjEuEBPU+tcoWjVWIQ+WTtZSM5B5oAZE6lnaPdsyARnsepp1yfLu1a0bJb5GJPp/EPQ0sREcW1Yzy2DgdPekmjFrcqkbCXaofco4Yfj3oAkjnjF04kwzOcEjOCR71EDGszycOc44/ixUjyJLEvlkqCzMMjA57VEsrPCBtVHXlTnhqAL+n6tJaXAljYkldpBHylf7pHeq9/pFprU3naNGlrdE4a2JwjkdShPT6HioSHZS5C7pWBJz94e3vTFkaCVPKfLscq3oPSgBJ7a5cEyea3lElR6D+tRxgMxkjdm81ssx4IP/AOqvSdQ1SCTT3t20h/t8eViaNcqWz3FcRDby3GrRQOhhd2K7iu0Ef/WoAyclJD5gIQglRnn6inK+Anl7mGCTIepGK6LxFouoWMzedbK9rGVUyxjKfMOMt61zEsjeTNHA6YXG4jvQA8AEpCh3ZIYsD07cmrUMp+eNHxhwVxxkjrUchhgWNWVo1QB25yWz7VHEnyks/lxupJyeVJP9aANOxu5Uv7dI5RLcIwKu5ztHTgV6peMuk+H7exsWZJbhDvlZc7Q3p7k15v4OtorvxDHF5fGfnx/Co5AzXp97FHqOt6HHMdv2m/t4xFkZdPM/QUAe43ulxwDw3o8eCmmWsSsMDhyACT/P8a4X4hamdb8Z2uk28LS2emk/MBgEdT7HkV6Nqtx9j8T6ndSBcJE+1mHyrhBgn8q8O0LV4zq1/dX7RRR9C8j7Ac9Sfr6UAdZbx2jvFDdo8lxKDjbg5IGTz7ZxWddrPdlnhUJaByjSP1YjrgDsPWjS9a0zUfLi0fUYjdSFvuMuFB6DHqaseJ9OmeKNNNtGE6jYxZxtJ6lgM8H+dAGPH5hWGeSRFUbmRV+UbAQAPXJ5qbUma42+TIRFLnJkX0FZv267dzaTwCNojhV8sKWb3Par8VyVj8uBYWdVA5OR15I/woAZbWrXJHm7njcbdqEYHofpUod1udjuRBHiOObywN5H8Iz3HINRtMMSAgi3B2zKuSxI7Z7LVhWtJ9SjPlBmYBYwMfIRwD19z2oAcQ1vZmWG3mDu3DEbsepx6VX0/TmniIu825D+aDnBH4d8+ldPbeGdRu8pIpLRtsWRztGz09/rVr/hB728uFzcIqxA4jU/e9Sx7UAU/DNoLqZ7TTZoj5SljKgKsPc1zD6tfWHxO06+uCy21lI8aSyggqOjMp7qfQ+uK09TkuPCt7JHHO4nkjxHsYcD06f561i6PFB4l8Vi2vCubKISyK7GQyE98+ntQB65/wALt0GDx4nhi9tbyNpAoW+Vd0O5hwG7r9ea4L9pDWbnXdVt/DttqKyaNHskuLK1Pz3Lnkb2HVVIBC9M4JzgY5HXEOl69eardWBg0zzAkcBjJY5HLMT2yOKPC9va3+vQXMPnXUlzIfKMRJYMex+lAGL/AMIXpl7Yi50yxFuEwjKykMsi9SD0rpfgt8QLjQ/EX9g6rLPLEWMYLt8qqejKD1rofD2pz31/cWUjwxadGrtc6ldABLbaPv56c/0rzvxJc/DC0neO08R6jf3gfJuUtiEVs5ypwOPzoA+sUhWU206gSwSDCzRvj8doH1zSl45pmbyxFIcjcjfOGHQgZwRxXk/wn8XRPZWMEVwL20e4Gy53HCv6H0znp616yftZLwTIQjOSsuzcASejY70AW2kVpos7kkKg7XHEnTkds1YkYoq+anyBt7Y+UrzwarLCZ42+1xKyKyogU4X/AGiPy6VPbh4EY+WXaR85cZyO3P0oA5f4s6EvinwBqlrszdIjS252cqR0/qK/PnWVxNHk5YLsYE9CCRX6dTxGVyp+6ykNhiDj0x071+dnxdsf7P8AGF3C0AiYSyA46N8x5oA4iiinIQHBYblB5GcZoA7n4J+Mk8C/EbS9YuSwscmC6wMkROME49jhvwr079p34w6X4ysbPw94Vne402OQXFzclGQSMAQqAHBwMkk464rn/j1qGieKPDvhTxD4Q0OSw0yKJ7C4m+zrEBKoUrGccHADYPvXlnhRdIbxJpo8SvcJo3nr9ra3GXEeecf5z6ZoAyaK7bWdK8JXt/4qvdD1prDSrNlOl2l1Ezz3mf4Rj7oBB5PYjPNcTQAUUUUAFFFFABRRRQAV9HfsTTsPGfiG2JHlS6erMp7lZAB/6Ea+ca94/Y2mZPirdRKceZpkv5h46APqY6cNL16J0ib5yJQ2emOq/wA683+MNtI3xBMu0iP7KhVl67hn+le3yGKW+2EBmUDJB6HPSvEPi7MZPHc8O2VpooIzGU6YYHIP+NAHzp4rnuZL6dL3yzcrISWLYG3tXOJMSG35bqGZT2J4/Wuv+KNssGu2zo5VJ4Bujc5Kn3rjg8gi86T93CuVJ6ZNAE0lzuKx7XDoeVVuAev5VKZYGuI2mDtFHyuB3z0zWejbSZOWIwD9DyRUqP8A8s2U+Wxyp29x7UATSRMZQUbmR+QW7fTtRdJ5mYoQMr0+XoO9RR3CklwGHQY28ipzIsjh2xvxjpjP1oAi3iON2wDIOARxjPQZ9KjjUr80gJYnBAHGPUmkESsMMsjDspOAO+aEkBkRd53gAgn7tAHv1zFaxSpLGqyNK7KuODkDv6H3pJNKtb5GjhtomuIxlHZMhQf8KISkV1JDefu9r7pUH3lyMjH+NTE/vFMIP2eRd0bM2PlHY9z1JoAz1to5vDU2gtNKlvMS+OD5rDB6/wAq5258IaDLPb26l0YYVwGGZGHUAV2k0luFCzREzoAwYL8ir0De9Y2qWsYv3mhVpZdmwsnVRnqMdDigDg9R+H94oe6spUIUEmJ+GZP4fqa4ueCVXWIjyti5dmXkEdeP5V7rFbb2eOIM77hIQ0nCIB1PpXMeNdPt761a6tFX7QSHbjqMHoPr/OgDP+HttbylpTHIu8FASRuB6D8zXWgy23j7wsJlXEV3FvBO4ooYYriPANybO8cpvdp8qQx+6fWu18RK8ctrcMxBVlnZIzyACOM/196APcfHOofZ9J1lnAQ3CEoCcfNkj/CvkD4qyva6rFp0Vxut1hWRlV8guc5z719L/Ee6hm8KQs7+fcXzeZDg8Rjg4r5Z+J8qP4wukj6QokZ+XHzBRn9TQBy0UjxSK8TsjryGU4I/GvSfCPxh1/QxFDfrDq1og2hLkfOB7MOT+Oa8zooA+n/D/wAR/CPiqMW96qWV8ckC6Ij3t2Accfniu3tvCdnMshs5vLiIL4RgQWI4xjtxXxTXReF/Gmv+GLhZNH1GaJV/5ZMdyEem08UAfWN7Y21mGjeF0lZSpcEYb/aJ7mopp9N0rQo54fsxnchGG3dIn1Pc/SvMPCXxe0/VmW08RA6ZcS53XakvDu7EryV/Wu21HSXjnikjuEurSYb451lxGAR19/rQBZj8TancWUpn1CWe34BMeEKD/ZPqauaLLeajrNvpULzhJlDCQNt2L/ebHWuahuvDtpCy6v4is7SHnKJIrNntwMnmsTUPip4U0cSw6Y19f5yMxLsGfXc2DigD0f4h276beJB5Alis4i73MgDL/uk+pFcJ4dTSLrU31DwzrynUEw7QRNyF7g56jjpXnnib4w32s6RcacNPjEM4KSNNM0hZcegxg15jBPNbszQSvEzKVJRiCQeooA+vZm1PW7220ZYze/acq0RALKD/ABN1AAx+FdHdeC7H4Y/D/U5bKTzfEWrlLGOd2wI3lOzbH/dAUs2ep289gPHP2W/EuraBP4j1nUJ4k8I2Nr5uozzx7pDJgiKOJ+u4k/d5HsCQa7zxZ8RND+K2s6Bp3h69mjW3t5r94Jo9j+fgqidcblwTwSMN1oA+f/ih4vvdVv5NHjm26dZOYisfAmdeC7evTiuBqzf29za3ksV9HJHcqx3rICGznmq1AHffBvX5tK8WQ2ZYtY3uUljPIDAEq4HqCOvvX3V8PNZ/t3w1b3DyK8wJRz0OR3x36V8C/Cy2afxnayjGy2jknkJGcKEI/mRX1J+zb4iZptQ0e7kjZmkaeLZj5M9vbrQB7YsCBIhGqCUFm+7zkZqcxMiJJlCm0KVIIGD069OadMsoddqiTIIyeD1FP2lWQxhdwGGA4yM+hoAjtlBfABETKQFAyBjjr618BftB4j+KGq26Sb0ibpuztJ5Ir9Aw0axlz8iqNzDGO1fnD8WdRTVfiP4guoWLRtdMqnP935f5g0AcjRRXY+DrDU/G8mk+CtIsNOFzJdPMl40W2UAr8weQclFAJxj+goArWvjTU7f4e3vg9fLbS7q8W9JYEsjAAYHscKfw965evT/jZ8KZPhe+ixy6rHqL6hHIzFI/L8soVyMZJx83Xvg8V5hQAUUV1/iPwPcaL4F8N+Jzf2tza6yZVEUWS0DIfusemcflQByFFFFAEkaKySFpUQqMgMDlvYYH88VHRRQAUUUUAFewfso362Pxn0xH6XUE1uPqULD/ANBrx+uz+D17/Z3xI0S93OvkTb8p16EflzQB+h2nyRi1mu5F2GRmYgjHCkjNeFfEqa1m+Jd1JmWPNomWjP3jyB/MV61dSzXqLO0vkxgAJGpyGBHf3rwrxZqgvfiDq05jXYWjtwq8AYAz+FAHmXxTtZHW1utnyCExtjquD1JPeuDU+bC1uF4kIyCMkEdcV6f8VLXfZWvkJuTcVK55DD+mK4Pw9b3aX4W1gM5U7CW+6p7HPsKAM+5t5rK48tpAWwSSgzj0qTRLe71W8+z2KF5iuRnqRjJP869DTwje3ckZvmhCQZkeGMAM4I/UCox8P5Gu7m4guxZ8gRqoxtLDkZ9KAPP9QtHtJjE0iu6k7mi6L7Gq6sifuznymOCByQf/AK9egXnw7mjVbi0uxMFUmRW43VN4e8HCBxPOim7RfOUYyo9PxoA4PymS4W2u1YThQY1wQfp+VOm06XyTMltMVH32UfdI7V2ujme88eC1v4YTdyZZXA3KV9R+Vd4LUnzIFgiSHkO+PlPPYdzQBl6Qt1rHiq60+yjea8G1FOPlZs4xn0z3ru08AeMLi880aZFE+5QfOmTbjGG6E8Y9qyfggsdj8TtOsbkSC4SG4RHUfK525wfcANXvXiXWNR0wzSQQwtGq7o1bkyev/wCqgDx7xT4I8QaDo0KJbnUbf7rSQ/O8S9wRjhfcfpXGi7LGKExeRuYCSNT90L93J9M19M+DfEI8Q6YZ5Ldra4RijxN/MexrwH41aetl8Q5obRY4Y5oY5wqjGC2QT+YP50Ac83kiGWQIxKjEuFP3iTg47iqMs1t5lsbVohMifvWByX47DtWjaQrFCjbX+1RALtJyssZOSx9SKpLDFZqEgtBLLIzSo2eTk4C5oA4JbGSy8QGOFmTeMmMnqrc9a7S4uPtmu3ltuBCoqY42nIwMe3Sp9X01je2900cTXLKBLDjAwR2Pcg5zWRGY7fxYIbmZUiliMDMnGR25/KgDrYZEv/DMFnK4W8tpQG3ZAKLjIH0r5+8duZPF+qOxyTN1/AV7HqkpsNUsZ/NdY1ZYpCDkMuOSPwrzb4u6abTxU13Flra9jWVJMYDHABH4cUAcPRRRQAUUUUAFTtd3LoqNcTMijaFLkgD0qCigAooooAK0vDui33iLXLHSNJhM99eSiKJB6nufQAZJPYAms2vVfghql1p8XiCHwno97qPjm7tvJ0+aEKUs4f8AltJyeHxgA+pHrggEvxi1qx0PTbL4ceFphJpWjvv1G5Tj7dfdHY+qr90D29ga8wjv54L+O8syLW4jIZHgym1h3Hp+FQTLIk0izhhKGIcOMMD3znvUdAHRt4u1G5c/2stvqaE8rdRgn8GGCPz4pltBompmYI1xp103MMTMJIic/d3HBH45+tc/RQB7n8LtBfw3aX13OHkupz5eY0OI415znuCcA10thLbeGdSOt2RKNEQ7LuJOCTwwrK+Hurz6t4HsVtygvrUPbMXPDBeQQB1OCPyNWNQuRa+HrqS7RJyisQWXcGJ449sH9KAPqjw34h0/xDpsF9YXCyh0IO0j5ScVubA20jjacqR6Yr4J8LfErUfAkwW33tGFGIc4B5z+XJrs9Q/aj1p7QRWOkwROB99pCcfgBQB7z8ffHlt4K8B3UsVwo1K6BgtUVgG3Hv8AQV+fsjtJIzuSzsSzE9STW54y8Wav4v1U32t3TTOMiOMcJGPRR2rAoAKtaZqF5pV9Fe6ZdT2l3EcxzQOUdT7Ec1VooA+g/wBl2/svE/xUvJ/G1wdV1Y2ZNjJqL+b86sM7d2fmC5I9BmvNvjlLZy/FvxSdNtoLa2S8aNY4AAmVAVmGOOWBb6muIikeGRZInZJFOQynBB9jTSSSSSSTySaAErt/h54r0rSbe90Xxdpcmq+Gr9kklijkKS20q5AmhOcBsHBHG4YBOBg8RRQB2Xj7wxpOlFNR8Jaz/bWgTPsWZozHLA5GRHKpA+bAODgA4PSuNpcnBGTg9qSgAooooAKKKKACuj8AxySeJLfySFZecntyOa5yu7+F+m/arm4uWB2phdwONvegD6+8Iyxz6Fe6rMzOYIwwjBOAR0wT615BpTy6hc3t0SscdzcNKobnLKTkfkK1/wDhIDa+Dp7dpMR4KYTIHIPJrjtNnceFTdtKI3RWKLjB59KAK/iW+Oqa7Dp+mxK2Tvfbzg/X6V1dlpNnY2dtax5YlVxgcM/3snH5Vzfw705oYDezYW7uh8gJ4xz19K6yWRGhBjPmW4OEVCQA3fJoASbMziaFJBKy5wG54+8DTjG4dEiPmRCQFlb+EY5+p9KZ+8jtGkgMKoQH3rJgEbvu5qZZ5I5vnQ+RI/3guRyMHn1FADbohbWWOIEocRso+UsOcc1VEaW1nHBM2HOfMIBG2M+nrU8pjt45NreUqk+WkhySB6D1xUtzeROVLIGwpDHHB4yB9KAOK8WQxwPZalpSNGbaUDcD1XOM/Sux843VrFKkikODwANuB6Vm6tOstjLa7YWjmAHAO1OO9QeE3UWXkSQMLi2kKh2b7y/7IoA1rG6/s/XItas38ya1dZD/AHlPQgj0IJFe+WfjPwzrVpbme4RXk+YQTxnerDn0r54voo7S4Xyy63eBG7oMqR1JNXIZHefzCwi85Cqkc+Wnrj696APdtKXSNT1E3fhrUYprmCQebEXPyAnnKnn868r+LyLcfEa+MjDbFBCnuMrkfhk81yOl+IR4V1y6viskN0kiOs5JxM3dG9QRxmut+L8P9pxab4t0yMtZajAI542+9HKo4HscZHHdfegDi9PklWFJtxuI0zFC6rjYx56emalewuthmtwAFBkkyOnP8PsOtMt2S4SGNZI0ZcDafleMnjOPxyaWckFkMs0FxG5Uvn/WAcdPfp+NADbu4aexQfuZGDhYphJhg38Q/KsbxfFH9u06+t1+eMmJj2cYzuH8qt6x5MST+VCY5ocHG0fePUfhxVfWbVjoREbCVFjRg/UqR1z7UAW7+2kktreVYcxFlHQkBW5/SuD+J8STeHNPljYNJbTvHLzz8w4P6Gvd/h9oseseEjBJKxmUMY0PPmgqDkH2xXlXjnQ5LJdX0u4iXzHjDod38ROQfx9KAPDaKUggkEYNJQAUUUUAFFFFAE9k0CXcLXcbS24cGRFbaWXPIB7UXiwrdyi2ffAGOxuRle3WoKKACut8OeMbjwvpMbeG2udN8Qee/m6hDJ/rICoxGVI7MM//AKq5KigCSeWSeaSaZ2klkYu7scliTkkmo6KKACiiigD0j4UaxFYR3NvdTCGNpVkWRs4BA5HHqK1/EPiTTZY/LMjSW8THiMffOfX05r1L9lf4ZWl34eudd8S2EVxBcZjt4ZxkEfxMR+QH416leeA/hnbQvv0myRUcyFYyxyf7o59ulAHwVrLySalPJKu1nO4AdMdqo19s/Eb4E+GPFnheSfwasdnq8S77dhMWjfuY3BJxn17H2r4y1fTbvSNSudP1KB7e8tnMcsTjlWHagCnRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAV7b4EsX0nwUjSMYmuGM77/lAzjaOfavKfCelNrXiKwsFXcsso3+yDlv0zXsXj6/t4pJLOBgWJA2EEFR2GDxQAalqMl3p4gGyONiSM4Jc56g+mKvaXbH+xltm2AIuzJP3s8kn8K5u3jQpYRAu7TOB5cfLMB6Z6ZNdlptqfO2M0bY3jZnpxn+lAGjb2T21tHEjK0UKnLOuAcDoPWnhrSW2hDRtbqJN+yM/wsOSaj3FpRPP+8j2q/lg8AYxgemSKS2lGCghCBEOxX+YDnI980AdJ8M/B9p4q8QXD6hZONItVD+WWKrIxPyoQO3BJH0r3a/uNHsPs1pdC1TecRQlF/MLXn/wKvQnhrWGnZT9muCX2DAACA1RvNPPjHXra5ndhcM+2Jos7URefz9TQBR+PPhuC1s7XVdGgt7eWdmjmcZHbKkDp6/pXm+kalE1jEstqEuVG2cEnKgjAP8AWvW/j9e21t4Z0fSbmRfNklEpAbnbGhBOPqwrxuSPz0e4tYERMKoZmKiQ9uO9AF2afT7aFnmgEisQVXdnJHHOKoTWF1Nq32qQrCHZZI/L+VQO4/HpUizRyRpbTKS4YM4AG4jPf0FNt4TFdxGe5eTdnbGq8ID0570AaUUzjTpPMb7TEchl+6U74BpFPlWJl+cxyK6xhfvwqeuP/r0OzzLIl0YoiF4XojkjGcj2qaW3WCKBA4Bk2CQhuR3x70AV4DHcQWovLdTCFAQSDcDhTkEetdt4Fheb4b+MI2xMlsvnQox3KkiqxGPwC1w19PHLFGVUraltjgDjzAev5cV3PwYxqul+LNGkAWS7gAjQNwSFZcg9+q0Aea2PmXcA+0ReVIyeYjp1BPC4z154rUtpGntzF9oLojKhDDJJH3j64yRj6VQ0QzWeq3sN3FJtALYY/wCpZTwPcZq8lz58TtH5Zu5F8sBSEkDDksB0bigCCWyt5WhtmklxGfMYfe356MfbAouoGggeCUPHBdQGOB+qtjsT2q3EIPspmt1ZhJJtbYwBCjqP61WuriSyicR+XNaM/lAyHAUsO4PTvzQB6D+zxPFN4d1Jbj5rvTp1ZkHPy4PT9a6H4teCoPFnhaTVNHVDrNmDJG6DaZFGCyN6nA4/+vXG/Aa6XSPiFqWlXO4NqdosiBk25aM9Pf5See+K9Jj1m38O+Kbi2mDRxXEv7wbTgZ6OPb1+tAHwF4ptTaa5crjAdvMHH97n+eaya9u/af8AAknhvxqdQso2bSdSUzwMOVQj76D6E5Hsa8RoAKKKKACiiigAooooAKWkooAcw2sRkHBxkcim0UUAFdP8O/D48ReKLW1mISyjPnXMrcKkY65PvwPxrmQMnA616b8KtCur/WtM06OV4ftt7DHOoON0ZPIP0GfxoA+x76SDSfCuj6Tp6Fp9itHbwnDMnc49CCetc4y3VxYao8dtGGlcW8ZdsFWJwV56EZ/Gtrxda/2n4mtpWSWOzspVWXyFxIwwec/3RnoM5q3pdkdY137TcjY1tIz2zRk7Zk2BQ7ej/MfyoA5/wrdNoV3NDITM8FwfOWEMfLO3bgD+IEkHI6ZrxD9pnwJfXnjMazolobmK+tjdBYRudgo+fPXJH8q9x8QRXukeHhbrFtvIJghnl+ZpEY/Mcjn0Oaw/iEl6Pg7JfaHdTQ6hojebHcINpeJyVcY6gYJJH+yKAPiKir2qWzRTtKBiN2P4HuKo0AFFFFABRRRQAUUUUAFFFFABRRRQAUoBJAAyfakrrfh5YPc6wpyYw6lRIU3BR/EfbAoA6/4Y2MGg6Nd6xeoDeSjZGpXlEx2PZifyH1p0K/2jfT3GoP8AZnmwUyu4qvHr0+tW5beS9LhJSunwOFWPGRIfXHqav3RhgiZpfLSQrtywDrGAOn1oAo6Ri78Qh7FHnt7c+Wm4YwAc7vrXVaZa/wBnX7tNJuaZ2Zx94JkHj0NZ+iWaW9pZ29sxmeZhJKo+XPc/zrbeN0lbdGs0mFZMKBs5P4Hr3oAja5ePYt6pYeX8oXpgHvjn8KtmRZNQR2ICYJdMgEqQOD6fzqOHbAw81y0o+9MPmYk9Rj/CpdN0zU/ENxDpkVuolmYxkKuSBn77HsAOaAPVPhhpclz4F1iKyjRDd3bQjdwNowrN78Z/Kuks73w74HsxZSXoe4BOQAGc5P3eOn0Ncv4w8RL4P0218L+G5Vjmtow1xcufuA8kf77ZJ9sivJLeaK7vjdQvLLO7uSXB2Ke5JPegDY8b6mmueI3167V5jjyrW2J/1USn07knk/Wsu1myPOKyEqwKq/Ajzn5QO5H9auXT/Z5Y5JHWVhn5kj4X2qOOA3N2kgUSISX37tvB4xQByficf2a1ldW8xVDM3mSMABkn5s+uK1rkxXCQ+VOLkZDI/Kg/h3rh/iRbX0TRpKTLaeYxViflDdxipvDGqyTaTFGuCVB3M/GPpQB3l6l1E4DRYtNw8wZBDD1z2qyI1uEaSx2+UzHcSx3Iw6Ee1RQDfaQ3NtcRy2kpDZYfMxz0Pb2qVLaRfKii2wmSUtt3ZA5+6fagBm2CJ0edHEdwCsqJyA3TcPxq3oOt3HhvUY763JM0DeXIuMA8nH5jANRWlx9gnuDcFQiDaPNTIUk/qBStbo7PApXc2EGDlSG5JH9KAPQdU03TPiHCdU8OMLTXbYhruxb5TLke/BJz97oe+K8U8V2F7pjRu8bWepWJViCMFctzx34610wuNQsL4ahYTSNdK22G5T5XCqeQw7/j1r0gT6H8VtAgttUKWHiJFIjZlwHbH6g/3c5HagDzHT7qG8kaV0hhWQCJVT+JurMD/nrWZ4jOElWRFRJgJFBHQD7p9++RV+/8Pa14R1OO21PT/LhiBWOcJ5kchP8AED6HH1qwXjvLJp3RZo2dm8rbyOMcHrjvQBR03WbjTtX0rVWGy7tZlZZU+dducFfoVyPavfviHo0viHSLXVtCkjeUxgru6SIwBH86+bNPl867a3jkPmx/uyowePXI7f1r3D4BeJodW0bUPC1wzCXTSRA+drSQsTz65Vsj8RQA9NLtPiV8P77wtqoW31fTjtiYnLxSL91/pzg+xr4r8W+HrzQdVvLW8gMM1vM0M0R6xsP6HqDX2lLp83hzxZe3lsrvdIRK7HrKp9+4I4xWN8WPh9afFvwtB4o8Kp5OtiMq0Ug2faQpwY3/ANoYIDfgeMYAPieitLV9Kn065nhlieOSBzHLG4w0bDggjtWbQAUUUUAFFFFABRRRQAUUVNawPczLEnUnk9gPU0Aa/he0t5J5bq+B8mJTsH96TsPw619N/BHwxLD4t0aWdWka1V5nl9yhAH61454N8OR3F5bwXspiso3DEqAS3uR2r3z4LeMI9P17WLfXJoIoLna9vJxuAX5SDjoMAGgD0ua1z4ogt7mWaSaV3lEsOQiDOQjc8kV15kgs1jWV44/MfavYMx54qtDLpdvaz6jDNapbPmWS4Eg2H1JbOK8T8a/Fi51K4VfDNgDBbXDKs9wpy4HAkUdh9exoA9s1LTLG486a8jUo0ZWXI4ZR69+K4XxVopX4d+LtPs1L+ZaHYJM/MME/y7Vd+HPxDs/E0H2W/MVpq8Z2mJmwJf8AaX/Ct3xPqlj4esNQvdTuS8c6bUt25LEKRtUe9AH573ennatsQzvIucZPy46fl/KubureS1uJIZhiRDgivXGg+36vFcOjQyI/7kyAhNuc7WrlPido32HxHd+TGQVw0gAwOR1HtQBxFS28ohuIpTGkgRg2xxlWwc4I9KiooA0vEWpR6xrd5qENhaadHcPvFraKVii46KCeB3rPCsQSASB1IHSm1btNRu7S0u7a2uJIre7UJPGpwJFB3AH6EZoAqVp315p82i6XbWum/Z7+DzftV35xb7TubKfL0XaOOOtZlFABRRRQAUUVJDE80ixxKXdjgADk0APs4DcTqnO3qSB2r2LwzpAsdNCwsBdTx5YY/wBXH/d+pqHwl4NTTLGO6v4yLyVQY488/wC9/wDWrdCssqwhVQfeyvzZOcnOO/tQBJHbxwvb+eJGXlvLQYYnHfNVbhTfX6xP5ey2BdowR128KfpVi/uF02Jb+9k/ekFYFJ+ZmxjJHpTtAto9P0mJZId087l3YHDMT79QB6UAakEEn2S1EcLLLL9zBwieuSP5VMdQgee5CEedESvzj5FPHze9T7FFjstEllQNtaSRtvHoB2+tUJ7SLzBfwW/lPGBnzG+Uj6UAWbie5kSRoNolkGWkX/ln6Yz0zivWPhfJH4a+Elz4kuQk17OJp2ZRkthyiJ78gfma8guHlur1YNO33VxOxCps79OnrXqXxBnfwn8LtC8OuU+3SLGJ/LPCBTuc/TdwPxoA8pjjvtS1Wa51ibfcXP7+Zc5Ac9Bj19q0IYQ9oksKMJEO3ZuOXYHv7VCsMcdu0zS4nSTcX5Chs9Tnr1rUkjAVt9yW8/DRMvq3t260AQOEjhZpHkkUSBkjQZyT1FQSW3mOPtsXkLExbygeTx3qe1ijsmnhRvmgJXeW6D1+tVYXDoJJwJbr7rNkn5c8GgCr4nt4p7EyXnltg4Ax8qE9Me/WvI5pv7M1A7SfJLZwP8PrXrXiZbaGCOGGWY3DYkVemO2STXj+vzPNqUpOGEJ2F1wNw9aANLw94vu9IQeVKJLYn/UycBee1dlP48UapYz2/wC+jZQZ42GcE9cV5VOkjyBlIIUjG05BHfNIspcN83BOE2E5UetAH0WksWpNGsg2xsjMMdWbsDVeOxjjVZw+yaPhGU5jZvp2rjvB/jFEihi1ICSOIZWVcAkYwM+9dbEIWgTypj5TFpsbhnp096AHTxXESypIwZI/nKqO/JyB/P2psqbreNbaSRLjG5xtIKnPJx6DjkVehlDX1vDk+WsR4Yeo4yfb3qG5c5Zp4nkXPl7kO7Oe4xzyBigDsfCXxNuoYFtL/wAvUI4l6TP8+BxjJ6n65rpbC48F+Mx5NtEmmaqSVQFAh3Hrj+Fv514+0CR3kd6YQ1sx5YLnYMjk4/zxTGh8+7f7PM5KzMVZfkJX1A6ZzzQBT8deHL/wv4uiE0BW5hw0bpxHcRZ7Hrn2Peq1leXGheJk8Q6HJ5stv+98snZIwP3o2H8QIzzXrWiXcHxG0A+G/FE8f9sw5exvgu1n29mB/iGPmHcc9RXlOtaNNo/iB9H1OGayvYmWRJAdw29Nyn+JDQB9L2eoaf4+8IW2q6SxZZFyEPDKw+9G3oQf6GuAs9f1Lwx4hiNsskuk523cLnlSepAPcdR6815j4J8W6j8O9elvBDNPptw2y6tEOFcD/looPRwPzHFfRiwaL4z0VdZ0N4rj7Sg2yKepHZh2YelAHHfGT4U6f8QtNGs+Hxbxa4E+WXGFul/uv7+hP0Pt8X+K/DGoeHtRntb+1kt54m2vC4OQf6ivvfwhPJoLJpt8QiSMWBbIye59vpT/AIl+ANK8b6YWniAvY1Bhnj6keh9RQB+clFeu+P8A4R6jotxK8S/IvQhcBuf515df6bd2EhS7gkjPqRxQBTooooAKKfFG8rhIkZ2PQKMmux0zwPLJpcl/qN1DCFAK2wb942T39KAOTs7Oe8k2W8TOe5A4FdTp2nx2sY6bh97ByxP+FaqXNnYaZJbwW4MnKq6nAXj+dYen6Pd6lc+TbxMFb5nmLfdWgDrdBvxdXok/eInVt+FGB1/OvcvB3wyk8deGVvNchl0R87bWSJQWljxw5HYHjHrXg2n6JJLbzWttM7S42sdvJX1r7Z+HHiTTvEHhy1WwkjE9rDHFcW6nBhYKBjHpxwaAPmbXvh9r/wAONec3Fxc3mjylpILmJm8ot/ddeQpI9c+xNSabqNncWjDf5ZJZOMlW5GQa+uru2hvLaS3uokmgkUq8bjKsPQivDNd+AssurSz6LrK29k7lxbyoflz2yOvHegDy+e5tpL4WkCu95IfLjjjTcTJ0A4657Yr0XRPgr4h1HSEfxH4imiuiAUtyzTbOc7Wbd/LNdx8N/hVZeErt7y9li1C7BBgdoseSeckZzzz1r0ugD5Gu7b+w/EVxa+N7Q21rpYLjaR/pPPyOnqreteVaxria3qdxNPBJHGW27kbJQZ4yD2xgV7h+0ybPxH4o0230jy7i80+3kW5lQ7l5YYjPbIwxP+9Xz7f6Bdxq8sKyHY2Dhs5HoaAMLWNIksT5qESQFiMqPun0NZNdnaIrtLHdwSlONwbjA74PeszU/D4jtmutOuFni3Y8o8SqPXHcUAc/RS0lABRRRQAUUVo6TpF1qcwWBNsf8Ur8Iv1NAFO2glup44YELyudqqO5r13wL4aGgGS+uVhlu4/lBZsqG9vWs3whpqaI4lZVNznBkdeMe1dWDcT3O61OwnkZwuc9T6D3oAsTebdT+dJ+5bG9g5IYZ9/THampc2dhbvMSkaBTvkOSHY+gqZLWOK3ZpJd4jG6Vt35gk9vQVzc4vdenR7tgtmHJjgzsBA/n2oAt6LYnxDqQ1C6LLaxDy4GbgDHU4PWuttID9tARJCiJ+7Cpu3N3J9BWfaedaoLZIEkkCBSy/ciz159celaD3y6fbMIcTqTtD5P6+mKALbLJEyQ3SwgBA5ywDL349agvbhrhCluiyM2UjiiUlmJPRV657VBoOl6z4k1jbZ2LySSrtRUXakS9NzN2+pr1GGLRPhdbIzgaz4qk4/64hv8A0EY/E+wNAFfw/pOm/DPR4tf8Toh1qZStlZqclDjn8fU9B9TXEavqNx4gnlv9SYyXcpDE9AB2VR6AVV1i/wBW1rxHdX+rXcV0zuIY41XKxr/sjtirVyxAhXBKqmS7J8wx1IH1oAS2Ms6CONZJSyksu3AY+56U60th5DNuJZGPyqcYz/M0sAuGUSCNjEqkBpHAKjufyrn/ABP4z03SER7SQT3bJ5aKDkIcYBA/xoA2r9oEjnu7kpCrKFWN2wW46D1PHWmX2p2On2ZN3ttv3asVL/Ng+w6mvHtV8Sapq8qJLcSLIhGAwAI9/esqW/8ANkhkuJJJ5ACjB260AdN4m8Si+VP7N82OGI4Zmx84PP51y8ZVLdnuSZJXYbFz79TVWb75LoxUEfMWwMfSiEIZNhDhW4Dt/KgB6qzXAKR5jDY+U4JBPApWjliY7HV1csRxnA9/Sn3MAjabyC4+UAZIJLdTTrYsJCtyRnb1HHXnmgCBJGkKR48st94dQfpWpp+t3MMsfzFI1fcEJ3KcDr+NZ25lbmLbufZgnIHHBHtRJE3lyRiRA5POf4RigDt9J8WSsryNOxDfKRjLLjpj1ruU8R6beMBHLDFcRqqsrZUSY6Z9D714ZtJZHi34GHGw96treSSGQTAyPhcHbhgeoB9qAPd5p1Ec7xurRSACNlb7pH8DUwBLaMCGT5zH5pwcKSOrD0PNeMWupSmNPssrwSiTecNgEY7/AI123hTxhNFiw1dY5yzr5crJn5T2OMUAdZqO+ILNaXFxb3lowuFIPzhhyHX1HTpXtVte6D498E6DfeIo4Yru9UwJOgx5UwyGAbsCVyAfavGoXguIreW3njISQ+WN4fYp52jvg44FexaV4JXUPhVBplwpWVnN9CMYZWJ3KPxH86APNvHnhGfw4WW+VzAXCwXpH7lh2DkfdY9Of1rjtG1bXvAmvDUfCw8u3nJNxYMxkt5gO/sevI5Fe/tqepaboOm2Os6TLqtjdB45leEkqoOFVs9/rXOfEvwnp9locer6Aot7aXAeN/8AVoMeh6UAb/gr4h+HPiLAtpOj6brQGDZ3Bw2fWNujr+vsK7mwtbnT/Lt0YS2oyS5+8D6Y9K+MrHTrmWeZ7W4DvBmRMEFlAPIBHUV6v4V+IuvaIiRaldfbICCqGVS4z2+brj2oA9o8TeHrbxBbO3AkKFCCOp9D6GvGPFfwbS43XXkyrGqldwIJA7gqetdRB8abfGy7slinQHeA+V+oPpWuvxT0y5tZEaEK5AxvbKSA+lAHzxqXwxtYYmiiskmJIUSN8mPf1rmpfh9LZ4RtPViW+UBd+fbP+NfUujeJ/CV9YyzEpBLN/wAsbiPA3Z521w3iLxppVvIywj7XLGx6AfJg+39aAPJILW70WPDWcVlE/CgRjcc8fePT8KpzafaNYpvE7XDuTuJyoHpiug1K4u9Z1MX7r5QU/JHuBXb1HHtU9rZxTMJJ4RvXO1lJO3Pt3oAydM8LWNvG09yZboleDHwiH+tReJBb6bBDbWcQh8xAcLjcR6tXY38MltZSXEMiBUXJG7aBx29a4Sxsr/UNRuL2aIGKNAcsdxIz2xQBp+H54tLRhJNtklO9iODJ8vA9h9K3tE1+bQtUkvdIcwakFVEKEP5iEZww6Y6da5u70C/glhuLgeTbsMKVKuSO3Her2qaCLa+hu28uFljEhti4yzdccdPpQB9K/C/4kWvjJZrK6iFjrlsMy2xPDr/fTPUeo7Vr6/4tt9Nu7+x2s11DbiVdmCckccHivmI63PpLaP4h0mAQ32nTb5UXJDIfvK2T0Kkivojxlf2pbR720Vpk1HyyNqgh0OCrEd/vCgDR8HXGtPBLe67Ltt2Tf+9ATaOucDgDFeO+Pfje2p6jc6L4Ym+zWjAxG9CnzDzgsp/hX8M9+K7D9ozWbmHw3a6Dp0wgl1Fs3EgbaUgXGR/wIkD6A14Vp/hm20q7WVNt7DIwSQuefm9D0oAoWGpvphTfzIHIjCAsJQT0Pr1NS+NNCkh2anYI1uXUNNZEktg9cA9qfqdrFaapFpumxmS8lbYjYJC45zn29RW/ZWl3cW0lxqt9vdPl+bk4/HpmgDz/AEi4g1N2t57cIYyNiAZ3A+/qPStPVvB8Ulu7xq8d4mHiYZ2uvT9Dwaz11FtG8SNctZf8S8sUdHIbH4/rXb2F+86b7WeOSInd5ewgxqf9o9RQB5pfaBaXED/2laz2d4nWSJeGHuO9c7eeEr2PLWjxXMZ5Xa2GP4GvbZktjqEE91PLIF4EZAK4989Kd4k8J2t1ALvT5BFE55Eacg+mfSgD56u9Kv7RttxaTITz93P8qktNEv7pWZICqL1ZztA/OvWRoF7ZzhZQ4h5w7fOW9eP8K0NP0uzecSPGYpccseOf900AcN4W8J6dKvm30rTyqc+Vjah/XJrt5p7OCOOKCFY1jGPLQ4B+gHStO40159rxqMHgPkBv/wBR9hSXVkLMq8sCISAME+YT/wDXoAht549oBtixQdQAWXPZfWpUjjt2md4GdIxukjY7APbJ/lT2aMQK9rFLbMpyzAeZI5+nasHxFc3xsNuphrOBn3JG0m6WY+px0FAFO+1C51vVUtbJVFkH5SLhS3frXbQ2cds8LMqS+Qm5225AHYe9ZvhGwgjt45drrLKu0Z+TcO9dBp1leavq0WjaUkTNKdgTJCrjkk98Ac80AaHhbRtR8VXZj0lWZEkBeQjZBAOxJ6k9eP8A9dekDwl4S8HwRXPie+F1dE5WN+Ax/wBiJeSPrmp/EOq2nw28NWmjaIEk1OZSQ8nODjmVh356Dpx7V5JFave3U2rXPn399MMPLNKVJX1A7CgDudb+JkT2b2HhezfSYZC6Lc+UoZgOMqo6Z9TzXCCNhG7wlpZZDuZmYsT6sSf51J9qdUA+z+VCcoqj5m9zgcmqGt61p+mWYneZzMQBHGxG+Q5P8I+6BQBfEcrMy26qFdA+4nlzmqt9q1vp0X2jULuKLOY0hU7iB/jXmur+K7i7mc28wtI0XaBnL4/oK5W5vjMY/MZmCkndyS3oKAOt8TeP7i8img06I2qHK7kGSR06epriPOlKlVhAZvmLZyxI6c0sjJHne6byWxg4K1BvkG1VlUlR8oUcn6mgCS4llPlSmJl5BJ6k+uajZroCZI4vlDb844AqzHbyyo6KD8y7woHHvU6PIpjZSMhceWp7d+e9AFJIkMeZSTJH90OeDn6VbTznjixEmFYDceR+APNaWj6PqGpTv9hsnkdm+Vc5JHQ4rdvLDSfC04fxPeLLeSLkWVt88g5/i7L0oA5B4pllxcIWKEsMjBBHT601SzIGngUscqTnp6cV2Vh4/wDD2u3Yt/E+kR2EbRmIXFrkhT2LDrgfjU+t+CDp9gmo6PdLqWnSHzEmi+bAx60AcFLbOrBAjtJgjd2z3H5Ux4SUYibyp9gCuxwGA7GtDdPAJAqO8shClD1z360NE8k7NhEAOSM43UAUQGO7zCrSHDK/+z9RUgSWS5VxKNuwLhjnd7Z9aluLBhc+UsO6Mc7kboOuMelQpGhh2iLDbwOuMn3oAIopN6iM7R5bDaecN6fjVm2llguI3DMfKBdweQRjHSoWUiZndAu5dr5flT2I9aescqzyzRyNGWXAyvGcUAbGkXMa3MAjma1IZXWXflRxkfr/ADr1Kw+OnizSYUsdQjMrW6lVfylBkGOBnocV4X5cpwrIN2QMKcA+hH0rZ0/VB+5j1IOtsysrEHd04z9aAPojwv8AH/UdVvtlzp1tDBjgnPPHfng5q94t8W3viXT7i0Z44lK/6kA889R2ORXztLZXOmyG4sLuO8ikQeTMgyH7jcvY10mlfEP7HFB9vgIUrg7edpHGOe3pQB1WiWFzZaj5j29uyno5fbgdDk+9bEywws8JtkDjloy4yR2YdjWIvjHR5uJbwyWswyyMBvU+/Y1cGraYbVPJu4biEkMFdgxUdDjPT6UARX+hWc8yyxyeZIB8khO0ZPRTWPNZ39pAyaWGy7ljgk8gfd6cV0iXbXVuDB5TRtgHaTw3QKwPY+1WZT88QuLeaGUsFKltu0+3r+NAHkN1qN/p8tujKROjtI3m/eJP9K6m0bTL6x81Iws8yCPELYJIPORXSanolnezyNf6eZgSNkrNtKgew4xVKDwdZ203n2kbLIrAhGfYr+oznj60AULKyhtblVMu95AcQvGd3054qtpqzP4uvdPeV0toovMCY4b0AHtXQSW0bxBdQa6SeNshHXO0ezDg/WucfUr3TfEyyzor28sYiAZMqQfXHQ0AbCQm4uTaXMLyIpIKuRkDsSDU2twXCW6NZG3h8sZMY+8Mdcjvmsy8nRZBcyK8gYbQ68sE7H3xT72+Om3lvHvjuEfJEp+UjPY59KAL+qNFNaWbvJEqiVZJMAALgYz6jntWH4rtFuLZ7/STMt6gEpL9GAPUE8fhWfrWs241KzljjWaIv/pKrkd8ciuqllT7PEWEbSs6ouSSDkjAoA5bVdM1X+xZLszCOZoRI8QGAy46kd819D+EIX8S/DL4cXbMS8MkKOAc5VcqwP4JXjHjIoVhtneO2Z2KBlkxn/ZAz05r6L+B9qIPhhoMbx7TGrlQex3sM/qfzoA8f+MN5e3/AMXL2NbVmgsrSOCN2TPUbzg9OrEVxGiSSavFdmSN4rpZDGqucbMcjAFdX8RdTRPifrkt1cS/Zo51RY4zgAhQpLfjXPxXcX2udVD2/moGV1PcHnOOTxQBMsoXXdNk1TckqKY8MnAPrgdfwrQmHnXjyJHugZSDOQe2cjHX0NcTd6vDL4iFxE+638sQysxIJYHOf0rq/wC1bW4u/LsJU3ECRsIQBxyD27d6AGT6bp8tzI88/niTGWA7/Ss6+jj0i4tpLN1jaVgGy3KnuNvpV6/kd5N1osUca4GBH80h/wB7tUF7fpHq1lE1grADzWY8tv8AagC9KBdQgMnnRyKdjIpcn0+hot5bhbc2jyKiYzEpIG7Hb61blmHklreCa3JG9Q0uMnv8oqvcaXdTHy7Jnh3DzGcAMqEjjJ7fSgDK1nWY7Gxka5neK5VwklqjqTtx1x2FURq9jcWkclpMZ5egUR5Kj3P+FXP+ENga4a81WUSzbst5YyzH6dxXRroWnWMcclsi2mcPyuR9B6UActaQ6pOhktbGURk4M8oPB9PoPatfTdD+zyg3V7IZpTlscjPtn/61b8UcFwfMa5MaYGFDEpn3HqanXzrRZRCsFtDsy08rZagCkmhxW53zRsr55nY/OwHQKg4B+tcXq6LrGplGTybGBtoZhuI/xJ9ulXPEvjCKzt47SKUh34yM42+vq2au+Dr20vmhkbO95RHEroAZPp7UAdBNcDT9NhitIn/upJJ/rD78dBXsHwk8Jx+HNEa/v0A1S7BllYnJVOoHt6msjSfAltol3HrOto95cDH2fT7VWcF+vOev6D6103iDUJ9O8G6zq2utHaSywmOOMN/qlPyqpb+8S2Sf8KAPIta1aHWfEt9qBQkyuQBjefLHA5+g6VyHiHxFbWdxtmuJpZ8bhDHxtAHcdhWZ4k8YaZpekG20m6AlYEMI2JaMfX1PrXlc967QSkybUnJZ2+8x9MmgDt9V8Z3txOUgnjs3MYQnIL+v4GuIurt5GIjxLI3LyAZcn2NQypDLM8bziQAKGYrjB20wSxoQAXdNmxTH1I/woACil5PMEkrjGNowVpwUyTKRGVyo2q7cfXHrU6RMZRkxwq/HPfjk5pS4QrGjxzOB/Fxj2/8Ar0AMa33KjRRD5eWYDjd/WkkX/V/P5hBKsTx1qZUlubhEtzLPK3yokXPPuO4rsLPwzb6Tp8mpeL7yPT7dkHlWx5llP+yvU0Acnp2lyahcpBbGW4mBwPLBwB0NdcNL0PwhbfaPE1yk11GAYbCM5kcn+9/dHuaxNb+JLwQCx8HWg0m1CeW9zgG4m9938P0H5153LI80jSSuzyMcszHJJ9zQB3evfFLXNQQQ6clto9qqlVSyTa4U9i/X8sVwhdpJS7sWdmyWJySfWmUq/eH1oAG+8frXSeDPGWp+FbvfZuJrN+JrOUkxSj3HY+4rm2+8frSUAe8wW2ifEOF7zw0RZanDEXnsXJLLtHDKf4hk9a88vtNu9Pkltr4neM9Md+orltI1O90fUIb7TLmS2u4TlJIzgj/Ee1eraN428NeKkNt4zthYahINv2+Ff3bH1YDlT+n0oA4xN9viRWcLGvlBlqxLcWs9wZJk3Dj5o0zx7+9dvqPw9uGtFv8AQ5YLuyPzF4nDKfxrg5rOSxu3huw/U70KEAEelAE8llY3LiO2ngRyA6nJBJ6kc1Elu6OzMuF3EjLbhjtVPzEkvIIgieWUDF+hB6GrdpcbYZniBZQflXOcg0AQFrhopkVA6jLoCuPrg9qaJYGcNs2OG2Njo3P/ANeraTwy3flyF4iclcg4wRg0jRzBEaRopYSShaPnntkdqAK9o81mzm3ykUbhiCSCFz2ru/A1/puoSyabrNujNNJiNnVQWJ7E1wduj/aXjcFNynDBeDSFCV3pIqzI25OwOBjBPrQB7Z/wgliz28sNuqK+4NCz5HB4GB0NIPCeji2lAhDBhuDRnIQdOPUZ6+lcP4b8aXljC8Nwr3SeWCm4YKn2Ir0HTfFOmXkKSRTLHFgM8RHzKe5H1oAy38KwW7CKPUriG4zkI4JBHbkcYNX7rw9qN0R5OpSAgZjViWy3dcnofrXQzbSts0V1BJHISd2eo/uj3oe3EyzjzJLlJSCeNpHv1yCPWgDA0+1vIbURPqRaVX2tFdLhgD1AqZbO5jhHnvIYxnAK/Ko5556fhWlcaZMVVpbncjHeG2Asw9Ce+Krql8kDJbSEuGO1WbKv3AHpQBD5F0VXyJUuIDjazDofTFZN3Y3l7btAk0KtuIZXJHfgDPWt0rd3MxN08cDcDkYMbY7+opJ2CxJ9obz4lxhk559znA9jQBwEPhLVYLtY4LwED5sDJKd+/am3/hrWLyWSW+ntJSABl2xu+nuK7hoY5VP76RZQMbg/z5/un296jYRKU8q+hOFLFWwMfUk/WgDgf+EQ1WGQCCRWkkQEbhlj/Q1Ygh8SQWi2jW0qSeYNk0pARSD713MN5ZeZA8+pxxDJVmjwc5HGO2a0bHUIDGwglhaAgkGR1zkH+6e9AHmWm2GqQXgudUgW7hD+btYYOR3HtX2v4SW3Xwxpf2J99ubdGRuOQRntXyrrXirSLW0khaRbxlYBTu2qp9D6CsnS/ix4h0W5uLfw+Y47F48Nbli6DjqmT8p9waALvxznm1Xx/rEOkl7nTnZFlYR8K+ADg+mRXFS2+tWsPkyLIwC+WwkOMD6iun8L+K9N1COOzuFlgmlUqySgbS2exB/U1tz6xp0TBpZbfzlBB2sDx05HegDyq20LWJ4tsNrI6REgmM9vXnvW54f0rXtJKubchNwZleQHcOnKk12a6vpsryST38K7QHBbIDZ68dKt2+r6chMi3toIxyVjGGcHjOaAEglmtArW9qV3KJDuZST6/Q0jSSJKbqPS/LLOCzEhjk9+as7dPniCpqNpC5bcjEjeAfUk0CW1tCbVtUhkdhgZYHafQYoAmgl1Bd7WtlFA+Dl8bcZ6g5OPyrDfVdchkWGDTo/ID4JBIJ981uCBZxHP9r3zoQskagsMY4IHrWntlTaYVlu2YAI+AqOB1H1oA5LWdd1fR7kS/wBlvcSSqNr8OT/sqMVkw+I9alL/AGLRigkyWSQljv8ARvevQIZ1tJZlhV4pXw27cXOP4gD/AIUrooJbyN80ny7EO4KexIHOfegDyu88R6/bTEpYx20xIOBHuYH2Hp71z2qeJNdvd0dzdzQ2xb/Vlslj69Ole630FoImknNs93Gvy7nCr7g98Vzmsan4c0ZDJeQQT3RQbVjxgE/3B6e5oA8c0k3H2p5kia5uucGRSwYenPAFb8d9rn7mSa4h06OEZhd3GV56BQKreKvE82qSqltbR2NjEMiOLAd8dyRWIWuJAPLZWJ+9ls4Pr+FAHqVn8XvE2n2UUMPiGSaSP5fLbacH3Yisvxb8SPEXjK0TTdTu2mt1kGyNNq5YD+Igc9a4MREOsnlB9pwJAQM8elTWiECTy2k3L9/HQewNAFSS1gNzKz+YJo/lJ+8pOeaU2uVxHO7IVyyYwfYVcFpbxIqfaXVdwDAfM2PYVEbqJIW+xqXYHKu64JNAET6fJG7SOyKi4JIHfHQ0yGK3SJvNhPmDAwCcH/61J808ih5GYqQWAOc1raJ4c1bWZGi0uBpFdsbn6j1NAGE8MvnK1x+8BJKovOPQAV2Hh/wbqGqRR3V75VjpafNNczfIEHXkmtbUV8N+AoyNVP8Aaetna32SKTOwj++38I9uted+MPGmreKZQL2byrJP9VaQ5WJPw7n3PNAHYaj470nwujWfgu0gnuguxtTlQ8H/AGFPX6n8q821bVL7V717vU7qa6uX6yStk/T2HtVKigAooooAKVfvD60lKv3h9aABvvH60lK33j9aSgAooooA3fDPivWvDMzPo99LCj/fhPzRv9VPB+ten6Z8RfDfiOIweJ9NTT7xs/6TDlonJPcdV/UfSvE6KAPdNf8Ahq0tq+paCyT2bAPHNAQwAbGOlcTqXh/VNNJZ4ZQXG4qo5z0rm/DvijWvDkjPouo3FqH++iNlG+qng16L4a+LVtM4g8X6Ys0bsSbq0G11z6qePfjFAHExCP5HlYEsCuCMbT9PrVmC+ubaOXysyoGBMe3BHuK9Tm8F6L4qsjc+FdQgvWALt5TEOp/2l4KnFcR4h8D6notw4UG4iVhudemCM80AZbajFINslqN3BHOCtMQ2TyAs5idsEKw7+x9KoTwyyyyRsJIudwwp4x2pAkTSMZpedu7DjdjtxQBsQWkk6krGyRsMHJBUEdDVa4snt5P30wUFgAy8Ej/GqUbSWyFFmUqWBAOcgfT0q2NQUlUuYY5ARyw43YPB9j2oAns9UuoMwwXZcIT/ABEnPY47GpV8Qa1JIwivZGUfKuWO4eox6VWeW1dv9QIZQ2MgZzjkBjmnl0fKCS2UAHG3duz7GgB39vazFJg3c+xmyu5sfgKSbXNYhkliivZR0DQOuCfX8ap+W+TGVlDE7g27IU/j2pWkmnmDzShnQbWRf4vTOehoAut4h1V4ljkv2KopZFOSyk9qqDXdQkUJNLLx1G/aD/hVYxqkfkuhU/wsfvc9j601VJYQnJDDqpHGPc9aAJXm1FmXN5ckN8y7ZMr7ZPWmpcXTRxLPPnaTtLdD7Z7j61EkhSVItyrk4I6KfpUgjWJSBGRMPvBuWP19PrQAW93LEskMm+RuW5cqB/jUiz3flBYThQMZfP1qtHJKJ1Rn+1xqpHlOvzL+FIoZosszR4zlGGAPpQBZg8yRv38ZBYDLsc5x7dMVZndWlRxIqYXkZ+Q/QCnt5MUSQwwqTtLeZklgP5VX09FScea6bGGc7ck//XoApssivG8k22M8qduFI+n41PGyMhUGdioIEkbAn6+uKmu0RSQrkqpyH6geoNVGUEk20DLhiQx4UZ7jHWgCeS2ktJI7oSGRcffQ78KfUHpUaXA8wPDvVmJRwmST+FQlpEjUkhGUZJyVLDuPQ1JK7PhZV8nzBgMo+Zz2wO1AEMszhWS4vJI2Viu3B5B7e1Tw3ctrhoC3ltw4LAZ/CpZWihVZNnzBBlSSSSPU1EHimBljuQidWLLnH0oA0LTV7+3P+i3sik/xI5B+n/66uxeLdZhBX7dNMVIBznCD2rHnt22Rjy4xCPmD4Acj8Klw0arJbxSPGRscsNyqfagDZl8ZeIFAMmo7e4ABH4DIquvibXXY7NQaE7fvqxBcemR3qjHYl4jM9xAw6EuxDJj09aY4PLCVNo+YBWyW98+lACz6xezsXvLmYHpy5JPuT3FRxRidpJhIWYdQdwJ/Oh78KQkdurSpyvy5J9M+1Q3N3PMAtyqjB44/PpQBcEaRjdJMqq3Jx1X6j0qNTCmXM+HJyPlx5n/1qpFItu5m8mRRuIJJYehx059KlWJFVZZmZgBleMso+nvQBajyH3CNZGY9W5z+PanKYyqwz3DQ85Ug5z9fX2qnbzG5RzbqqyMNixoGBB9Me/rXU6P4A1e+iVRZsrYC/MC2MnHXtQBzgjb7THIEO/5vlHdf8TV7TNNvdSjJ0qGdY2PzFxkfh716P/whGgeC4RN4n1eODb0+bLPx0EfJNcxrHxZj05DbeCbH7Kg4N1cgMzY7qnRfxz+FAG7beD9I8P6a2oeL7yG0DYZU3fNKOmFUck1yfiz4oSSxNYeELY6TYbfLNxn/AEiUe5H3foPzrz3VNSvdWvHu9Supbm4flpJGyf8A61U6AHMSxJYkk8knvTaKKACiiigAooooAKVfvD60lKv3h9aABvvH60lK33j9aSgAooooA1NCv7KymkTVNOXULKVdrxiQxSIccNG4B2sPcMD3BrPn8vzpPI3+VuOzf97bnjOO9R0UAFFFFAFmxvbqwuVuLG4lt50OVkicqR+Ir0bw/wDGHWbYrB4gii1e0O1WLqEmAHowHP4j8a8wooA+gLLxN4C8S5ikaXT5ZXB23mEx6YcZFVdU+HdlLcrHo97aTbpN0ZgcSF1I+teE1LBcTQOrwSyRspyCjEEH8KAPXbz4Ya8hQzp8m3zI2ZgOR2+uea53UPDesRCSO50+eR0bDLGuF9zkfnTPD/xY8W6Mqxm/GoW6nIhv084A+x+8PzrsbP43W90U/tzQ3yjb99nPty3+6w6dutAHB/ZLoeTatbqZFJQNyWwOhzULRzRSyiSN4kIxmQYB9CD2Ir0q5+LXhQ3ELxaDevt53MUBB9DzzWnp3jz4f6y0cF9E9iZcq4uIN0Yz/tAnH1oA8nS5kVFhaNFkUYIALHHqKkjuEBXz4iDjH38fiPX6V63qPwstLuMy6beZgcYikR9ysOo+YcVizfC2WNXjE4R1wSfL3An3+vrQBwipaXP7t1ERIAGMtn3yen0pTb2TkQyzhSGIx0BHqDXUSfDnW5QyWrxknDJ55wwHt/8AXrJ1PwBrNl5bvGskT8nDYYHvgdqAKbaZBtGxjKFTJVT83P17/SkeyDLHJueRSP3chOXUY6PitCw8Na0yyRyWUtsCPlkZSN3/ANaqn/CN63BA0wtJnVOCE5CjruB6GgDPNpdIebYeb1WQEAEetEthcPu85VZWOeSOPqK07Tw9rD2rSRQzTW0pDEAEd+cUyTQtYS422lhLMBkFCSSue+7v9KAKAtZzjynjMK4Hup9KiS2aOSJJBHuZsHHJ/Gr1xp10086mOben8O3aF9frVNrO+nleGJZdxcYzGQG46f8A16ALs8LlsyNEy8gE9Pp71WkspnlJZggIBwrY3fgKcdPAZCRcRXpQkRkEpn/YPrTY7PUpJkKwPEFADFwQCfcdzQBGLYLCiOvkh8hS/OasxWcKRFZGt9o54bJYe/ertn4d1bUJhbw2czzHIbzFGSR/IYrZ034d38yxLfusbNn7qkkfUjtQBzS/YImVnt3kJJwFOB+POT9KqtqNvcusJtFUDPyYx+P1r0Cz+G1xHcm5E5QBMmRV35I4x7dKuSfC2e4P/H4EiY+YqunfHYmgDy2W5mhjJtpAVTgHaAUJ6HnrUQuLiUHbcyBj94lSPqAOma9ch+EwkmEK30yM6HiSLcrD+lPt/hUYowt1HP5XPETfNn056Z9aAPJCbdXEhZHkQ7WA4yP649Khkk8qQBsuV+64bnB7AV7ZD8K9DsJEa5xFEw3M08oTaf7uSetJH4f8GaXDN9v1fRGRWJRFuVYoAe4yf0oA8UiZipSENEwGQSoPXtirUOlXkv8AqLOSQthSVQ8E+x6ivWrvxJ8NrVhcG/Er7Svl2tuxZfoSAOaz5/i74UsZm/szRdRuUAyBK6RqzduOeKAOV0vwFql7dL58EkErHChuDwM5b0+ldppnwmtrOGXU9du1jgwC8jyeUoOecZ61xHiL4z+JNTVotOFvpUBOf3CBpD9Xb+gFefajql/qb79Rvbm6f1mlL/zNAHumr+NPAfhVEh0aEa3P0cRLsTj1cjn8K4vxJ8ZPEGpho9Jjg0WE97XJlI7Auf6AV5lRQBNd3U95cPPdzSTzuctJIxZifcmoaKKACiiigAooooAKKKKACiiigApV+8PrSUq/eH1oA9RPwxfXfMl8LWfiKLPMcep6ayq+T0Eq5X8wK841XTrzSNRuLDU7aW1vbdtksMq7WQ+4ro9M8f8AjPSpt9h4o1iLB4U3jsv/AHySR+laOofEzxBrLl/E0Ok665ATzL6xj8wKOgDoFb9aAOAortreXwfqylLzS9S0m6Kttk0+cTxluxMcmDj2Dim/EH4f3vgw2MlxeW11bXyGSBowyvtwPvqRgHnsTQBxdFSeU3qKPKb1FAEdFSeU3qKPKb1FAEdFSeU3qKPKb1FAEdFSeU3qKPKb1FAEdFSeU3qKPKb1FAEdFSeU3qKPKb1FAFux1fUrBNljf3dumc7IpmVc/QHFdNp3xP8AF9girDrMrqo2jzUV+PTJGa47ym9RR5TeooA9HtfjR4riI897G6Xp+9txn8CMVtWnx41OKXzbjQtNnkKhWYlgSBXj3lN6ijym9RQB7pB8fYpJWF/4bR4Dn5Y7nn6critGx+NnhU7DPod/andlljZHQ/hxXz15Teoo8pvUUAfRv/C3PBTsH8vVY2ViQvkqVIJ9N3Fa9l8UfAjhjbX72Kk7/Lntn6+20Gvlvym9RR5TeooA+pT4m+HGs3PmHW7WOTGW+0ROmT6gkVcGveDpYgkGtaMION/mSqG3Do2Tz+VfJ3lN6ijym9RQB9VN4r+HltHGt3rGnzfKVISNnGD6YBxWZc/EjwNZuCNTmvIVXYkUNq2QB0BLAelfNHlN6ijym9RQB9EXvxp8J2qu+maVqNxJIwYo+2IAjvnJNcTrfxr1u4lYaJa2mmQ7iQQvmyEe7N/hXlvlN6ijym9RQB3t38YPGVxbGEajFCG+80VugYj0zis5fiV4wW2Nv/b10Yj1DBWP5kZrk/Kb1FHlN6igDp2+Ifi4xhP+Eg1AKOm2Xb+orOufFXiG6BFxruqSg9Q13IR+WayfKb1FHlN6igAklklJMkjuTySxJzUdSeU3qKPKb1FAEdFSeU3qKPKb1FAEdFSeU3qKPKb1FAEdFSeU3qKPKb1FAEdFSeU3qKPKb1FAEdFSeU3qKPKb1FAEdFSeU3qKPKb1FAEdFSeU3qK3PBfhW98XeIbfR9OltoriYMVedmCDAyc4BPb0oA5+lUFiAoJPoK9G1TT/AAl4Mv7mwvbG/wDEOpQMUYzSC0t1IPZULO34sPoKzrjx9q6SD+xLfS9CjCFAunWio2D6yMC+ffdQBL4U+F/ijX9PbULfRL97LgI2Fi8zPdTIQCvvXf8AhTwvbeHrKSfXfhvb63JakSSmHW0mlQe8KE5Htg141qmsaxqyKuqarfXqqcqLm4eQA+24mqMHmwzpJFIUkUgqykgg+xoA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 54-year-old man presented with shortness of breath. CT chest demonstrated a right upper lobe mass with bronchial obstruction and right paratracheal adenopathy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_33_23060=[""].join("\n");
var outline_f22_33_23060=null;
var title_f22_33_23061="Botryoid rhabdomyosarcoma";
var content_f22_33_23061=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F76459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F76459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Botryoid rhabdomyosarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 351px; height: 468px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Botryoid variant of embryonal rhabdomyosarcoma involving the nasal cavity with overlying intact respiratory mucosa. Subepithelial dense aggregates of rhabdomyoblasts (the so-called \"cambrium\" layer) are characteristic. (H&amp;E, 200x original magnification).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_33_23061=[""].join("\n");
var outline_f22_33_23061=null;
var title_f22_33_23062="Cardiovascular effects of hyperthyroidism";
var content_f22_33_23062=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiovascular effects of hyperthyroidism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/33/23062/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/33/23062/contributors\">",
"     Irwin Klein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/33/23062/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/33/23062/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/33/23062/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/33/23062/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/33/23062/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hormone has important effects on cardiac muscle, the peripheral circulation, and the sympathetic nervous system that alter cardiovascular hemodynamics in a predictable way in patients with hyperthyroidism. The main changes are [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increases in heart rate, cardiac contractility, systolic and mean pulmonary artery pressure, cardiac output, diastolic relaxation, and myocardial oxygen consumption",
"     </li>",
"     <li>",
"      Reductions in systemic vascular resistance and diastolic pressure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major cardiovascular manifestations of hyperthyroidism will be reviewed here. Other symptoms associated with this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=see_link\">",
"     \"Overview of the clinical manifestations of hyperthyroidism in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cellular actions of thyroid hormone are mediated by the binding of triiodothyronine (T3) to nuclear receptors. It is T3 and not T4 that is transported into the cardiac myocyte. The subsequent binding of the T3-receptor complexes to DNA regulates the expression of genes, specifically those regulating calcium cycling in the cardiac myocyte [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. T3 may also have non-nuclear actions through mechanisms not yet fully understood [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Adrenergic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some actions of T3 on the heart produce clinical findings similar to those of beta-adrenergic stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/4\">",
"     4",
"    </a>",
"    ]. The interaction between T3 and the adrenergic nervous system is best exemplified by the ability of essentially all beta blockers to alleviate many of the symptoms of hyperthyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=see_link\">",
"     \"Beta blockers in the treatment of hyperthyroidism\"",
"    </a>",
"    .) This may involve increased beta-adrenergic receptor density, increased expression of the stimulatory guanine nucleotide-binding protein (G protein), and down-regulation of the cardiac-specific isoform of the adenylyl cyclase catalytic subunit [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Whether humans with hyperthyroidism have increased sensitivity to catecholamines is uncertain, but it seems clear that T3 effects on the heart can occur independently of beta-adrenergic receptor stimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Chronotropic and inotropic stimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthyroidism predictably increases heart rate and cardiac contractility [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Virtually all measures of cardiac function, including left ventricular ejection fraction, the rate of ventricular pressure development, diastolic relaxation, and cardiac output, are increased [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, cardiac output increases by as much as 250 percent and pulse pressure widens (",
"    <a class=\"graphic graphic_figure graphicRef85918 \" href=\"UTD.htm?33/21/34135\">",
"     figure 1",
"    </a>",
"    ). These functional changes are most likely the result of an increase in expression of myocardial sarcoplasmic reticulum calcium-dependent adenosine triphosphatase, a decrease in the expression of its inhibitor, phospholamban, and a decline in systemic vascular resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular symptoms and signs are common in patients with hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/8\">",
"     8",
"    </a>",
"    ], and in some patients, these symptoms predominate (",
"    <a class=\"graphic graphic_table graphicRef56219 \" href=\"UTD.htm?17/12/17611\">",
"     table 1",
"    </a>",
"    ). They include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tachycardia, at rest, during sleep, and exaggerated during exercise",
"     </li>",
"     <li>",
"      Palpitations, due to both tachycardia and more forceful cardiac contractility",
"     </li>",
"     <li>",
"      Hyperdynamic precordium, indicative of the increase in cardiac contractility",
"     </li>",
"     <li>",
"      Systolic hypertension with widened pulse pressure [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Exertional dyspnea, which is due more to respiratory and skeletal muscle weakness than cardiac dysfunction",
"     </li>",
"     <li>",
"      Angina-like chest pain, with EKG changes suggesting myocardial ischemia, which can occur especially in women; this appears to be the result of coronary vasospasm and responds to treatment with orally administered calcium channel blockers",
"     </li>",
"     <li>",
"      Increase in left ventricular mass index and left ventricular hypertrophy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased ventricular irritability, especially in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      treated patients with a prior history of ventricular ectopy (often in the setting of implanted cardiac defibrillators) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/12\">",
"       12",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increased vitamin K metabolism leading to an increase in sensitivity to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      anticoagulation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hyperthyroidism is also associated with an increased risk of atrial fibrillation, heart failure, pulmonary hypertension, and angina, as described in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Atrial fibrillation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthyroid patients with normal hearts have more premature supraventricular depolarizations, atrial premature contractions (APCs), more non-sustained supraventricular tachycardias, increased heart rate and reduced heart rate variability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/14\">",
"     14",
"    </a>",
"    ]. The latter is primarily the result of decreased parasympathetic tone. These electrical triggers may contribute to paroxysmal atrial tachycardia, atrial fibrillation, and atrial flutter. Among these arrhythmias, atrial fibrillation is the most common, occurring in 5 to 15 percent of patients, especially patients &ge;60 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/6,15,16\">",
"     6,15,16",
"    </a>",
"    ]. In a population-based study of 40,628 patients with clinical hyperthyroidism, 8.3 percent had atrial fibrillation or flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/15\">",
"     15",
"    </a>",
"    ]. Factors associated with increased risk included male sex, increasing age, coronary heart disease, heart failure, and valvular heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/4\">",
"     4",
"    </a>",
"    ]. The association with increasing age presumably reflects the age-related reduction in the threshold for developing atrial fibrillation.",
"   </p>",
"   <p>",
"    Complications of atrial fibrillation in patients with hyperthyroidism include heart failure and thromboembolism, although it remains controversial whether atrial fibrillation in hyperthyroidism is associated with a higher thromboembolic risk than atrial fibrillation in other settings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/1,6,16\">",
"     1,6,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=see_link\">",
"     \"Risk of embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The other atrial arrhythmias associated with hyperthyroidism are most likely to be detected by monitoring, because they do not often cause symptoms. The risk of ventricular arrhythmias in the nonischemic (normal) heart is not increased [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heart failure is most commonly seen as a result of coexistent atrial fibrillation. In one study, only 6 percent of hyperthyroid patients had heart failure, average age was 66 years; 94 percent had coexistent atrial fibrillation and 47 percent had left ventricular systolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/17\">",
"     17",
"    </a>",
"    ]. In others, it is a complication of prolonged marked sinus tachycardia. The signs and symptoms of heart failure resolve when the ventricular rate is slowed, normal sinus rhythm is restored, and the patients are rendered euthyroid [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/4,5,17\">",
"     4,5,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, only 6 percent of 591 consecutive hyperthyroid patients had heart failure; half had left ventricular (LV) systolic dysfunction with LV ejection fraction &lt;50 percent, and 85 percent had resolution of LV dysfunction after attaining euthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heart failure in the absence of underlying cardiac disease or arrhythmia is thought to reflect a rate-related cardiomyopathy, which disappears when the hyperthyroidism is treated. There is no clear histopathologic correlate of this cardiomyopathy, and treatment is primarily directed at rate control with beta-adrenergic blockade [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/5\">",
"     5",
"    </a>",
"    ]. Pulmonary hypertension can also produce signs of isolated right heart failure with a rise in central venous pressure, neck vein distension, and hepatic congestion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Pulmonary hypertension'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=see_link\">",
"     \"Tachycardia-mediated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperthyroidism is associated with an increase in N-terminal pro-B natriuretic peptide (NT-proBNP) in hyperthyroid patients without cardiac insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/19\">",
"     19",
"    </a>",
"    ]. NT-proBNP was positively correlated with LV end-diastolic diameter and interventricular septal thickness, and negatively correlated with LV ejection fraction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/19\">",
"     19",
"    </a>",
"    ]. Mild iatrogenic hyperthyroidism is also associated with an increase in NT-proBNP, without a measurable increase in systolic blood pressure or pulse pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/19\">",
"     19",
"    </a>",
"    ]. This may reflect the increased atrial size which results from increased renal sodium reabsorption, plasma volume, or pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tricuspid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mitral regurgitation have also been described in patients with hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary hypertension (PH) has been reported with increasing frequency in patients with overt hyperthyroidism. Pulmonary artery pressures average twice normal values (10 mmHg) and may be as high as 30 to 50 mmHg. These changes reverse with treatment of the hyperthyroidism and may reflect the increase in cardiac output without the concomitant decline in pulmonary vascular resistance observed in the systemic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Angina pectoris",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with angina may have chest pain more often when they become hyperthyroid, presumably because of the increase in cardiac oxygen consumption, due either to a direct effect of T3 on cardiac muscle or to an increase in peripheral oxygen demand. In the young patient with normal coronary anatomy, this may be due to coronary vasospasm (Prinzmetal Angina).",
"   </p>",
"   <p>",
"    Other patients first develop angina when they become hyperthyroid. In a hospital-based study of 1049 patients who were admitted emergently, 6 percent had high serum T3 concentrations at the time of admission; these patients had a 2.6-fold higher risk of having angina pectoris or a myocardial infarction at that time, as compared with those patients with normal serum T3 concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemic cerebrovascular disease is a rare complication of hyperthyroidism. However, cardiogenic embolism may occur due to atrial fibrillation. In addition, multiple intracranial stenoses, similar to that seen in moyamoya disease, have been described in several patients with Graves' disease, especially those of Asian origin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=see_link\">",
"     \"Neurologic manifestations of hyperthyroidism and Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUBCLINICAL HYPERTHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with subclinical hyperthyroidism (normal serum thyroid hormone and low serum TSH concentrations) have more subtle cardiac findings. These include increases in heart rate and cardiac contractility and modest degrees of cardiac hypertrophy and, at least in the elderly, a sixfold increase in risk of atrial fibrillation as compared with euthyroid subjects (",
"    <a class=\"graphic graphic_figure graphicRef55024 \" href=\"UTD.htm?19/0/19469\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/25\">",
"     25",
"    </a>",
"    ]. Subclinical hyperthyroidism is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=see_link\">",
"     \"Subclinical hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cardiovascular manifestations of hyperthyroidism are best corrected by treating the hyperthyroidism, whether with radioactive iodine or an antithyroid drug, with the former being the preferred therapy in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/6,26\">",
"     6,26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=see_link\">",
"     \"Radioiodine in the treatment of hyperthyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=see_link\">",
"     \"Thionamides in the treatment of Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Beta blockers, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    (120 to 160",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    are also useful in relieving palpitations and in slowing the heart rate in patients with sinus tachycardia.",
"   </p>",
"   <p>",
"    Additional measures may be needed in patients with atrial fibrillation, marked palpitations, or severe tachycardia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/1,5,27\">",
"     1,5,27",
"    </a>",
"    ]. The management of atrial fibrillation is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H26#H26\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Patients with hyperthyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with overt heart failure, standard therapy including diuretics and digitalis should be given if the patient is elderly, known or suspected to have preexisting heart disease or hypertension, or the heart failure does not improve when the heart rate is slowed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    .) In certain circumstances, especially with severe hyperthyroidism or thyroid storm, intensive cardiovascular monitoring and treatment of other comorbid conditions (infection, trauma, acute psychiatric illness) is required [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23062/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33655?source=see_link\">",
"     \"Thyroid storm\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3253683\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cellular actions of thyroid hormone are mediated by the binding of triiodothyronine (T3) to nuclear receptors. The subsequent binding of the T3-receptor complexes to DNA regulates the expression of genes, specifically those regulating calcium cycling in the cardiac myocyte. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some actions of T3 on the heart produce clinical findings similar to those of beta-adrenergic stimulation. Hyperthyroidism predictably increases heart rate and cardiac contractility. Virtually all measures of cardiac function, including left ventricular ejection fraction, the rate of ventricular pressure development, diastolic relaxation, and cardiac output, are increased (",
"      <a class=\"graphic graphic_table graphicRef56219 \" href=\"UTD.htm?17/12/17611\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Chronotropic and inotropic stimulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperthyroidism is also associated with an increased risk of atrial fibrillation, heart failure, pulmonary hypertension, and angina-like symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cardiovascular manifestations of hyperthyroidism are best corrected by treating the hyperthyroidism, whether with radioactive iodine or an antithyroid drug. Beta blockers, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      (120 to 160",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"       atenolol",
"      </a>",
"      (50",
"      <span class=\"nowrap\">",
"       mg/day),",
"      </span>",
"      are also useful in relieving palpitations and in slowing the heart rate in patients with sinus tachycardia. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=see_link\">",
"       \"Radioiodine in the treatment of hyperthyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=see_link\">",
"       \"Thionamides in the treatment of Graves' disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=see_link\">",
"       \"Beta blockers in the treatment of hyperthyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Additional measures may be needed in patients with atrial fibrillation, marked palpitations, severe tachycardia, or heart failure. In certain circumstances, especially with severe hyperthyroidism or thyroid storm, intensive cardiovascular monitoring and treatment of other comorbid conditions (infection, trauma, acute psychiatric illness) is required. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H26#H26\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Patients with hyperthyroidism'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33655?source=see_link\">",
"       \"Thyroid storm\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/1\">",
"      Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/2\">",
"      Brent GA. The molecular basis of thyroid hormone action. N Engl J Med 1994; 331:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/3\">",
"      Davis PJ, Davis FB. Nongenomic actions of thyroid hormone on the heart. Thyroid 2002; 12:459.",
"     </a>",
"    </li>",
"    <li>",
"     Klein I. Endocrine disorders and cardiovascular disease. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, 9th, Bonow RO, Mann DL, Zipes DP, Libby P (Eds), Elsevier Saunders, Philadelphia 2012. p.1829.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/5\">",
"      Ventrella, S, Klein, I. Beta-adrenergic receptor blocking drugs in the management of hyperthyroidism. Endocrinologist 1994; 4:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/6\">",
"      Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007; 116:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/7\">",
"      Mintz G, Pizzarello R, Klein I. Enhanced left ventricular diastolic function in hyperthyroidism: noninvasive assessment and response to treatment. J Clin Endocrinol Metab 1991; 73:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/8\">",
"      Osman F, Franklyn JA, Holder RL, et al. Cardiovascular manifestations of hyperthyroidism before and after antithyroid therapy: a matched case-control study. J Am Coll Cardiol 2007; 49:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/9\">",
"      Iglesias P, Acosta M, S&aacute;nchez R, et al. Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function. Clin Endocrinol (Oxf) 2005; 63:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/10\">",
"      Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993; 77:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/11\">",
"      D&ouml;rr M, Wolff B, Robinson DM, et al. The association of thyroid function with cardiac mass and left ventricular hypertrophy. J Clin Endocrinol Metab 2005; 90:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/12\">",
"      Dahl P, Danzi S, Klein I. Thyrotoxic cardiac disease. Curr Heart Fail Rep 2008; 5:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/13\">",
"      Kellett HA, Sawers JS, Boulton FE, et al. Problems of anticoagulation with warfarin in hyperthyroidism. Q J Med 1986; 58:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/14\">",
"      Wustmann K, Kucera JP, Zanchi A, et al. Activation of electrical triggers of atrial fibrillation in hyperthyroidism. J Clin Endocrinol Metab 2008; 93:2104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/15\">",
"      Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med 2004; 164:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/16\">",
"      Petersen P. Thromboembolic complications in atrial fibrillation. Stroke 1990; 21:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/17\">",
"      Siu CW, Yeung CY, Lau CP, et al. Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart 2007; 93:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/18\">",
"      Ismail HM. Reversible pulmonary hypertension and isolated right-sided heart failure associated with hyperthyroidism. J Gen Intern Med 2007; 22:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/19\">",
"      Schultz M, Kistorp C, Langdahl B, et al. N-terminal-pro-B-type natriuretic peptide in acute hyperthyroidism. Thyroid 2007; 17:237.",
"     </a>",
"    </li>",
"    <li>",
"     Danzi S, Klein I. Treatment of hypertension and thyroid disease. In: Advanced Therapy in Hypertension and Vascular Disease, Mohler ER, Townsend RR (Eds), BC Decker Inc., Ontario, Canada 2006. p.354.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/21\">",
"      Lozano HF, Sharma CN. Reversible pulmonary hypertension, tricuspid regurgitation and right-sided heart failure associated with hyperthyroidism: case report and review of the literature. Cardiol Rev 2004; 12:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/22\">",
"      Merc&eacute; J, Ferr&aacute;s S, Oltra C, et al. Cardiovascular abnormalities in hyperthyroidism: a prospective Doppler echocardiographic study. Am J Med 2005; 118:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/23\">",
"      Siu CW, Zhang XH, Yung C, et al. Hemodynamic changes in hyperthyroidism-related pulmonary hypertension: a prospective echocardiographic study. J Clin Endocrinol Metab 2007; 92:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/24\">",
"      Peters A, Ehlers M, Blank B, et al. Excess triiodothyronine as a risk factor of coronary events. Arch Intern Med 2000; 160:1993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/25\">",
"      Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/26\">",
"      DELIT C, SILVER S, YOHALEM SB, SEGAL RL. Thyrocardiac disease and its management with radioactive iodine I-131. JAMA 1961; 176:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23062/abstract/27\">",
"      Featherstone HJ, Stewart DK. Angina in thyrotoxicosis. Thyroid-related coronary artery spasm. Arch Intern Med 1983; 143:554.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7853 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-197.136.42.3-BB90AC98B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_33_23062=[""].join("\n");
var outline_f22_33_23062=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3253683\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Adrenergic effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Chronotropic and inotropic stimulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Angina pectoris",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUBCLINICAL HYPERTHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3253683\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7853\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7853|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/21/34135\" title=\"figure 1\">",
"      Thyroid hormone changes cardiac output",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/0/19469\" title=\"figure 2\">",
"      Increased incidence of AF in subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7853|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/12/17611\" title=\"table 1\">",
"      Heart in hyperthyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/17/275?source=related_link\">",
"      Beta blockers in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=related_link\">",
"      Neurologic manifestations of hyperthyroidism and Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14279?source=related_link\">",
"      Overview of the clinical manifestations of hyperthyroidism in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=related_link\">",
"      Radioiodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/22/23913?source=related_link\">",
"      Subclinical hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/29/27097?source=related_link\">",
"      Tachycardia-mediated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=related_link\">",
"      Thionamides in the treatment of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33655?source=related_link\">",
"      Thyroid storm",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_33_23063="JE map distribution";
var content_f22_33_23063=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    Geographic distribution of Japanese encephalitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 366px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Center for Disease Control and Prevention 2010 Yellow Book. Japanese encephalitis. Available at: file://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-2/japanese-encephalitis.aspx.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_33_23063=[""].join("\n");
var outline_f22_33_23063=null;
var title_f22_33_23064="Ziprasidone: Pediatric drug information";
var content_f22_33_23064=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ziprasidone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"    see \"Ziprasidone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?21/5/21590?source=see_link\">",
"    see \"Ziprasidone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F235894\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Geodon&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5498099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zeldox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1043093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antipsychotic Agent, Atypical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1043131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"      see \"Ziprasidone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Bipolar I disorder:",
"     </b>",
"     Children and Adolescents 10-17 years:",
"     <b>",
"      Note:",
"     </b>",
"     In June 2009, an FDA advisory panel advised that ziprasidone is effective in patients 10-17 years of age for the treatment of mixed and manic episodes of bipolar disorder, but did not conclude that it was safe due to large number of subjects lost to follow-up and ambiguity within QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation data; limited data available (DelBello, 2008; DelBello, 2008a; Elbe, 2008; Findling, 2008; Mechcatie, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Initial dose:  20 mg/day; titrate dose upwards as tolerated, using twice daily dosing over a 2-week period to the weight-based target range: 60-80 mg/day (&le;45 kg) divided into twice daily doses or 120-160 mg/day (&gt;45 kg) divided into twice daily doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Alternate dosing: An open-label, 8-week study of 21 patients [6-17 years (mean: 10.3 years)] with bipolar disorder and comorbid conditions (eg, ADHD, depression, conduct disorder) used the following weight-based dosing regimen (Biederman, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Initial dose: 1 mg/kg/day divided twice daily; increase to 1.5 mg/kg/day divided twice daily by  Week 2 and increase to 2 mg/kg/day divided twice daily by Week 3 if tolerated; maximum dose: 160 mg/day;",
"     <b>",
"      Note:",
"     </b>",
"     Only 14 of the 21 patients completed the study; five dropped out due to lack of efficacy; two dropped out due to adverse reactions; patients experienced a high incidence of sedation (46%) and headaches (38%).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Tourette's syndrome, tic disorder:",
"     </b>",
"     Children and Adolescents 7-16 years: Limited data available; dose not established. Initial dose: 5 mg/day for 3 days then using twice daily dosing, titrate dose as tolerated up to 40 mg/day divided twice daily.  Dosing is based on a double-blind, placebo-controlled pilot study (n=28), mean daily dose at the end of trial: 28.2 + 9.6 mg/day (Sallee, 2000).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Autism and PDD-NOS  irritability:",
"     </b>",
"     Children and Adolescents 8-20 years: Limited data available; dose not established. Reported final dose range: 20-160 mg/day divided twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     A prospective, open-labeled study of 12 patients (12-18 years) used the following individually titrated doses (Malone, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Patient weight &le;35 kg: Initial: 20 mg every other day given at bedtime for 2 doses; then increase dose in weekly increments based on clinical response and tolerability: Week 1: 10 mg twice daily (20 mg/day); Week 2: 20 mg twice daily (40 mg/day); Week 3: 40 mg twice daily (80 mg/day); Week 4: 80 mg twice daily (160 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:10em;\">",
"     Patient weight &gt;35 kg: Initial: 20 mg/day at bedtime for 3 doses; then increase dose in weekly increments based on clinical response and tolerability: Week 1: 20 mg twice daily (40 mg/day); Week 2: 40 mg twice daily (80 mg/day); Week 4: 80 mg twice daily (160 mg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     A case series of 12 patients (8-20 years) initiated with 20 mg/day given at bedtime and then increased by 10-20 mg/week divided twice daily based on clinical response and tolerability; final ziprasidone dosage ranged between 20-120 mg/day (mean: ~60 mg/day) divided twice daily (McDougle, 2002)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: Acute agitation (schizophrenia): Children and Adolescents: Limited information available; dose not established (Barzman, 2007; Khan, 2006; Staller, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children 5-11 years: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents &ge;12 years: 10-20 mg;",
"     <b>",
"      Note:",
"     </b>",
"     One study (n=59; age range: 5-19 years) reported that 69% of 20 mg doses surpassed the desired calming therapeutic effect and caused varying degrees of sedation (4% of patients were unable to be aroused) (Barzman, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Bipolar mania: Initial: 40 mg twice daily; adjustment: May increase to 60 or 80 mg twice daily on second day of treatment; average dose 40-80 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Schizophrenia: Initial: 20 mg twice daily; adjustment: Increases (if indicated) should be made no more frequently than every 2 days; ordinarily patients should be observed for improvement over several weeks before adjusting the dose. Maintenance: Range: 20-100 mg twice daily; however, dosages &gt;80 mg twice daily are generally not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: Acute agitation (schizophrenia): 10 mg every 2 hours",
"     <b>",
"      or",
"     </b>",
"     20 mg every 4 hours; maximum: 40 mg/day; oral therapy should replace I.M. administration as soon as possible. Use &gt;3 days has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Oral: No dosage adjustment is recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: Cyclodextrin, an excipient in the I.M. formulation, is cleared by renal filtration; use with caution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     No dosage adjustment is recommended; use with caution",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F235867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 20 mg, 40 mg, 60 mg, 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Geodon&reg;: 20 mg, 40 mg, 60 mg, 80 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as mesylate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Geodon&reg;: 20 mg [contains cyclodextrin]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F235853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1043137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Administer with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Injection is for I.M. use only; do not administer I.V. Reconstitute with 1.2 mL SWI for final concentration 20 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1043117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Store at controlled room temperature of 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Store at controlled room temperature of 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F). Protect from light. Following reconstitution, injection may be stored at room temperature up to 24 hours or up to 7 days if refrigerated and protected from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1043094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to its greater capacity to prolong the QT interval, ziprasidone is generally not considered to be a first-line agent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Treatment of schizophrenia (FDA approved in adults); treatment as monotherapy of acute manic or mixed episodes associated with bipolar disorder with or without psychosis (FDA approved in adults); maintenance adjunctive therapy (to lithium or valproate) for bipolar I disorder (FDA approved in adults).",
"     <b>",
"      Note:",
"     </b>",
"     In June 2009, an FDA advisory panel advised that ziprasidone is effective in patients 10-17 years of age for the treatment of mixed and manic episodes of bipolar disorder, but did not conclude that it was safe due to large number of subjects lost to follow-up and ambiguity within QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation data. Has also been used in children and adolescents for treatment of Tourette's syndrome, tic disorders, irritability associated with autism, and pervasive development disorders not otherwise specified (PDD-NOS).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Acute agitation in patients with schizophrenia (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F10524190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ziprasidone may be confused with TraZODone",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F235924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, chest pain, facial edema, hypertension, orthostatic hypotension, tachycardia, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, akathisia, akinesia, amnesia, anxiety, ataxia, chills, confusion, coordination abnormal, delirium, dizziness, dystonia, extrapyramidal symptoms, fever, headache, hostility, hypothermia, insomnia, oculogyric crisis, personality disorder, psychosis, somnolence, speech disorder, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Fungal dermatitis, photosensitivity reaction, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, anorexia, buccoglossal syndrome, constipation, diarrhea, dyspepsia, dysphagia, nausea, rectal hemorrhage, salivation increased, tongue edema, vomiting, weight gain, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Priapism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Abnormal gait, back pain, choreoathetosis, cogwheel rigidity, dysarthria, dyskinesia, hyper-/hypokinesia, hyper-/hypotonia, hypoesthesia, myalgia, neuropathy, paresthesia, tremor, twitching, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Diplopia, vision abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, infection, pharyngitis, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, flank pain, flu-like syndrome, furunculosis, withdrawal syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abnormal ejaculation, albuminuria, alkaline phosphatase increased, allergic reaction, alopecia, amenorrhea, anemia, angioedema, angina, anorgasmia, atrial fibrillation, AV block (first degree), basophilia, blepharitis, bruising, BUN increased, bundle branch block, cardiomegaly, cataract, cerebral infarction, cerebrovascular accident, cholestatic jaundice, circumoral paresthesia, conjunctivitis, contact dermatitis, CPK increased, creatinine (serum) increased, dehydration, depression, dry eyes, eczema, enuresis, eosinophilia, epistaxis, exfoliative dermatitis, facial droop, fatty liver, fecal impaction, galactorrhea, GGT increased, gingival bleeding, glycosuria, gout, gynecomastia, hematemesis, hemoptysis, hematuria, hepatitis, hepatomegaly, hyper-/hypochloremia, hyper-/hypocholesterolemia, hyper-/hypoglycemia, hyper-/hypokalemia, hyper-/hypothyroidism, hyperlipemia, hyper-reflexia, hyperuricemia, hypocalcemia, hypomagnesemia, hyponatremia, hypoproteinemia, impotence, jaundice, keratitis, keratoconjunctivitis, ketosis, lactation (female), laryngismus, LDH increased, leukocytosis, leukopenia, leukoplakia (mouth), lymphadenopathy, lymphedema, lymphocytosis, maculopapular rash, mania/hypomania, melena, menorrhagia, metrorrhagia, monocytosis, myocarditis, myoclonus, myopathy, neuroleptic malignant syndrome, nocturia, nystagmus, ocular hemorrhage, oliguria, opisthotonos, paralysis, peripheral edema, phlebitis, photophobia, pneumonia, polycythemia, polyuria, pulmonary embolism, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation &gt;500 msec, respiratory alkalosis, seizure, serotonin syndrome, sexual dysfunction (male and female), syncope, tardive dyskinesia, tenosynovitis, thirst, thrombocytopenia, thrombocythemia, thrombophlebitis, thyroiditis, tinnitus, torsade de pointes, torticollis, transaminases increased, trismus, urinary incontinence, urinary retention, urticaria, uterine hemorrhage, vaginal hemorrhage, vesiculobullous rash, visual field defect",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1043100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ziprasidone or any component; known history or current prolonged QT interval; congenital long-QT syndrome; recent myocardial infarction; history of arrhythmias; uncompensated heart failure; concurrent use of other QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging agents, including arsenic trioxide, chlorpromazine, cisapride, class Ia antiarrhythmics (disopyramide, quinidine, procainamide), class III antiarrhythmics (amiodarone, dofetilide, ibutilide, sotalol), dolasetron, droperidol, gatifloxacin, levomethadyl, mefloquine, mesoridazine, moxifloxacin, pentamidine, pimozide, probucol, sparfloxacin, tacrolimus, and thioridazine",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F9837215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with seizure disorders (rare seizure reports); in suicidal patients, in patients with concomitant systemic illnesses or unstable heart disease or a recent history of MI (these patients not adequately studied); and in patients at risk of aspiration pneumonia (esophageal dysmotility and aspiration have been associated with antipsychotic agents).  May cause orthostatic hypotension; use with caution in patients at risk for this effect or in those who would not tolerate transient hypotensive episodes (eg, cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication which predisposes to hypotension). Use with caution in patients with breast cancer or other prolactin-dependent tumors; ziprasidone increases prolactin  concentrations; high concentrations of prolactin may reduce pituitary gonadotropin secretion; galactorrhea, amenorrhea, gynecomastia, impotence, decreased bone density may occur. Use with caution in children and adolescents; adverse effects due to increased prolactin concentrations have been observed; long-term effects on growth or sexual maturation have not been evaluated. May cause somnolence (dose-related), priapism (rarely), alteration of temperature regulation; use with caution in patients exposed to temperature extremes.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Use with caution in patients with hepatic disease or impairment. Use with caution during diarrheal illnesses; monitor electrolytes closely (K and Mg) (Blair, 2004). Use the intramuscular formulation with caution in patients with renal impairment due to cyclodextrin excipient, an excipient which may accumulate in renal insufficiency.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1043101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Ziprasidone is generally not considered to be a first-line agent; dose-related prolongation of the QT",
"     <sub>",
"      c",
"     </sub>",
"     may occur and may be associated with torsade de pointes and sudden death. Observed QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation with ziprasidone was greater than with other atypical antipsychotic agents (eg, risperidone, olanzapine, quetiapine), but less than with thioridazine. A prospective study followed 20 children (mean age: 13.2 years) for an average of 4.6 months and reported significant QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation at relatively low ziprasidone doses (mean daily dose: 30 mg &plusmn; 13 mg/day); the authors suggest the effect is not dose-dependent in children unlike adults and recommend reserving ziprasidone use as second- or third-line for patients at risk for QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation or when using doses &gt;40 mg/day (Blair, 2005). Hypokalemia or hypomagnesemia may increase risk of torsade de pointe and/or sudden death; baseline electrolyte measurements are recommended. Use caution in patients with bradycardia. Discontinue in patients found to have persistent QT",
"     <sub>",
"      c",
"     </sub>",
"     intervals &gt;500 msec. Patients with symptoms of dizziness, palpitations, or syncope should receive further cardiac evaluation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause neuroleptic malignant syndrome; symptoms include hyperpyrexia, altered mental status, muscle rigidity, autonomic instability, acute renal failure, rhabdomyolysis, and increased CPK. May cause extrapyramidal reactions, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia. Risk of these reactions is dose-dependent. To decrease risk of tardive dyskinesia: Use smallest dose and shortest duration possible; evaluate continued need periodically. Risk of dystonia is increased with the use of high potency and higher doses of conventional antipsychotics and in males and younger patients. May cause hyperglycemia, which may be severe and include potentially fatal ketoacidosis or hyperosmolar coma; use with caution and monitor glucose closely in patients with diabetes mellitus (or with risk factors such as family history or obesity); measure fasting blood glucose at the beginning of therapy and periodically during therapy in these patients; monitor for symptoms of hyperglycemia in all patients treated with ziprasidone; measure fasting blood glucose in patients who develop symptoms. May cause development of a dose-related rash and/or urticaria (5%) which may also involve systemic illness; discontinue if alternative cause cannot be identified. Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports with antipsychotic use; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment. Discontinue therapy at first signs of blood dyscrasias or if absolute neutrophil count &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An increased risk of death has been reported with the use of antipsychotics in elderly patients with dementia-related psychosis",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; most deaths seemed to be cardiovascular (eg, sudden death, heart failure) or infectious (eg, pneumonia) in nature. An increased incidence of cerebrovascular adverse events (eg, transient ischemic attack, stroke), including fatalities, has been reported with the use of antipsychotics in elderly patients with dementia-related psychosis. Ziprasidone is not approved for the treatment of patients with dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pediatric psychiatric disorders are frequently serious mental disorders which present with variable symptoms that do not always match adult diagnostic criteria. Conduct a thorough diagnostic evaluation and carefully consider risks of psychotropic medication before initiation in pediatric patients. Medication therapy for pediatric patients with bipolar disorder is indicated as part of a total treatment program that frequently includes educational, psychological, and social interventions.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F235911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F235861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Ziprasidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): Antipsychotics (Atypical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Ziprasidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F10865971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food increases absorption by up to twofold.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F235863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F235877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Developmental toxicity demonstrated in animals. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies risk to the fetus. Healthcare providers are encouraged to enroll women 18-45 years of age exposed to ziprasidone during pregnancy in the Atypical Antipsychotics Pregnancy Registry (1-866-961-2388 or file://www.womensmentalhealth.org/pregnancyregistry).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1043140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; serum potassium and magnesium; CBC with differential; fasting lipid profile and fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     (prior to treatment, at 3 months, then annually); weight, BMI, waist circumference; personal/family history of diabetes; blood pressure; mental status, abnormal involuntary movement scale (AIMS), extrapyramidal symptoms. Weight should be assessed prior to treatment, at 4 weeks, 8 weeks, 12 weeks, and then at quarterly intervals. Consider titrating to a different antipsychotic agent for a weight gain &ge;5% of the initial weight. Monitor patient periodically for symptom resolution.  In children, baseline and periodic (eg, when initially reach steady state, with dose changes or addition of an interacting drug) ECG monitoring in children has been recommended by several pediatric clinicians (Blair, 2004; Blair, 2005; Elbe, 2008). Discontinue drug in patients found to have persistent QT",
"     <sub>",
"      c",
"     </sub>",
"     intervals &gt;500 msec.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1043120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ziprasidone is a benzylisothiazolylpiperazine antipsychotic; its therapeutic effects may be mediated through a combination of antagonist activity at D",
"     <sub>",
"      2",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      2A",
"     </sub>",
"     , and 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     receptors and agonist activity at the 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     receptor; it may cause orthostatic hypotension via its antagonist activity at adrenergic alpha",
"     <sub>",
"      1",
"     </sub>",
"     receptors. It also moderately inhibits the reuptake of serotonin and norepinephrine. Ziprasidone has high affinity for D",
"     <sub>",
"      2",
"     </sub>",
"     , D",
"     <sub>",
"      3",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      2A",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      2C",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      1D",
"     </sub>",
"     , and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -adrenergic receptors; and no appreciable affinity for alpha",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors, beta-adrenergic, 5-HT",
"     <sub>",
"      3",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      4",
"     </sub>",
"     , cholinergic, mu, sigma, or benzodiazepine receptors. It has moderate affinity for histamine H",
"     <sub>",
"      1",
"     </sub>",
"     receptors which may account for somnolence.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1043122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed; presence of food increases by up to twofold",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Apparent V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%, primarily to albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic, primarily via aldehyde oxidase; less than",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     of total metabolism via CYP3A4 and CYP1A2 (minor)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: I.M.: 100%, Oral: ~60% under fed conditions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: 2-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: Mean: 3.3-4.1 hours (Sallee, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adult: 7 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M.: &le;60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: Mean: 5-5.5 hours (Sallee, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adult: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Feces (66%) and urine (20%) as metabolites; little as unchanged drug (&lt;1% urine, &lt;4% feces)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children: Mean: 11.5-13.1 mL/minute/kg (Sallee, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adult: Mean: 7.5 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dialysis:  Not removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1043144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/5/21590?source=see_link\">",
"      see \"Ziprasidone: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause dizziness or drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth; may cause postural hypotension, especially during initial dose titration (use caution when changing position from lying or sitting to standing).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Report the use of other medications, nonprescription medications, and herbal or natural products to your physician and pharmacist; avoid alcohol and the herbal medicine, St John's wort. Report persistent CNS effects (eg, trembling fingers, altered gait or balance, excessive sedation, seizures, unusual muscle or skeletal movements), rapid heartbeat, severe dizziness, vision changes, skin rash, weight gain or loss, or worsening of condition to your physician. If you have diabetes, monitor blood glucose concentrations closely at beginning of therapy and periodically thereafter (may cause hyperglycemia). Patients may be more vulnerable to overheating and dehydration while taking this medication; maintain adequate hydration unless advised by prescriber to restrict fluids. May rarely cause photosensitivity reactions; avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); use a sunscreen; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1043146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-term usefulness of ziprasidone should be periodically re-evaluated in patients receiving the drug for extended periods of time. A Phase III trial designed to evaluate ziprasidone in adolescents with schizophrenia was terminated early due to lack of efficacy; no safety concerns were noted.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Agitation and/or aggression after traumatic brain injury (TBI):  A case series of 20 patients [ages: 9 months to 17 years (median: 8 years)] reported using age-based ziprasidone dosing during the immediate TBI recovery phase with a total duration of therapy range of 3-8 days.  To discontinue, ziprasidone dose was tapered over ~2 days. Doses were initiated at a low dose and titrated up based on agitation level and Riker SAS score; however, minimal dosage adjustments were required during the study. The drug appeared to be safe and effective; further studies are needed (Scott, 2009). Initial dosing:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;2 years: 1.7 mg/kg/day divided 2-3 times/day (final dose: 1.8 mg/kg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     2-6 years: 0.9 mg/kg/day divided twice daily (final dose: 1.5 mg/kg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     7-12 years: 0.7 mg/kg/day divided twice daily (final dose: 1.5 mg/kg/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &ge;13 years: 0.6 mg/kg/day divided twice daily (final dose: 0.7 mg/kg/day)",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10806709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 2.5 mg/mL oral solution may be made with the injection. Use 8 vials of the 20 mg injectable powder. Add 1.2 mL of distilled water to each vial to make a 20 mg/mL solution. Once dissolved, transfer 7.5 mL to a calibrated bottle and add quantity of vehicle (Ora-Sweet&reg;) sufficient to make 60 mL. Label \"shake well\" and \"refrigerate\". Stable for 14 days at room temperature or 42 days refrigerated (preferred).",
"    </p>",
"    <div class=\"reference\">",
"     Green K and Parish RC, \"Stability of Ziprasidone Mesylate in an Extemporaneously Compounded Oral Solution,\"",
"     <i>",
"      J Pediatr Pharmacol Ther",
"     </i>",
"     , 2010, 15:138-41.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Barzman DH, DelBello MP, Forrester JJ, et al, \"A Retrospective Chart Review of Intramuscular Ziprasidone for Agitation in Children and Adolescents on Psychiatric Units: Prospective Studies Are Needed,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2007, 17(4):503-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/33/23064/abstract-text/17822344/pubmed\" id=\"17822344\" target=\"_blank\">",
"        17822344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Biederman J, Mick E, Spencer T, et al, \"A Prospective Open-Label Treatment Trial of Ziprasidone Monotherapy in Children and Adolescents With Bipolar Disorder,\"",
"      <i>",
"       Bipolar Disord",
"      </i>",
"      , 2007, 9(8):888-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/33/23064/abstract-text/18076539/pubmed\" id=\"18076539\" target=\"_blank\">",
"        18076539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blair J, Scahill L, State M, et al, \"Electrocardiographic Changes in Children and Adolescents Treated With Ziprasidone: A Prospective Study,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2005, 44(1):73-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/33/23064/abstract-text/15608546 /pubmed\" id=\"15608546 \" target=\"_blank\">",
"        15608546",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blair J, Taggart B, and Martin A, \"Electrocardiographic Safety Profile and Monitoring Guidelines in Pediatric Psychopharmacology,\"",
"      <i>",
"       J Neural Transm",
"      </i>",
"      , 2004, 111(7):791-815.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/33/23064/abstract-text/15205999/pubmed\" id=\"15205999\" target=\"_blank\">",
"        15205999",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DelBello MP, Findling RL, Wang PP, et al, \"Efficacy and Safety of Ziprasidone in Pediatric Bipolar Disorder,\" Presented at the 161st Annual Meeting of the American Psychiatric Association (APA); May 3-8, 2008; Washington DC (poster).",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DelBello MP, Versavel M, Ice K, et al, \"Tolerability of Oral Ziprasidone in Children and Adolescents With Bipolar Mania, Schizophrenia, or Schizoaffective Disorder,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2008a, 18(5):491-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/33/23064/abstract-text/18928413/pubmed\" id=\"18928413\" target=\"_blank\">",
"        18928413",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Elbe D and Carandang CG, \"Focus on Ziprasidone: A Review of Its Use in Child and Adolescent Psychiatry,\"",
"      <i>",
"       J Can Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2008, 17(4):220-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/33/23064/abstract-text/19018327/pubmed\" id=\"19018327\" target=\"_blank\">",
"        19018327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Findling RL, DelBello MP, Wang PP, et al, \"Long-Term Safety and Tolerability of Ziprasidone in Pediatric Bipolar Disorder,\" Presented at the 161st Annual Meeting of the American Psychiatric Association (APA); May 3-8, 2008; Washington DC (poster).",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Juncos JL, Shea SA, Stover N, et al, \"Safety and Efficacy of Ziprasidone in Tourette Syndrome,\"",
"      <i>",
"       Movement Disord",
"      </i>",
"      , 2002, 17(5):S340 (abstract).",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khan SS and Mican LM, \"A Naturalistic Evaluation of Intramuscular Ziprasidone Versus Intramuscular Olanzapine for the Management of Acute Agitation and Aggression in Children and Adolescents,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2006, 16(6):671-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/33/23064/abstract-text/17201611/pubmed\" id=\"17201611\" target=\"_blank\">",
"        17201611",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Malone RP, Delaney MA, Hyman SB, et al, \"Ziprasidone in Adolescents With Autism: An Open-Label Pilot Study,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2007, 17(6):779-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/33/23064/abstract-text/18315450/pubmed\" id=\"18315450\" target=\"_blank\">",
"        18315450",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDougle CJ, Kem DL, and Posey DJ, \"Case Series: Use of Ziprasidone for Maladaptive Symptoms in Youths With Autism,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2002, 41(8):921-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/33/23064/abstract-text/12164181/pubmed\" id=\"12164181\" target=\"_blank\">",
"        12164181",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mechcatie, E, &ldquo;MD Consult: News: Mixed Votes on Ziprasidone&rsquo;s Safety and Efficacy for Pediatric Indications, &ldquo; June 16, 2009. Date accessed: January 20, 2010.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sallee FR, Miceli JJ, Tensfeldt T, et al, \"Single-Dose Pharmacokinetics and Safety of Ziprasidone in Children and Adolescents,\"",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2006, 45(6):720-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/33/23064/abstract-text/16721322/pubmed\" id=\"16721322\" target=\"_blank\">",
"        16721322",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sallee FR, Kurlan R, Goetz CG, et al, &ldquo;Ziprasidone Treatment of Children and Adolescents With Tourette's Syndrome: A Pilot Study,&rdquo;",
"      <i>",
"       J Am Acad Child Adolesc Psychiatry",
"      </i>",
"      , 2000, 39(3):292-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Scott LK, Green R, McCarthy PJ, et al, \"Agitation and/or Aggression After Traumatic Brain Injury in the Pediatric Population Treated With Ziprasidone. Clinical Article,\"",
"      <i>",
"       J Neurosurg Pediatr",
"      </i>",
"      , 2009, 3(6):484-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/33/23064/abstract-text/19485732/pubmed\" id=\"19485732\" target=\"_blank\">",
"        19485732",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Staller JA, \"Intramuscular Ziprasidone in Youth: A Retrospective Chart Review,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2004, 14(4):590-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/33/23064/abstract-text/15662151/pubmed\" id=\"15662151\" target=\"_blank\">",
"        15662151",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15622 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-125.69.132.100-B0D0D57A02-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_33_23064=[""].join("\n");
var outline_f22_33_23064=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708843\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235894\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5498099\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043093\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043131\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235867\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235853\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043137\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043117\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043094\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10524190\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235924\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043100\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9837215\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043101\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235911\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235861\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10865971\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235863\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F235877\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043140\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043120\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043122\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043144\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1043146\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10806709\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15622\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15622|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=related_link\">",
"      Ziprasidone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?21/5/21590?source=related_link\">",
"      Ziprasidone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_33_23065="Management of hypertensive emergencies and urgencies in children";
var content_f22_33_23065=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of hypertensive emergencies and urgencies in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/33/23065/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/33/23065/contributors\">",
"     Joseph T Flynn, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/33/23065/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/33/23065/contributors\">",
"     George A Woodward, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/33/23065/contributors\">",
"     F Bruder Stapleton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/33/23065/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/33/23065/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/33/23065/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute severe hypertension resulting in hypertensive emergencies and urgencies occurs infrequently in children. Proper management of this potentially life-threatening condition and prevention of its complications depend on prompt recognition and treatment.",
"   </p>",
"   <p>",
"    The clinician should understand that there is a spectrum of severity of acute hypertension. Any classification scheme that divides the clinical presentation of acute severe hypertension into &rdquo;urgent&rdquo; or &ldquo;emergent&rdquo; is by its nature arbitrary [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Clinical findings, especially symptoms manifested by the patient, must be used to gauge the severity of acute hypertension and guide management.",
"   </p>",
"   <p>",
"    This topic discusses the rapid assessment and treatment of hypertensive emergencies and urgencies in children. The diagnostic evaluation to acute severe hypertension is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17241?source=see_link\">",
"     \"Approach to hypertensive emergencies and urgencies in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute severe hypertension has traditionally been divided into hypertensive emergencies and hypertensive urgencies. The clinician should understand that there is a spectrum of severity of acute hypertension. Any classification scheme that divides the clinical presentation of acute severe hypertension into separate categories is by its nature arbitrary [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Clinical judgment must be used to gauge the severity of acute hypertension and guide management.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypertension in children is defined as either systolic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic blood pressure (BP) &ge;95th percentile measured upon three or more occasions. As in adults, hypertension in children is further divided into the two following stages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Stage 1 hypertension",
"      </strong>",
"      &ndash; Systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP between the 95th percentile and 5 mmHg above the 99th percentile.",
"     </li>",
"     <li>",
"      <strong>",
"       Stage 2 hypertension",
"      </strong>",
"      &ndash; Systolic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic BP &ge;99th percentile plus 5 mmHg.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision process for evaluation and treatment varies with the severity of the hypertension. Stage 2 identifies those children who need more prompt evaluation and immediate pharmacologic treatment, while stage 1 hypertension allows for more time for evaluation and initial treatment with nonpharmacologic therapy unless the patient is symptomatic or has hypertensive target-organ damage. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link&amp;anchor=H2#H2\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Definition'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hypertensive emergency",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acute severe symptomatic elevation in BP",
"    <strong>",
"     WITH",
"    </strong>",
"    evidence of potentially life-threatening symptoms or target organ damage defines a hypertensive emergency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Blood pressures are commonly elevated far above the level at which stage 2 hypertension is diagnosed.",
"   </p>",
"   <p>",
"    The most commonly involved organs are the brain, kidneys, eyes, and heart. Careful intervention to lower blood pressure should begin emergently upon recognition of a hypertensive emergency and should be accomplished with intravenous antihypertensive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hypertensive emergencies in children usually manifest as hypertensive encephalopathy: severe BP elevation with neurological symptoms of lethargy, coma,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/1,2,6\">",
"     1,2,6",
"    </a>",
"    ]. Cardiopulmonary manifestations (congestive heart failure, pulmonary edema) may also be seen. The absolute level of BP elevation is less important than whether symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    target end organ damage is present. For example, a child with chronic hypertension may have very high BP measurements without symptoms. Another child with an acute rise in BP may manifest a hypertensive emergency despite a BP that seems to be only moderately elevated. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Hypertensive urgency'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypertensive urgency",
"    </span>",
"    &nbsp;&mdash;&nbsp;An acute severe elevation in BP",
"    <strong>",
"     WITHOUT",
"    </strong>",
"    severe symptoms or evidence of acute target organ damage describes a hypertensive urgency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The duration of hypertension (acute or chronic) is an important determinant of intervention. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Hypertensive urgency goal'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to a patient presenting to the emergency department with acute severe hypertension requires immediate confirmation of marked BP elevation, rapid assessment of severity of disease, exclusion of causes of severe hypertension for which rapid reduction of BP might be harmful, and prompt initiation of antihypertensive therapy (",
"    <a class=\"graphic graphic_table graphicRef82046 \" href=\"UTD.htm?14/13/14557\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/1,2,4-9\">",
"     1,2,4-9",
"    </a>",
"    ]. Knowledge of the most prevalent etiologies by age group also helps guide treatment decisions (",
"    <a class=\"graphic graphic_table graphicRef73225 \" href=\"UTD.htm?37/15/38139\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17241?source=see_link\">",
"     \"Approach to hypertensive emergencies and urgencies in children\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18\">",
"     'Specific pediatric hypertensive emergencies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Confirmation of severe hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with less severe hypertension, once an elevated BP is discovered, the measurement should be confirmed, preferably using auscultation with careful attention to cuff size and placement. A BP cuff that is too small will artificially elevate the BP reading (",
"    <a class=\"graphic graphic_figure graphicRef73414 \" href=\"UTD.htm?1/0/1025\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58304 \" href=\"UTD.htm?36/49/37659\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link&amp;anchor=H13#H13\">",
"     \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Technique of BP measurement'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A reliable method for obtaining frequent repeat blood pressures (intra-arterial line, oscillometric device) should be established to assist with ongoing management.",
"   </p>",
"   <p>",
"    Specific causes of hypertension that may require other management approaches should be identified before antihypertensive treatment is started. These etiologies would include aortic coarctation, head trauma, intracranial mass lesion, sympathomimetic drug overdose, and severe pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20922?source=see_link\">",
"     \"Management of coarctation of the aorta\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coarctation of the aorta\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"     \"Initial approach to severe traumatic brain injury in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     General measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the presence of severe acute hypertension is confirmed, the patient should be placed in a treatment area that can support critical care functions and monitoring. Treatment includes (",
"    <a class=\"graphic graphic_table graphicRef82046 \" href=\"UTD.htm?14/13/14557\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Placement of continuous cardiorespiratory and pulse oximetry.",
"     </li>",
"     <li>",
"      Frequent, continual BP monitoring (eg, automatic BP measurements every minute).",
"     </li>",
"     <li>",
"      Assessment of airway and breathing and performance of endotracheal intubation in patients with depressed mental status, respiratory failure, or status epilepticus. Patients with findings suggestive of head trauma require cervical spine immobilization and maintenance of inline cervical stabilization during airway procedures. Medications that might increase blood pressure (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/18/40229?source=see_link\">",
"       ketamine",
"      </a>",
"      ) should be avoided during rapid sequence intubation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=see_link\">",
"       \"Emergent endotracheal intubation in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=see_link\">",
"       \"Pediatric cervical spine immobilization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravenous access consisting of two IV lines, if possible. Initial laboratory studies should be obtained, if not already available (",
"      <a class=\"graphic graphic_table graphicRef57292 \" href=\"UTD.htm?11/26/11691\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17241?source=see_link&amp;anchor=H18#H18\">",
"       \"Approach to hypertensive emergencies and urgencies in children\", section on 'Ancillary studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intra-arterial measurement of BP, if possible during antihypertensive therapy. However, treatment should not be delayed by arterial cannulation. Frequently repeated BP measurement by means of auscultation or an automatic oscillometric BP device may suffice during initial care.",
"     </li>",
"     <li>",
"      Seizures, if present, should be treated with anticonvulsants, such as",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"       lorazepam",
"      </a>",
"      (initial dose: 0.05 to 0.1",
"      <span class=\"nowrap\">",
"       mg/kg)",
"      </span>",
"      until seizures stop. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=see_link\">",
"       \"Management of status epilepticus in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Blood pressure management",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no randomized clinical trials evaluating management of pediatric hypertensive emergencies. Despite the lack of evidence, many antihypertensive agents have found widespread use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/2\">",
"     2",
"    </a>",
"    ]. Treatment recommendations are based upon limited pediatric evidence from small observational studies and have been largely extrapolated from randomized controlled trials in adults. The choice of medication should be dictated by the suspected underlying cause of the hypertensive emergency. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Specific pediatric hypertensive emergencies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Studies in adults suggest that intravenous medications are superior to oral medications for hypertensive emergencies and that a controlled decrease in BP typically avoids permanent hypertension-induced organ damage AND ischemic end organ damage related to overly rapid lowering of BP. An experienced clinician, such as a pediatric nephrologist or intensivist, should guide therapy of pediatric hypertensive emergencies whenever possible once emergency care is accomplished. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=see_link\">",
"     \"Malignant hypertension and hypertensive encephalopathy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Hypertensive emergency goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend that children with acute severe hypertension and life-threatening symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    target-organ involvement should emergently receive intravenous medication that lowers blood pressure in a controlled fashion by no more than 25 percent over the first eight hours of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/2-4,9,10\">",
"     2-4,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the author's experience, this goal can be accomplished by first administering one to two intravenous boluses of an antihypertensive medication (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=see_link\">",
"     labetalol",
"    </a>",
"    0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/53/4949?source=see_link\">",
"     hydralazine",
"    </a>",
"    0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per dose) followed by the initiation of a continuous infusion of labetalol or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/38/32361?source=see_link\">",
"     nicardipine",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_algorithm graphicRef65359 \" href=\"UTD.htm?9/22/9582\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef80380 \" href=\"UTD.htm?1/60/1997\">",
"     table 5",
"    </a>",
"    ). The infusion rate should be titrated to maintain a blood pressure no more than 25 percent below the presenting value during the first eight hours of treatment and to prevent additional symptomatic blood pressure increases.",
"   </p>",
"   <p>",
"    Overly rapid lowering of BP by more than 25 percent in the first eight hours of treatment can cause irreversible target organ damage, including permanent neurologic sequelae, visual defects, myocardial infarction, and renal insufficiency due to abnormalities of autoregulation induced by chronic hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/1,5,7,11\">",
"     1,5,7,11",
"    </a>",
"    ]. The amount of time taken for further blood pressure reduction after the initial eight hours of therapy will depend on the clinical setting. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'First line intravenous agents'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H15\">",
"     'Other intravenous agents'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Specific pediatric hypertensive emergencies'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hypertensive urgency goal",
"    </span>",
"    &nbsp;&mdash;&nbsp;A child with a hypertensive urgency warrants an immediate evaluation. When the urgency arises from an acute process with a rapid change in mean arterial pressure (eg, poststreptococcal glomerulonephritis), intervention should occur promptly (within hours), and treatment with intravenous antihypertensive medications is appropriate (",
"    <a class=\"graphic graphic_table graphicRef80380 \" href=\"UTD.htm?1/60/1997\">",
"     table 5",
"    </a>",
"    ). However, in the setting of a chronic condition (eg, chronic kidney disease), where blood pressure has increased gradually over time, lowering of the blood pressure should occur less quickly (eg, over one to two days or more), and oral medications should be used (eg, oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7879?source=see_link\">",
"     isradipine",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef57259 \" href=\"UTD.htm?15/44/16076\">",
"     table 6",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef65359 \" href=\"UTD.htm?9/22/9582\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Mode of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest that pediatric hypertensive emergencies be managed with continuous intravenous antihypertensive administration (",
"    <a class=\"graphic graphic_table graphicRef80380 \" href=\"UTD.htm?1/60/1997\">",
"     table 5",
"    </a>",
"    ). This approach allows for rapid modification of treatment based upon patient response [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/1,2,6,9\">",
"     1,2,6,9",
"    </a>",
"    ]. There is a wide range of dosing for continuous intravenous infusion of antihypertensive agents. In general, the clinician should start with the lowest dose of the range and adjust the infusion rate based on BP response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     First line intravenous agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/38/32361?source=see_link\">",
"     Nicardipine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=see_link\">",
"     labetalol",
"    </a>",
"    are typically used in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/2,9\">",
"     2,9",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/48/5895?source=see_link\">",
"     Esmolol",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/35/5684?source=see_link\">",
"     fenoldopam",
"    </a>",
"    are less frequently employed. Sodium",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/52/40773?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , which had commonly been used in the past, is no longer recommended as a first-line agent due to problems with cyanide toxicity, especially when used in children with renal impairment or when used for prolonged periods, unless other agents are unavailable (",
"    <a class=\"graphic graphic_table graphicRef80380 \" href=\"UTD.htm?1/60/1997\">",
"     table 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. Further information regarding pharmacology and side effects of these medications is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18853?source=see_link\">",
"     \"Drug treatment of hypertensive emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with volume overload also require diuretic therapy, for example,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    bolus dose IV, to maximize antihypertensive treatment effect, but diuretics should never be used alone in such patients.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/38/32361?source=see_link\">",
"       Nicardipine",
"      </a>",
"      &ndash; Some experts recommend the following: Initial: 0.5 to 1",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per minute; titrate dose according to blood pressure; rate of infusion may be increased every 15 to 30 minutes; maximum dose: 4 to 5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per minute. Bolus doses of 30",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      have been reported effective in adults but have not been studied in children. (See",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?12/10/12453?source=see_link\">",
"       \"Nicardipine: Patient drug information\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=see_link\">",
"       Labetalol",
"      </a>",
"      &ndash; An alpha and beta adrenergic blocker, labetalol is given as an initial bolus of 0.2 to 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum dose: 40 mg) followed by an infusion of 0.25 to 3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour. Limited information regarding labetalol use in pediatric patients is currently available in the literature [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/13\">",
"       13",
"      </a>",
"      ]; labetalol should be initiated cautiously in pediatric patients (using the lower doses listed) with careful dosage adjustment and blood pressure monitoring. (See",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=see_link\">",
"       \"Labetalol: Pediatric drug information\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Other intravenous agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/53/4949?source=see_link\">",
"     Hydralazine",
"    </a>",
"    is an acceptable alternative to bolus-dose",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=see_link\">",
"     labetalol",
"    </a>",
"    .",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/36/14917?source=see_link\">",
"     Phentolamine",
"    </a>",
"    may be indicated in specific forms of severe hypertension due to excessive circulating catecholamines. Recent clinical trials have expanded the information available on pediatric use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/48/5895?source=see_link\">",
"     esmolol",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/35/5684?source=see_link\">",
"     fenoldopam",
"    </a>",
"    , but these agents aren't widely used.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/20/19783?source=see_link\">",
"     Enalaprilat",
"    </a>",
"    may occasionally be useful in children, but must be used with extreme caution because of significant risk for inducing renal insufficiency (",
"    <a class=\"graphic graphic_table graphicRef80380 \" href=\"UTD.htm?1/60/1997\">",
"     table 5",
"    </a>",
"    ).",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/11/13492?source=see_link\">",
"     Diazoxide",
"    </a>",
"    is no longer recommended for treatment of pediatric hypertensive emergencies because of uncontrolled and excessive lowering of blood pressure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/53/4949?source=see_link\">",
"       Hydralazine",
"      </a>",
"      &ndash; A direct vasodilator of arterial smooth muscle, hydralazine can be given as a bolus dose of 0.2 to 0.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum dose: 20 mg). Onset of action is slower than",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/38/32361?source=see_link\">",
"       nicardipine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=see_link\">",
"       labetalol",
"      </a>",
"      , and duration of action is longer than either of these agents. Previous reports of overshoot hypotension with target organ ischemia were probably related to use of high doses of hydralazine. It is also suggested for use in treatment of preeclampsia. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Specific pediatric hypertensive emergencies'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link&amp;anchor=H3#H3\">",
"       \"Management of hypertension in pregnant and postpartum women\", section on 'Preeclampsia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/36/14917?source=see_link\">",
"       Phentolamine",
"      </a>",
"      &ndash; An alpha adrenergic blocker, phentolamine is given as an intravenous bolus in a dose of 0.1",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      maximum dose 5 mg, for the treatment of secondary hypertension caused by excessive circulating catecholamines (eg, pheochromocytoma, cocaine or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/8/20613?source=see_link\">",
"       pseudoephedrine",
"      </a>",
"      overdose) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. (See",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/36/14917?source=see_link\">",
"       \"Phentolamine: Pediatric drug information\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/48/5895?source=see_link\">",
"       Esmolol",
"      </a>",
"      &ndash; A beta adrenergic blocker, esmolol is given as 100 to 500",
"      <span class=\"nowrap\">",
"       micrograms/kg",
"      </span>",
"      loading dose followed by an initial infusion of 50 to 150",
"      <span class=\"nowrap\">",
"       micrograms/kg",
"      </span>",
"      per minute; titrate dose by 50 to 100",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per minute every 10 minutes until desired effect or maximum dose of 1000",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per minute is reached. It is most commonly used in the operating room or intensive care settings after cardiac surgery due to the rapidity of its onset of action and short duration of effect. (See",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/48/5895?source=see_link\">",
"       \"Esmolol: Pediatric drug information\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/35/5684?source=see_link\">",
"       Fenoldopam",
"      </a>",
"      &ndash; A peripheral dopamine receptor agonist, fenoldopam is given as a starting infusion of 0.2",
"      <span class=\"nowrap\">",
"       micrograms/kg",
"      </span>",
"      per minute; the dose is titrated at 15 minute intervals, depending upon the blood pressure response to a maximum of 0.8",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per minute (the loading dose may be omitted according to some published recommendations). Fenoldopam is less potent than other intravenous agents and is therefore not recommended for first-line use. (See",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35284?source=see_link\">",
"       \"Fenoldopam: Drug information\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/20/19783?source=see_link\">",
"       Enalaprilat",
"      </a>",
"      &ndash; Intravenous bolus of enalaprilat, an angiotensin converting enzyme inhibitor, is sometimes used for patients with high renin states (eg, renal parenchymal disease). However, the safe and effective pediatric dose is unknown, and it may cause prolonged hypotension and renal insufficiency, especially in neonates [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Use of oral antihypertensive agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral antihypertensive agents are not recommended for use in treatment of children with hypertensive emergencies but are useful in some children with hypertensive urgencies arising from chronic conditions (eg, chronic kidney disease) and associated with relatively slow rise in mean arterial BP (",
"    <a class=\"graphic graphic_table graphicRef57259 \" href=\"UTD.htm?15/44/16076\">",
"     table 6",
"    </a>",
"    ). Potential agents include",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"     clonidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7879?source=see_link\">",
"     isradipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/53/4949?source=see_link\">",
"     hydralazine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/47/31472?source=see_link\">",
"     minoxidil",
"    </a>",
"    . Short-acting oral",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/2/9256?source=see_link\">",
"     nifedipine",
"    </a>",
"    is no longer recommended in children due to difficulties with dosing, prolonged and unpredictable action, risk of hypotension, and rebound hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"       Clonidine",
"      </a>",
"      &ndash; A centrally-acting alpha 2-adrenergic agonist, clonidine reduces blood pressure by reducing cerebral sympathetic output. It has a relatively rapid onset of effect, approximately 15 to 30 minutes following oral administration [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/18\">",
"       18",
"      </a>",
"      ], making it attractive for use in management of acute hypertension. Although the effective dose for acute hypertension in infants and toddlers is unknown, doses of 0.05 to 0.1",
"      <span class=\"nowrap\">",
"       mg/dose",
"      </span>",
"      may be used in older children and adolescents, and can be repeated hourly for up to eight hours (maximum total dose: 0.8 mg) until the desired blood pressure is reached.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7879?source=see_link\">",
"       Isradipine",
"      </a>",
"      &ndash; A rapidly acting calcium channel blocker, isradipine usually reduces blood pressure within one hour of administration, with its peak effect occurring in two to three hours [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/19\">",
"       19",
"      </a>",
"      ]. Doses of 0.05 to 0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose are usually effective. Lower doses of 0.03 to 0.05",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose should probably be used in children less than two years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/20\">",
"       20",
"      </a>",
"      ]. Unlike",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/2/9256?source=see_link\">",
"       nifedipine",
"      </a>",
"      , a stable extemporaneous suspension of isradipine can be compounded, facilitating precise dosing, even in infants and small children.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/53/4949?source=see_link\">",
"       Hydralazine",
"      </a>",
"      &ndash; As discussed above, hydralazine is a direct vasodilator usually given in doses of 0.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      when administered orally. Its onset of action is 30 minutes to two hours. Duration of action varies from 6 to 12 hours.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?30/47/31472?source=see_link\">",
"       Minoxidil",
"      </a>",
"      &ndash; Another direct arterial vasodilator, minoxidil opens potassium channels in vascular smooth muscle cells, causing potassium efflux, which in turn leads to hyperpolarization and relaxation. Doses of 0.1 to 0.2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per dose up to 10",
"      <span class=\"nowrap\">",
"       mg/dose",
"      </span>",
"      have been used in children [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/21\">",
"       21",
"      </a>",
"      ]. Minoxidil is the most potent oral vasodilator and also has the longest duration of action, up to 8 to 12 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Ongoing antihypertensive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Further antihypertensive therapy in children who have experienced a hypertensive emergency is best guided by a pediatric nephrologist or other physician with expertise in the management of pediatric hypertension.",
"   </p>",
"   <p>",
"    Once initial control of severe hypertension is achieved, plans should be made for further diagnostic evaluation and correction of any identifiable underlying cause, if possible. If an intravenous infusion was required to control the child's blood pressure, gradual conversion to oral antihypertensive medications should be undertaken until definitive treatment can be arranged.",
"   </p>",
"   <p>",
"    If the underlying cause cannot be corrected so that hypertension is abolished, or if hypertension persists after treatment, chronic pharmacologic therapy should be continued. Choice of drug depends on the underlying cause of hypertension, physician comfort, and the presence of any co-morbid conditions (eg, diabetes mellitus and kidney disease). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=see_link&amp;anchor=H23#H23\">",
"     \"Treatment of hypertension in children and adolescents\", section on 'Choice of drug'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-pharmacologic measures (eg, salt restriction, weight control) should be utilized in conjunction with antihypertensive medications in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of hypertension in children and adolescents\", section on 'Management approach'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rare patient with primary hypertension as the cause of their acute severe hypertension should also receive both non-pharmacologic and pharmacologic therapy. Non-pharmacologic measures, if successfully adhered to by the patient, offer the possibility of eventual discontinuation of drug therapy, especially if obesity is a significant contributor to the blood pressure elevation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=see_link&amp;anchor=H20#H20\">",
"     \"Treatment of hypertension in children and adolescents\", section on 'Management approach'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SPECIFIC PEDIATRIC HYPERTENSIVE EMERGENCIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient age and etiology of the hypertensive emergency also determine the optimal therapy in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hypertensive encephalopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of a continuous infusion of an intravenous antihypertensive agent is imperative to avoid producing cerebral ischemia from overly rapid blood pressure reduction (",
"    <a class=\"graphic graphic_table graphicRef80380 \" href=\"UTD.htm?1/60/1997\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/2,5,22\">",
"     2,5,22",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=see_link\">",
"     Labetalol",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/38/32361?source=see_link\">",
"     nicardipine",
"    </a>",
"    are typically used in this clinical setting; sodium",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/52/40773?source=see_link\">",
"     nitroprusside",
"    </a>",
"    (IV continuous infusion: Start 0.3 to 0.5",
"    <span class=\"nowrap\">",
"     mcg/kg/minute,",
"    </span>",
"    titrate to effect; usual dose: 3",
"    <span class=\"nowrap\">",
"     mcg/kg/minute;",
"    </span>",
"    maximum dose: 8 to 10",
"    <span class=\"nowrap\">",
"     mcg/kg/minute,",
"    </span>",
"    give",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/56/1924?source=see_link\">",
"     sodium thiosulfate",
"    </a>",
"    on regular schedule during infusion) may be considered due to its rapid onset and short duration of action, but cannot be used for prolonged periods of time due to the risk of cyanide toxicity. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'First line intravenous agents'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Great care must be taken to differentiate hypertensive encephalopathy from hypertension associated with acute intracranial injury or an intracranial mass lesion for which antihypertensive treatment is contraindicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=see_link\">",
"     \"Initial approach to severe traumatic brain injury in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=see_link\">",
"     \"Elevated intracranial pressure in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with acute kidney injury or underlying chronic kidney disease and hypertensive emergencies may require dialysis in addition to antihypertensive treatment, depending on the degree of renal impairment.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=see_link\">",
"     Labetalol",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/38/32361?source=see_link\">",
"     nicardipine",
"    </a>",
"    avoid the potential for cyanide toxicity seen with sodium",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/52/40773?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , especially if high dose or long duration of antihypertensive therapy is anticipated (",
"    <a class=\"graphic graphic_table graphicRef80380 \" href=\"UTD.htm?1/60/1997\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/23\">",
"     23",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/20/19783?source=see_link\">",
"     Enalaprilat",
"    </a>",
"    may be very effective in these patients due to blockade of the renin-angiotensin system, but may exacerbate renal insufficiency.",
"   </p>",
"   <p>",
"    Since many patients with renal disease and hypertension are volume overloaded, diuretics (eg, intravenous",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/26/5544?source=see_link\">",
"     furosemide",
"    </a>",
"    1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    initial bolus dose; maximum 40 to 80 mg in patients with moderate renal insufficiency) should be considered as adjunctive treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40710?source=see_link&amp;anchor=H2#H2\">",
"     \"Loop diuretics: Maximum effective dose and major side effects\", section on 'Maximum effective dose'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Neonatal hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited experience suggests that",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/38/32361?source=see_link\">",
"     nicardipine",
"    </a>",
"    is the drug of choice for this age group (",
"    <a class=\"graphic graphic_table graphicRef80380 \" href=\"UTD.htm?1/60/1997\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37833?source=see_link\">",
"     \"Etiology, clinical features, and diagnosis of neonatal hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/38/32361?source=see_link\">",
"     Nicardipine",
"    </a>",
"    has been reported as effective in reducing hypertension caused by many different etiologies in neonates, including renal artery thrombosis, coarctation of the aorta, bronchopulmonary dysplasia, polycystic kidney disease and renal vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=see_link\">",
"     Labetalol",
"    </a>",
"    may be relatively contra-indicated if bronchopulmonary dysplasia is also present.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/20/19783?source=see_link\">",
"     Enalaprilat",
"    </a>",
"    should generally be avoided in neonates due to their high-renin state as it may cause prolonged oliguria [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/2,16\">",
"     2,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Coarctation of the aorta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although preoperative patients typically do not receive antihypertensive agents, if severe symptoms are present, consideration should be given to use of either",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=see_link\">",
"     labetalol",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/48/5895?source=see_link\">",
"     esmolol",
"    </a>",
"    until a corrective procedure can be performed. In neonates, prostaglandin E1 reopens the ductus arteriosus so that blood flow bypasses the coarctation and stabilizes the patient prior to repair. Patients with heart failure should receive inotropic support with dopamine or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/48/25348?source=see_link\">",
"     dobutamine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20922?source=see_link\">",
"     \"Management of coarctation of the aorta\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Post-coarctectomy hypertension, while less common in the current era, is likely caused by activation of the renin-angiotensin system and increased circulating catecholamines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/27\">",
"     27",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/38/32361?source=see_link\">",
"     Nicardipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=see_link\">",
"     labetalol",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/48/5895?source=see_link\">",
"     esmolol",
"    </a>",
"    have been successfully used in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Sodium",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/52/40773?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , which had been used in the past for postoperative hypertension, has fallen out of favor because it may increase myocardial oxygen consumption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Preeclampsia/eclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delivery of the fetus prevents progression of maternal hypertension and avoids fetal complications. Severe preeclampsia dictates delivery if the pregnancy is beyond 32 weeks gestation. Women who have severe preeclampsia at less than 32 weeks require management at a tertiary care obstetrical center [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=see_link&amp;anchor=H31268927#H31268927\">",
"     \"Preeclampsia: Management and prognosis\", section on 'Severe preeclampsia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=see_link\">",
"     Labetalol",
"    </a>",
"    is the first line treatment for severe preeclampsia in pregnant women.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/53/4949?source=see_link\">",
"     Hydralazine",
"    </a>",
"    is an acceptable alternative although it is associated with a greater risk of maternal hypotension.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/38/32361?source=see_link\">",
"     Nicardipine",
"    </a>",
"    has also been used successfully [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Sodium",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/52/40773?source=see_link\">",
"     nitroprusside",
"    </a>",
"    is contraindicated because of potential cyanide toxicity in the fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=see_link&amp;anchor=H53704941#H53704941\">",
"     \"Management of hypertension in pregnant and postpartum women\", section on 'Drugs to avoid in pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Cocaine or amphetamine overdose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indirect alpha adrenergic effects cause increased norepinephrine release and decreased reuptake. Hypertension is frequently transient, and many patients need no specific treatment.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?25/22/25959?source=see_link\">",
"     Lorazepam",
"    </a>",
"    (1 mg IV every five minutes, 0.05",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every five minutes in children) is often effective in treating hypertension and agitation in this clinical setting. Patients experiencing hypertensive emergencies after cocaine or amphetamine exposure should initially receive",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/36/14917?source=see_link\">",
"     phentolamine",
"    </a>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    maximum dose: 5 mg). Patients with chest pain should also receive sublingual",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/7/34934?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    . Beta adrenergic blockers are contraindicated because they can cause unopposed alpha adrenergic effects with exacerbation of hypertension and myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23065/abstract/15,35\">",
"     15,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=see_link\">",
"     \"Cocaine: Acute intoxication\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8735200\">",
"    <span class=\"h2\">",
"     Pheochromocytomas and paragangliomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The signs and symptoms of pheochromocytomas and paragangliomas are caused by hypersecretion of norepinephrine, epinephrine, and dopamine by the tumor; although increased central sympathetic activity also may contribute. The classic triad of symptoms in these disorders consists of episodic headache, sweating, and tachycardia, usually accompanied by hypertension. Abdominal pain and back pain are also common in children. Although surgical resection is the primary treatment, all patients should be treated with a medical regimen prior to surgery to reduce the risk of perioperative complications from catecholamine release. Alpha adrenergic blockade with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/58/19364?source=see_link\">",
"     phenoxybenzamine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/63/27638?source=see_link\">",
"     doxazosin",
"    </a>",
"    , or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?29/20/30021?source=see_link\">",
"     prazosin",
"    </a>",
"    is typically employed as initial treatment, with the addition of beta blockade only after alpha blockade has been accomplished. Alternatively, calcium channel blockers or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/25/2452?source=see_link\">",
"     metyrosine",
"    </a>",
"    may be used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38121?source=see_link&amp;anchor=H2#H2\">",
"     \"Pheochromocytoma in children\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38121?source=see_link&amp;anchor=H20#H20\">",
"     \"Pheochromocytoma in children\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Definition",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An acute severe elevation in BP",
"      <strong>",
"       WITHOUT",
"      </strong>",
"      severe symptoms and evidence of acute end organ damage describes a hypertensive urgency. A child with hypertensive urgency warrants an immediate evaluation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hypertensive urgency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An acute severe elevation in BP",
"      <strong>",
"       WITH",
"      </strong>",
"      severe, life-threatening symptoms",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      evidence of acute end organ damage establishes the presence of a hypertensive emergency. Hypertensive emergencies in children usually manifest as hypertensive encephalopathy: severe BP elevation with neurological symptoms of lethargy, coma,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      seizures. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Hypertensive emergency'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Management of hypertensive emergency",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once an elevated BP is discovered, the measurement should be confirmed, preferably using auscultation with careful attention to cuff size and placement. A BP cuff that is too small will artificially elevate the BP reading (",
"      <a class=\"graphic graphic_figure graphicRef73414 \" href=\"UTD.htm?1/0/1025\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef58304 \" href=\"UTD.htm?36/49/37659\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=see_link&amp;anchor=H13#H13\">",
"       \"Definition and diagnosis of hypertension in children and adolescents\", section on 'Technique of BP measurement'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The approach to a patient presenting to the emergency department with severe hypertension requires immediate confirmation of marked BP elevation, rapid assessment of severity of disease, exclusion of other causes of severe hypertension for which rapid reduction of BP might be harmful, and prompt institution of antihypertensive therapy (",
"      <a class=\"graphic graphic_table graphicRef82046 \" href=\"UTD.htm?14/13/14557\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef65359 \" href=\"UTD.htm?9/22/9582\">",
"       algorithm 1",
"      </a>",
"      ). Knowledge of the most prevalent etiologies by age group also helps guide treatment decisions (",
"      <a class=\"graphic graphic_table graphicRef73225 \" href=\"UTD.htm?37/15/38139\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17241?source=see_link&amp;anchor=H19#H19\">",
"       \"Approach to hypertensive emergencies and urgencies in children\", section on 'Etiology of hypertensive emergency'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H18\">",
"       'Specific pediatric hypertensive emergencies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with a hypertensive emergency should receive intravenous medication to lower BP. We suggest treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=see_link\">",
"       labetalol",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/38/32361?source=see_link\">",
"       nicardipine",
"      </a>",
"      &nbsp;(",
"      <a class=\"graphic graphic_table graphicRef80380 \" href=\"UTD.htm?1/60/1997\">",
"       table 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef65359 \" href=\"UTD.htm?9/22/9582\">",
"       algorithm 1",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Nicardipine is preferred in children with contraindications for labetalol (eg, asthma, bronchopulmonary dysplasia, or heart failure). We recommend that the BP be lowered in a controlled fashion by no more than 25 percent over the first eight hours of treatment (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Hypertensive emergency goal'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'First line intravenous agents'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Other intravenous agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patient age and etiology of the hypertensive emergency also determine the optimal therapy in children (see",
"      <a class=\"local\" href=\"#H18\">",
"       'Specific pediatric hypertensive emergencies'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Management of hypertensive urgency",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A child with hypertensive urgency warrants an immediate evaluation. We suggest that children with hypertensive urgencies, who have a rapid rise in mean arterial blood pressure associated with an acute condition (eg, poststreptococcal glomerulonephritis), receive intravenous bolus doses of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=see_link\">",
"       labetalol",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/53/4949?source=see_link\">",
"       hydralazine",
"      </a>",
"      to control blood pressure (BP) promptly (",
"      <a class=\"graphic graphic_table graphicRef80380 \" href=\"UTD.htm?1/60/1997\">",
"       table 5",
"      </a>",
"      )&nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest that children with hypertensive urgencies, who have a gradual rise in mean arterial BP associated with a chronic condition (eg, chronic kidney disease), receive oral medications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In these patients, lowering of blood pressure should occur less rapidly (eg, hours to days), and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/14/13545?source=see_link\">",
"       clonidine",
"      </a>",
"      or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/44/7879?source=see_link\">",
"       isradipine",
"      </a>",
"      are commonly used (",
"      <a class=\"graphic graphic_table graphicRef57259 \" href=\"UTD.htm?15/44/16076\">",
"       table 6",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef65359 \" href=\"UTD.htm?9/22/9582\">",
"       algorithm 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/1\">",
"      Adelman RD, Coppo R, Dillon MJ. The emergency management of severe hypertension. Pediatr Nephrol 2000; 14:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/2\">",
"      Flynn JT, Tullus K. Severe hypertension in children and adolescents: pathophysiology and treatment. Pediatr Nephrol 2009; 24:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/3\">",
"      Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/4\">",
"      Flanigan JS, Vitberg D. Hypertensive emergency and severe hypertension: what to treat, who to treat, and how to treat. Med Clin North Am 2006; 90:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/5\">",
"      Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet 2000; 356:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/6\">",
"      Constantine E, Linakis J. The assessment and management of hypertensive emergencies and urgencies in children. Pediatr Emerg Care 2005; 21:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/7\">",
"      Fenves AZ, Ram CV. Drug treatment of hypertensive urgencies and emergencies. Semin Nephrol 2005; 25:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/8\">",
"      Varon J, Marik PE. Clinical review: the management of hypertensive crises. Crit Care 2003; 7:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/9\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/10\">",
"      Temple ME, Nahata MC. Treatment of pediatric hypertension. Pharmacotherapy 2000; 20:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/11\">",
"      Deal JE, Barratt TM, Dillon MJ. Management of hypertensive emergencies. Arch Dis Child 1992; 67:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/12\">",
"      Marik PE, Varon J. Hypertensive crises: challenges and management. Chest 2007; 131:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/13\">",
"      Thomas CA, Moffett BS, Wagner JL, et al. Safety and efficacy of intravenous labetalol for hypertensive crisis in infants and small children. Pediatr Crit Care Med 2011; 12:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/14\">",
"      Tuncel M, Ram VC. Hypertensive emergencies. Etiology and management. Am J Cardiovasc Drugs 2003; 3:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/15\">",
"      Hollander JE. Cocaine intoxication and hypertension. Ann Emerg Med 2008; 51:S18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/16\">",
"      Wells TG, Bunchman TE, Kearns GL. Treatment of neonatal hypertension with enalaprilat. J Pediatr 1990; 117:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/17\">",
"      Flynn JT. Safety of short-acting nifedipine in children with severe hypertension. Expert Opin Drug Saf 2003; 2:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/18\">",
"      Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich) 2007; 9:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/19\">",
"      Flynn JT, Pasko DA. Calcium channel blockers: pharmacology and place in therapy of pediatric hypertension. Pediatr Nephrol 2000; 15:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/20\">",
"      Miyashita, Y, Peterson, D, Rees, JM, et al. Isradipine treatment of acute hypertension in hospitalized children and adolescents. J Clin Hypertens 2010; .",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/21\">",
"      Strife CF, Quinlan M, Waldo FB, et al. Minoxidil for control of acute blood pressure elevation in chronically hypertensive children. Pediatrics 1986; 78:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/22\">",
"      Pancioli AM. Hypertension management in neurologic emergencies. Ann Emerg Med 2008; 51:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/23\">",
"      Vesey CJ, Cole PV. Blood cyanide and thiocyanate concentrations produced by long-term therapy with sodium nitroprusside. Br J Anaesth 1985; 57:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/24\">",
"      Gouyon JB, Geneste B, Semama DS, et al. Intravenous nicardipine in hypertensive preterm infants. Arch Dis Child Fetal Neonatal Ed 1997; 76:F126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/25\">",
"      Milou C, Debuche-Benouachkou V, Semama DS, et al. Intravenous nicardipine as a first-line antihypertensive drug in neonates. Intensive Care Med 2000; 26:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/26\">",
"      Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: diagnosis, management and outcome. Pediatr Nephrol 2012; 27:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/27\">",
"      Rocchini AP, Rosenthal A, Barger AC, et al. Pathogenesis of paradoxical hypertension after coarctation resection. Circulation 1976; 54:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/28\">",
"      Will RJ, Walker OM, Traugott RC, Treasure RL. Sodium nitroprusside and propranolol therapy for management of postcoarctectomy hypertension. J Thorac Cardiovasc Surg 1978; 75:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/29\">",
"      Rouine-Rapp K, Mello DM, Hanley FL, et al. Effect of enalaprilat on postoperative hypertension after surgical repair of coarctation of the aorta. Pediatr Crit Care Med 2003; 4:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/30\">",
"      Nakagawa TA, Sartori SC, Morris A, Schneider DS. Intravenous nicardipine for treatment of postcoarctectomy hypertension in children. Pediatr Cardiol 2004; 25:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/31\">",
"      Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive versus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol 1994; 171:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/32\">",
"      Duley L, Henderson-Smart DJ, Meher S. Drugs for treatment of very high blood pressure during pregnancy. Cochrane Database Syst Rev 2006; :CD001449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/33\">",
"      Magee LA, Cham C, Waterman EJ, et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ 2003; 327:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23065/abstract/34\">",
"      Hanff LM, Vulto AG, Bartels PA, et al. Intravenous use of the calcium-channel blocker nicardipine as second-line treatment in severe, early-onset pre-eclamptic patients. J Hypertens 2005; 23:2319.",
"     </a>",
"    </li>",
"    <li>",
"     Hoffman RS. Cocaine. In: Goldfrank's Toxicologic Emergencies, 8th, Goldfrank LR, Floembaum NE, Hoffman RS, Howland MA.  (Eds), McGraw-Hill, Philadelphia 2006. p.1133.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6468 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-617C8121F3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_33_23065=[""].join("\n");
var outline_f22_33_23065=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hypertensive emergency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypertensive urgency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Confirmation of severe hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      General measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Blood pressure management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Hypertensive emergency goal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hypertensive urgency goal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Mode of administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      First line intravenous agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Other intravenous agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Use of oral antihypertensive agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Ongoing antihypertensive therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SPECIFIC PEDIATRIC HYPERTENSIVE EMERGENCIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hypertensive encephalopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Renal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Neonatal hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Preeclampsia/eclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Cocaine or amphetamine overdose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8735200\">",
"      Pheochromocytomas and paragangliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Definition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Management of hypertensive emergency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Management of hypertensive urgency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6468\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6468|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?9/22/9582\" title=\"algorithm 1\">",
"      Initial management of children with severe hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6468|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?1/0/1025\" title=\"figure 1\">",
"      Determining BP cuff size",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6468|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/13/14557\" title=\"table 1\">",
"      Rapid overview of hypertensive emergencies in children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/15/38139\" title=\"table 2\">",
"      Causes of pediatric hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/49/37659\" title=\"table 3\">",
"      BP cuff sizes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/26/11691\" title=\"table 4\">",
"      Laboratory studies for pediatric hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/60/1997\" title=\"table 5\">",
"      IV medications for pediatric hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/44/16076\" title=\"table 6\">",
"      Oral medications for pediatric hypertensive urgencies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/53/17241?source=related_link\">",
"      Approach to hypertensive emergencies and urgencies in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23385?source=related_link\">",
"      Clinical manifestations and diagnosis of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/30/23018?source=related_link\">",
"      Cocaine: Acute intoxication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17113?source=related_link\">",
"      Definition and diagnosis of hypertension in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18853?source=related_link\">",
"      Drug treatment of hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/48/29450?source=related_link\">",
"      Emergent endotracheal intubation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/48/5895?source=related_link\">",
"      Esmolol: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37833?source=related_link\">",
"      Etiology, clinical features, and diagnosis of neonatal hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/29/35284?source=related_link\">",
"      Fenoldopam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/9/4250?source=related_link\">",
"      Initial approach to severe traumatic brain injury in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/59/39863?source=related_link\">",
"      Labetalol: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/48/40710?source=related_link\">",
"      Loop diuretics: Maximum effective dose and major side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41398?source=related_link\">",
"      Malignant hypertension and hypertensive encephalopathy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/27/20922?source=related_link\">",
"      Management of coarctation of the aorta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/50/30505?source=related_link\">",
"      Management of status epilepticus in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/10/12453?source=related_link\">",
"      Nicardipine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/44/6854?source=related_link\">",
"      Pediatric cervical spine immobilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/36/14917?source=related_link\">",
"      Phentolamine: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/14/38121?source=related_link\">",
"      Pheochromocytoma in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/62/27626?source=related_link\">",
"      Treatment of hypertension in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_33_23066="Assessment of myocardial viability by nuclear imaging in coronary heart disease";
var content_f22_33_23066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Assessment of myocardial viability by nuclear imaging in coronary heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/33/23066/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/33/23066/contributors\">",
"     Prem Soman, MD, PhD, FACC, FRCP (UK)",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/33/23066/contributors\">",
"     James E Udelson, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/33/23066/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/33/23066/contributors\">",
"     Ami E Iskandrian, MD, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/33/23066/contributors\">",
"     Jeroen J Bax, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/33/23066/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/33/23066/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/33/23066/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coronary heart disease (CHD) is the major cause of heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=see_link\">",
"     \"Epidemiology and causes of heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the past, severe left ventricular (LV) dysfunction was considered an irreversible condition, as regional akinesis was thought to represent infarcted myocardial tissue. It is now understood that, among patients with ischemic cardiomyopathy, LV systolic dysfunction can result from myocardial necrosis, myocardial hibernation, or repetitive myocardial stunning. While myocardial necrosis is irreversible, systolic dysfunction resulting from hibernation and stunning are potentially reversible states of ventricular dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23335?source=see_link\">",
"     \"Pathophysiology of stunned or hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with chronic heart failure have an admixture of all three pathophysiologic entities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/2\">",
"     2",
"    </a>",
"    ]. Clinical studies have shown that viable myocardium can be demonstrated in a substantial number of patients with CHD and LV dysfunction, even in the absence of angina [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=see_link\">",
"     \"Evaluation of hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with significant amounts of viable myocardium, LV function may improve markedly, and even normalize, following successful revascularization (",
"    <a class=\"graphic graphic_figure graphicRef55621 \" href=\"UTD.htm?10/24/10638\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. An estimated 20 to 40 percent of patients with chronic ischemic LV dysfunction have the potential for significant improvement in LV function after revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The outcome following revascularization is dependent not only on the presence, but also the extent, of viability, and a critical threshold mass of viable myocardium may be necessary for functional recovery and prognostic benefit to occur from revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. Therefore, while several clinical and laboratory parameters including anginal symptoms, absence of Q waves on the electrocardiogram, and regional hypokinesis (as opposed to akinesis) on echocardiography indicate the presence of some viability, a systematic assessment of the degree and extent of viability is indicated for management planning and prognostication.",
"   </p>",
"   <p>",
"    To the extent that improvement in regional or global LV function, and thereby prognosis, is a significant goal in such patients, the ability to accurately assess regional myocardial viability in a dysfunctional territory prior to revascularization becomes an important component of the decision making process.",
"   </p>",
"   <p>",
"    For the detection of viability, noninvasive imaging techniques depend on the demonstration of cell membrane integrity (Thallium-201 imaging), intact mitochondrial function (Tc-99m sestamibi and tetrofosmin imaging), preserved myocardial metabolism (Positron Emission Tomography with F- 18 deoxyglucose), microvascular integrity (myocardial contrast echocardiography) or the absence of scar tissue (gadolinium-enhanced magnetic resonance imaging) in areas of dysfunctional myocardium.",
"   </p>",
"   <p>",
"    The most commonly used radionuclide imaging techniques for assessing myocardial viability in this setting will be reviewed here (",
"    <a class=\"graphic graphic_figure graphicRef50864 \" href=\"UTD.htm?43/30/44526\">",
"     figure 2",
"    </a>",
"    ). The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography for assessing myocardial viability is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=see_link\">",
"     \"Dobutamine stress echocardiography in the evaluation of hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Thallium-201 radionuclide myocardial perfusion imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thallium-201 was introduced as a perfusion tracer because of its high (about 80 percent) first pass myocardial extraction fraction across physiologic ranges of myocardial blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/14\">",
"     14",
"    </a>",
"    ]. The myocardial uptake of thallium-201 is a sarcolemmal membrane",
"    <span class=\"nowrap\">",
"     Na/K",
"    </span>",
"    ATPase-dependent active process requiring cell membrane integrity, and is therefore indicative of myocardial viability. Thallium-201 uptake by myocytes is a reflection both of regional perfusion (required for delivery of tracer to the myocyte) and viability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35192?source=see_link\">",
"     \"Basic properties of myocardial perfusion agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several different approaches have been employed to optimize the information obtained from thallium-201 imaging. Table 1 (",
"    <a class=\"graphic graphic_table graphicRef74921 \" href=\"UTD.htm?0/16/267\">",
"     table 1",
"    </a>",
"    ) lists the various protocols that have been used for viability assessment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Stress-redistribution imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1977, it was reported that some stress-induced thallium defects could normalize or \"redistribute\" on serial images repeated several hours later [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/15\">",
"     15",
"    </a>",
"    ]. It was proposed that regional thallium redistribution activity represented the extent of regional myocardial viability. As a result, stress-redistribution thallium imaging following a single stress injection became the standard imaging protocol for assessing the presence of coronary disease and the extent of inducible ischemia.",
"   </p>",
"   <p>",
"    The demonstration of reversible ischemia by the conventional stress-four hour redistribution protocol implies the presence of viable myocardium. However, up to 47 percent of segments that have fixed defects at 4 hours show evidence of viability on PET scanning [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/11\">",
"     11",
"    </a>",
"    ] or recover either perfusion or function following revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Therefore several modifications of the stress-4 hour redistribution protocol were developed to improve the accuracy of viability detection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Late redistribution imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some instances, the redistribution of thallium-201 appears to take longer than the four hours allowed in standard stress-redistribution protocols. This variability may reflect relatively lower blood levels of thallium-201 throughout the redistribution period, thereby reducing thallium-201 input over time into severely ischemic areas [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This observation led to the development of late redistribution protocols, which generally involve redistribution imaging 18 to 24 hours after thallium-201 injection. With these protocols, thallium-201 redistribution is seen in a significant number of perfusion defects deemed fixed by imaging at four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. In one study, for example, late distribution at 24 hours occurred in one fifth of defects thought to be fixed by conventional four hour imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Late redistribution has been validated as an accurate predictor of viability, with up to 95 percent of segments with late redistribution showing improved stress perfusion following revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/23\">",
"     23",
"    </a>",
"    ]. However, even with delayed imaging, a proportion of segments with fixed defects improve function after revascularization, suggesting that some viable segments may never redistribute unless blood levels of thallium-201 are augmented [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/9\">",
"     9",
"    </a>",
"    ]. In one study, 37 percent of segments labeled as fixed defects even after late imaging improved perfusion after revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the presence of thallium-201 uptake at late redistribution is an accurate marker of regional viability, while its absence may underestimate viable myocardial tissue to a significant degree. Late redistribution imaging may also result in images of poor quality due to tracer washout and decay.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Thallium-201 reinjection protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reinjection of a second, smaller dose of thallium-201 immediately following the redistribution images increases the blood level of thallium-201, and may circumvent some of the problems associated with redistribution imaging, resulting in enhanced detection of stress defect reversibility [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/25\">",
"     25",
"    </a>",
"    ]. This method has been shown to identify viable territories in as many as 50 to 70 percent of regions which were deemed to be scar by standard three to four hour redistribution [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Additional delayed imaging does not appear to improve sensitivity of viability detection with this protocol, which has positive and negative predictive values of 69 percent and 89 percent, respectively, indicating good sensitivity and modest specificity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/25,26,29\">",
"     25,26,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occasionally, a minority of segments that demonstrate reversible defects at redistribution appear to have more severe defects following reinjection. This infrequent phenomenon has been ascribed to \"differential uptake,\" a relatively smaller increment in regional thallium-201 uptake following reinjection in ischemic compared to normal zones, giving the appearance of a defect [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/30\">",
"     30",
"    </a>",
"    ]. The implication of differential uptake is that in most patients, it is probably necessary to obtain all three image sets (stress, redistribution, and reinjection) to optimize assessment of ischemia and viability fully.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Rest-redistribution imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since thallium-201 was initially thought of as a blood flow tracer, a defect seen on an image taken soon after a rest injection of thallium-201 was assumed to be associated with regional infarction. However, a significant percentage of resting thallium-201 defects show redistribution when reimaged several hours after injection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Segments which show a reversible resting thallium-201 defect often have improved perfusion after revascularization, suggesting that this finding is indicative of regional myocardial viability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/32\">",
"     32",
"    </a>",
"    ]. An increase of tracer uptake of 10 percent or more on the redistribution images is usually considered indicative of viability in this setting.",
"   </p>",
"   <p>",
"    Rest-redistribution imaging is useful when viability information is required after a dual isotope rest&ndash;stress study has demonstrated an apparently fixed perfusion defect. In dual isotope protocols, a rest thallium-201 study is followed by a stress study with either Tc-99m sestamibi or Tc-99m tetrofosmin. This has the advantage of a shorter overall study time compared to a single-isotope (ie, Tc-99m based tracer only) rest-stress study. When a fixed defect is encountered on a dual isotope study, the patient can be brought back the next day for delayed thallium-201 imaging for viability assessment. At this time, Tc-99m, which has a half&ndash;life of around six hours, is no longer present in the myocardium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Quantitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Quantitation of thallium-201 uptake on redistribution images further improves the prediction of viability, with higher counts being more reliably predictive of improvement in regional perfusion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    function after revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/10\">",
"     10",
"    </a>",
"    ]. The quantitation of relative regional thallium-201 activity in rest-redistribution studies is generally highly concordant with findings from stress-redistribution-reinjection imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/33\">",
"     33",
"    </a>",
"    ]. Viability assessment based on quantification of thallium-201 uptake more accurately predicts improvement in perfusion or function after revascularization than a dichotomous visual analysis of the presence or absence of stress defect reversibility.",
"   </p>",
"   <p>",
"    Quantitative techniques may be of particular utility in segments that appear on inspection to have fixed defects. In such segments, significant thallium-201 uptake may still be present. The presence of thallium uptake &gt;50 percent to 60 percent of that in normal segments is indicative of the presence of viable myocardium as demonstrated in comparative studies with PET imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/34\">",
"     34",
"    </a>",
"    ]. One report, for example, evaluated a group of patients with planar thallium-201 stress-redistribution imaging: 45 percent of fixed thallium-201 defects preoperatively showed improved thallium-201 uptake following bypass grafting [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/18\">",
"     18",
"    </a>",
"    ]. However, with the use of quantitative analysis of the magnitude of thallium-201 uptake within these fixed defects, stratification of segments into those more or less likely to improve perfusion after revascularization was achieved.",
"   </p>",
"   <p>",
"    In general however, fixed defects, even mild, are less likely to improve resting function following revascularization than reversible defects, because this pattern may be seen both in \"transmurally hibernating\" segments (which have a high likelihood of functional recovery after revascularization) and in segments with subendocardial necrosis but retained epicardial viability (which are far less likely to improve resting function after revascularization) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/10,35\">",
"     10,35",
"    </a>",
"    ]. Thus, the use of quantitation to define a \"cut-off\" threshold for viability (usually 50 to 60 percent of activity in the normal segments) may not accurately reflect the likelihood of myocardial recovery.",
"   </p>",
"   <p>",
"    Instead, it may be more effective to use quantitative methods to define a probability of recovery. There appears to be a continuous relationship between the amount of tracer uptake and the likelihood of functional recovery after revascularization. In one study, 56 percent of segments with 50 to 60 percent uptake and 88 percent of segments with greater than 80 percent uptake of thallium-201 improved after revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Nitrate enhanced imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitrate administration enhances the flow to peri-infarct regions and improves thallium-201 delivery to myocytes. One study compared a nitrate enhanced rest thallium-201 perfusion scan with conventional exercise and four-hour redistribution thallium-201 imaging in 100 patients, six weeks after a myocardial infarction and thrombolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/36\">",
"     36",
"    </a>",
"    ]. The non&ndash;nitrate enhanced protocol demonstrated reversible ischemia in 29 patients; the incidence of cardiac events was similar in those with and without a reversible defect (48 versus 32 percent, p = NS) after a 21-month follow-up. In comparison, a nitrate enhanced thallium-201 scan detected a\" reversible\" defect in 68 patients. A cardiac event occurred significantly more often in those with a reversible defect than in those without such a defect (49 versus 13 percent, hazard ratio 8).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of thallium-201 radionuclide myocardial perfusion imaging for viability detection can be summarized as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With stress imaging protocols, the finding of stress defect reversibility (inducible ischemia) on redistribution",
"      <strong>",
"       or",
"      </strong>",
"      reinjection images strongly implies the presence of ischemic, viable myocardium, and a high likelihood for functional improvement of a resting wall motion abnormality in that territory.",
"     </li>",
"     <li>",
"      The finding of a fixed thallium-201 defect of only mild-to-moderate severity using quantitative methods implies the presence of a degree of viable tissue. However, dysfunctional segments demonstrating this pattern probably have only a moderate chance of functional recovery.",
"     </li>",
"     <li>",
"      The finding of a fixed defect with a severe reduction in thallium-201 activity in stress-redistribution-reinjection protocols or rest-redistribution protocols implies a high likelihood of predominantly nonviable myocardium. In most studies, there is a 10 to 25 percent incidence of functional recovery following revascularization in such territories, a figure similar to that seen when PET imaging identifies a territory as predominantly nonviable.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SPECT IMAGING WITH TC-99M LABELED RADIOTRACERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technetium-99m sestamibi, a lipophilic cationic compound, and Tc-99m tetrofosmin, a diphosphine agent, are Tc-99m labeled radiotracers; their uptake across myocyte cell membranes is by passive diffusion, in contrast to the active uptake of thallium-201. The uptake and retention of these compounds within myocytes depends upon the presence of intact electrochemical gradients across sarcolemmal and mitochondrial membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. The technetium label imparts better gamma camera imaging characteristics to these agents compared to thallium-201, and their myocardial uptake generally parallels myocardial perfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/38\">",
"     38",
"    </a>",
"    ]. A significant difference from thallium-201 is that these agents show minimal redistribution within the myocardium [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35192?source=see_link\">",
"     \"Basic properties of myocardial perfusion agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The passive nature of Tc-99m sestamibi uptake by myocytes and its relative lack of redistribution within the myocardium were initially perceived as properties that would hinder the use of Tc-99m sestamibi for viability assessment. However, the uptake and retention of this agent requires the presence of intact sarcolemmal and mitochondrial membranes, making it conceptually a good tracer of regional cellular viability. It was also thought that the absence of significant myocardial redistribution would result in underestimation of viability in areas with severe resting hypoperfusion (and therefore, poor initial tracer uptake). This, again, has proven to be a largely theoretical concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Comparison of thallium and technetium imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies comparing viability detection with thallium-201 and Tc-99m sestamibi have generally demonstrated good agreement between these agents, both in the amount of their uptake into areas of viable myocardium (the resting Tc-99m sestamibi image correlating with the thallium-201 redistribution or reinjection image), and also in their ability to predict recovery of function following revascularization.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report evaluated an animal model of short-term low flow ischemia that was accompanied by regional dysfunction without infarction [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/41\">",
"       41",
"      </a>",
"      ]. Thallium-201 and Tc-99m sestamibi were injected at rest, with counting of regional tracer activity three hours after injection. Contrary to the expectation of higher thallium-201 activity at this time point, thallium-201 and Tc-99m sestamibi activities were equivalent across all levels of reduced flow (as determined by radioactive microspheres). Thus, the kinetics of Tc-99m sestamibi (and of thallium-201) under low-flow conditions is more complex than can be explained by a simple flow-dependent model.",
"     </li>",
"     <li>",
"      A study in humans used quantitative techniques after resting thallium-201 and Tc-99m sestamibi injections [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/42\">",
"       42",
"      </a>",
"      ]. Among dyssynergic segments, those with reversible dysfunction following revascularization had similar relative regional activities of thallium-201 (at redistribution) and Tc-99m sestamibi. Activities within persistently dysfunctional segments were also similar, and the sensitivity and specificity for identifying improved regional wall motion were not statistically different.",
"     </li>",
"     <li>",
"      Another study found analogous results using SPECT imaging in patients with LV dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/35\">",
"       35",
"      </a>",
"      ]. Thallium-201 (at redistribution after rest injection) and Tc-99m sestamibi activities were similar in both reversibly and persistently dysfunctional myocardium, and both isotopes had equivalent positive and negative predictive values for identifying reversible dysfunction. There also was a general correlation between the relative magnitude of isotope uptake (using either thallium-201 or Tc-99m sestamibi) and the probability of regional viability. Segments with well-preserved regional uptake had a very high likelihood of being viable by wall motion criteria; segments with moderately reduced levels of isotope uptake had a moderate probability; and segments with severe reductions in isotope activity had a low probability of being viable. Similar results have been reported in comparative studies of Tc-99m sestamibi with PET imaging [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of nitrates in conjunction with Tc-99m sestamibi has been shown to improve its ability to detect viable myocardium, analogous to the data with thallium-201 imaging. Compared with resting Tc-99m sestamibi studies, nitrate enhanced SPECT has been shown to have a greater ability to predict improvement of regional function after revascularization [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/44,45\">",
"       44,45",
"      </a>",
"      ], and to provide important prognostic information [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/46\">",
"       46",
"      </a>",
"      ]. The demonstration of \"defect reversibility\" on nitrate-enhanced compared to resting images may have better accuracy than either technique alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these studies suggest that by using quantitative measures of regional activity, Tc-99m sestamibi is capable of providing similar data to thallium-201 regarding regional viability and the propensity for improvement in regional wall motion following revascularization. These findings are a reflection of the fact that the magnitude of Tc-99m sestamibi activity within a dysfunctional territory correlates with mitochondrial metabolic activity and the probability of functional recovery. They are consistent with the concept that chronic but reversible regional dysfunction may often exist in the presence of preserved blood flow at rest. Both Tc-99m sestamibi imaging and thallium-201 imaging were recommended (class I indications) for predicting functional recovery in the 2003 guidelines of the American College of Cardiology and the American Heart Association [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/47\">",
"     47",
"    </a>",
"    ]. Figure 3 (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50087 \" href=\"UTD.htm?39/1/39952\">",
"     image 1",
"    </a>",
"    ) shows examples of the use of Tc-99m sestamibi rest imaging for viability assessment.",
"   </p>",
"   <p>",
"    Despite some minor differences in tracer kinetics, a limited amount of data suggests comparable utility of Tc-99m tetrofosmin imaging for viability detection. One report, for example, evaluated a resting injection of Tc-99m tetrofosmin in patients with prior myocardial infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/23\">",
"     23",
"    </a>",
"    ]. Quantitative regional activity of Tc-99m tetrofosmin was significantly higher in those territories supplied by an occluded coronary artery with well developed collaterals compared to territories supplied by an occluded artery with poor or no collaterals, similar to data reported with Tc-99m sestamibi [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/24\">",
"     24",
"    </a>",
"    ]. Other studies have found that quantitative regional activity of Tc-99m tetrofosmin after rest injection was similar to that of redistribution thallium-201 activity after rest injection in patients with LV dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/19\">",
"     19",
"    </a>",
"    ], analogous to equivalently designed comparisons of Tc-99m sestamibi and thallium-201 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The cellular mechanisms responsible for Tc-99m tetrofosmin uptake and retention, particularly in low-flow situations, remain to be determined. As With Tc-99m sestamibi, nitrate enhancement improves the accuracy of Tc-99m tetrofosmin imaging for viability detection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. When compared to FDG PET, the accuracy of Tc-99m tetrofosmin, especially in the inferior-septal regions of the left ventricle, is improved with attenuation correction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/10/25768?source=see_link&amp;anchor=H15#H15\">",
"     \"Attenuation artifact in SPECT radionuclide myocardial perfusion imaging\", section on 'attenuation correction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tc-99m sestamibi ECG-gated SPECT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard (non-gated) radionuclide scanning of the heart includes data from throughout the cardiac cycle in a single image, without discrimination of systole and diastole. Using a technique called ECG gating, sequential data can be obtained with timing to the cardiac cycle, thus providing images specific to phases of systole and diastole.",
"   </p>",
"   <p>",
"    The development of gated SPECT imaging has enabled the assessment of regional left ventricular function as well as perfusion. One study of 50 patients with CAD and LV dysfunction addressed the question of whether the addition of functional data to perfusion data improves the accuracy of viability detection. Tc-99m sestamibi ECG-gated SPECT imaging at rest was performed preoperatively and one and six weeks after revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/50\">",
"     50",
"    </a>",
"    ]. Perfusion and wall motion data combined had a sensitivity, specificity, positive and negative predictive value and overall accuracy of 95, 55, 96, 50, and 91 percent, respectively, for identifying myocardial viability. Compared to perfusion data alone, this was an improvement in sensitivity, but at the cost of a lower specificity, and no change in the overall accuracy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Stress imaging versus rest only imaging for viability detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the data on viability assessment with Tc-99m-labeled agents (where, in contrast to thallium-201 testing, separate injections of tracer are required for stress and rest studies) pertains to the analysis of resting tracer uptake. When the presence or absence of clinically significant amounts of viable myocardium can be determined confidently from the resting study, stress testing is not required for the assessment of myocardial viability. However, when resting tracer uptake is in the \"intermediate range,\" as might occur in regions of non-transmural infarction subtended by a non-critically stenosed coronary artery, the demonstration of inducible ischemia in these regions argues for the presence of viable myocardium. In one study, the finding of reversible ischemia was a more powerful predictor of functional recovery than a fixed defect with a similar degree of resting tracer uptake [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     POSITRON EMISSION TOMOGRAPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positron emission tomography (PET) is an established noninvasive method of evaluating myocardial perfusion and viability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/52\">",
"     52",
"    </a>",
"    ]. This technique has the advantage of being able to assess perfusion and metabolism simultaneously. PET requires the use of positron-emitting isotopes (such as oxygen-15, carbon-11, nitrogen-13, and fluorine-18), which are incorporated into physiologically active molecules.",
"   </p>",
"   <p>",
"    Ischemia shifts myocyte metabolism preferentially to glucose from fatty acids. Thus, uptake of a glucose analog, fluorine-18 labeled deoxyglucose (FDG) by myocytes in an area of dysfunctional myocardium indicates metabolic activity and thus, viability. Regional perfusion can be simultaneously assessed with an agent that remains in the vascular space and thus demonstrates the distribution of blood flow (such as N-13 ammonia or Rb-82). As a result, PET imaging has the potential to differentiate between normal, stunned, hibernating, and necrotic myocardium. The presence of enhanced FDG uptake in regions of decreased blood flow (known as a \"PET mismatch\") defines hibernating myocardium by PET imaging, while a concordant reduction in both metabolism and flow (\"PET match\") is thought to represent predominantly necrotic myocardium. Regional dysfunction in presence of normal perfusion is indicative of stunning.",
"   </p>",
"   <p>",
"    Myocardial segments with significant reductions in both blood flow and FDG uptake have only a 20 percent chance of functional improvement following revascularization. In comparison, dysfunctional territories deemed to be hibernating by PET have approximately an 80 to 85 percent chance of functional improvement following revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/11,29,53-58\">",
"     11,29,53-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study, for example, examined 43 patients with regional asynergy and a mean left ventricular (LV) ejection fraction of 41 percent who were evaluated by PET imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/58\">",
"     58",
"    </a>",
"    ]. The positive and negative predictive values of PET imaging for improvement in asynergy and wall motion score after revascularization were 76 and 96 percent, respectively. Other studies have shown that the extent of myocardium that demonstrates enhanced FDG uptake in patients with ischemic cardiomyopathy may predict the magnitude of improvement in ejection fraction, exercise tolerance and heart failure symptoms after surgical revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another analysis reported that scar size on FDG PET was an independent predictor of improvement in ejection fraction after revascularization. In 70 patients with a mean resting EF of 26 percent, scars were divided into tertiles graded as small, moderate, or large (0 to 16, 16 to 27.5, and 27.5 to 47 percent of total myocardium, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/61\">",
"     61",
"    </a>",
"    ]. The change in EF after revascularization was significantly greater for patients with smaller scars (change of 9.0, 3.7, and 1.3 percent, for small, moderate, or large scars respectively).",
"   </p>",
"   <p>",
"    Outcome after coronary artery bypass grafting may be improved by incorporating PET derived viability information, in addition to clinical and angiographic data, into the process of selecting patients with impaired LV function for revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. As an example, one study evaluated the prognostic significance of the presence of viable myocardium, and its interaction with myocardial revascularization, in patients with LV dysfunction after MI [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/63\">",
"     63",
"    </a>",
"    ]. Nonfatal ischemic events occurred in 48 percent of medically-treated FDG (+) patients compared with only 8 percent of FDG (+) revascularized patients and 5 percent of patients with FDG (-) myocardium; however, mortality was similar among FDG (+) and FDG (-) patients.",
"   </p>",
"   <p>",
"    It remains unclear if PET is more useful than SPECT for viability assessment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. Some studies, including one randomized trial, found that the ability to detect myocardial viability with PET or SPECT imaging was the same and that there was no difference in patient outcome when management decisions were based upon the results of either technique [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/64\">",
"     64",
"    </a>",
"    ]. Patients in this study had generally moderate LV dysfunction (LV EF approximately 30 percent). PET may have an advantage over SPECT in the setting of very severe LV dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     FDG-SPECT IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of specialized collimators has allowed the adaptation of widely available SPECT imaging cameras to capture the 511 KeV positrons emanating from F-18 FDG [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. Preliminary data from some studies of patients revascularized for CAD-related LV dysfunction have demonstrated superior predictive values for functional recovery with FDG-SPECT compared to other techniques (particularly thallium-201 SPECT with reinjection and low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/13,54,70\">",
"     13,54,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, one study of patients with LV dysfunction reported that significant improvement of global LV function occurred in those with three or more viable segments on FDG-SPECT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/70\">",
"     70",
"    </a>",
"    ]. Another study found that the combined use of both FDG-SPECT and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography derived data resulted in the most accurate prediction of functional recovery in hypokinetic segments [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/13\">",
"     13",
"    </a>",
"    ]. On the other hand, one study comparing FDG-SPECT with PET and thallium-201 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/71\">",
"     71",
"    </a>",
"    ] SPECT did report that although FDG-SPECT significantly increased the sensitivity for detecting viable myocardium, 27 percent of segments were falsely identified as viable when judged nonviable by both PET and thallium-201 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Therefore, the relative merits of FDG-SPECT and the more conventional techniques for viability assessment need to be assessed in further clinical trials. Analogous to PET, obtaining simultaneous perfusion data during FDG SPECT imaging may improve accuracy for viability detection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Future studies will determine whether the physical problems associated with gamma camera imaging of this agent, as well as technical issues such as the need for attenuation correction, can be overcome to a degree that this technique can provide superior information, rather than just similar information, to conventional (and less expensive) SPECT approaches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     FATTY ACID IMAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ischemia shifts myocardial metabolism from long-chain fatty acids, which is the predominant substrate under aerobic conditions, to glucose [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/75\">",
"     75",
"    </a>",
"    ]. This finding prompted the investigation of several radionuclide-labeled fatty acid compounds for use in myocardial imaging. The uptake and washout kinetics of these agents are reflective of distinct pathways of myocardial fatty acid metabolism that are altered in acute ischemia, chronic ischemia and the different states of dysfunctional but viable myocardium. Initial studies used C-11 palmitate and PET imaging with encouraging results [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. Subsequent efforts were directed towards adapting these tracers and protocols for the more widely available SPECT cameras, and obviating the need for cyclotron production, thus resulting in the introduction of I-123 labeled agents.",
"   </p>",
"   <p>",
"    123 I- iodophenylpentadecanoic acid (IPPA) is a straight chain fatty acid that is taken up by the myocardium in proportion to regional perfusion. Under non-ischemic conditions this tracer is rapidly metabolized and released, resulting in rapid washout kinetics [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/78\">",
"     78",
"    </a>",
"    ]. Suppressed metabolism in the presence of ischemia results in longer myocardial retention and a \"redistribution\" pattern on serial imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/79\">",
"     79",
"    </a>",
"    ]. Qualitative and semi-quantitative analysis of IPPA uptake and washout have been used in various clinical trials to successfully diagnose coronary stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/78\">",
"     78",
"    </a>",
"    ], detect myocardial ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/80\">",
"     80",
"    </a>",
"    ], determine myocardial viability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/81-83\">",
"     81-83",
"    </a>",
"    ] and predict recovery of regional LV dysfunction following revascularization [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/84\">",
"     84",
"    </a>",
"    ]. One study, for example, demonstrated superiority of this agent over rest-redistribution thallium-201 imaging for viability detection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/83\">",
"     83",
"    </a>",
"    ]. However, the rapid dynamics of straight chain fatty acid uptake and metabolism is a critical problem for SPECT imaging.",
"   </p>",
"   <p>",
"    Methyl-branching of the fatty acid chain protects against beta oxidation and considerably slows down washout from the myocardium (metabolic trapping) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/85\">",
"     85",
"    </a>",
"    ]. Of the methyl-branched fatty acid tracers, 123 I- (p-iodophenyl)-3-(R,S)-methylpentadecanoic acid (BMIPP) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/86\">",
"     86",
"    </a>",
"    ] has been extensively studied in Japan and Europe, and more recently in the United States. Excellent quality images with high heart to background ratios can be obtained 15 to 30 min after tracer administration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/87\">",
"     87",
"    </a>",
"    ]. Because of the metabolic modulation however, separate imaging with thallium-201 or one of the Tc-99m ligands is required for perfusion assessment.",
"   </p>",
"   <p>",
"    The clinical utility of BMIPP imaging stems from the fact that abnormalities of fatty acid metabolism resulting from transient ischemia persist for prolonged periods [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/87\">",
"     87",
"    </a>",
"    ]. Therefore, a defect on BMIPP imaging is indicative of recent ischemia, even when perfusion has returned to normal (ischemic memory). Detection of ischemic memory has potential utility in many clinical situations including assessment of chest pain in the emergency department, diagnosis of CAD without stress testing, and vasospastic angina. In dysfunctional myocardium, a disproportionately greater decrease in BMIPP compared to a perfusion trace uptake likely represents ongoing ischemia with recurrent stunning, and has been shown to correlate with preserved inotropic reserve [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/88\">",
"     88",
"    </a>",
"    ], histological evidence of viability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/89\">",
"     89",
"    </a>",
"    ], and predict post &ndash;revascularization recovery of function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/90-93\">",
"     90-93",
"    </a>",
"    ]. On the other hand a concordant, severe reduction in both BMIPP uptake and perfusions indicates scar tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     COMPARISON WITH NON-NUCLEAR TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     Dobutamine",
"    </a>",
"    echocardiography is an established technique for viability detection. Newer techniques such as cardiovascular magnetic resonance (CMR) and myocardial contrast echocardiography (MCE) have also been tested in clinical trials. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=see_link\">",
"     \"Dobutamine stress echocardiography in the evaluation of hibernating myocardium\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=see_link\">",
"     \"Evaluation of hibernating myocardium\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relative predictive value of the different forms of radionuclide myocardial perfusion imaging and of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography for detecting hibernating myocardium was evaluated in an analysis from 52 published studies that utilized thallium stress-redistribution-reinjection SPECT, thallium rest-redistribution SPECT, FDG-PET scanning, technetium-sestamibi SPECT, or low dose dobutamine echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For each technique, the negative predictive value was higher than the positive predictive value. The highest negative predictive values were seen with FDG-PET, reinjection thallium SPECT, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography, while lower values were noted for rest-redistribution thallium SPECT and technetium-sestamibi SPECT.",
"     </li>",
"     <li>",
"      The highest positive predictive value was seen with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography, with intermediate values for FDG-PET, rest-redistribution thallium SPECT, and technetium-sestamibi SPECT, and the lowest value for reinjection thallium SPECT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of these studies did not compare imaging techniques in the same patients. In a subset of studies in which two techniques were compared to detect viability, the pooled results showed that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography had a significantly higher positive predictive value than nuclear imaging (84 versus 75 percent) and a significantly lower negative predictive value (69 versus 80 percent).",
"   </p>",
"   <p>",
"    CMR enhanced with gadolinium is being increasingly used for viability assessment. Lack of enhancement is a sensitive marker of the absence of scar tissue, and is taken to imply the presence of viability. Comparison to prior data from Thallium-201 studies suggests a similar lack of discriminatory power for predicting functional recovery in segments with intermediate amounts of residual viability. Recent studies suggest that some segments of severely dysfunctional myocardium which are deemed non-viable with conventional techniques may show functional recovery after revascularization if there is no enhancement on CMR. Thus, contrast-enhanced CMR may be more sensitive for the prediction of function recovery in the most severely dysfunctional myocardial segments [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/96\">",
"     96",
"    </a>",
"    ]. To some degree, this may reflect the better resolution of the CMR technique compared to SPECT for instance, which would be advantageous in the setting of a very dilated LV with relatively thin walls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Clinical implications of viability assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previously, knowledge of the clinical implications of viability testing in patients with LV dysfunction was limited by the lack of randomized clinical trial data. The best available data came from a meta-analysis and pooled analysis of observational series [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/2,94,95,97\">",
"     2,94,95,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 3088 patients from 24 observational studies reported that revascularization, compared with medical therapy, significantly reduced mortality in patients with heart failure and myocardial viability. Among such patients, average annual mortality with revascularization and medical therapy were 3.2 and 16, respectively. Patients without significant viability did poorly irrespective of therapy (annual mortality 7.7 and 6.2 percent respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a pooled analysis, there was a mean increase in LVEF of about 8 percent after revascularization when hibernating myocardium was present (37 versus 45 percent) compared to no change in the absence of hibernation (36 versus 37 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/94,95\">",
"       94,95",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study using propensity analysis suggested that some patients with LV dysfunction may benefit from early revascularization irrespective of the presence or absence of myocardial viability [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Subsequently, two randomized controlled trials comparing mechanical revascularization and optimal medical therapy have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. Surprisingly, and perhaps contrary to expectation, both studies reported a lack of association between the presence or absence of residual myocardial viability, treatment allocation (revascularization versus medical therapy), and patient outcome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Surgical Treatment for Ischemic Heart Failure (STICH) trial randomized 1212 patients with symptomatic ischemic cardiomyopathy (mean LV ejection fraction 27 percent) to standard medical therapy alone or medical therapy with CABG and failed to show a difference in the primary outcome of all-cause mortality, although cardiovascular mortality and the combined outcome of cardiovascular hospitalization and all-cause mortality were lower in patients who received CABG [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/98\">",
"       98",
"      </a>",
"      ]. In a STICH substudy carried out in 601 patients who had viability assessed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/57/25494?source=see_link\">",
"       dobutamine",
"      </a>",
"      echocardiography or SPECT imaging, although the unadjusted all-cause mortality data showed a better outcome in patients with viability, there was no difference in outcome based on the interaction between treatment allocation and the presence or absence of viability. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link&amp;anchor=H12#H12\">",
"       \"Diagnosis and management of ischemic cardiomyopathy\", section on 'Revascularization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The Canadian PPAR study randomized 430 patients with severe LV dysfunction to management assisted by FDG PET or standard care [",
"      <a class=\"abstract\" href=\"UTD.htm?22/33/23066/abstract/99\">",
"       99",
"      </a>",
"      ]. At one year, the cumulative proportion of patients who experienced the primary endpoint (composite of cardiac death, myocardial infarction, or hospitalization for cardiac cause) was no different between groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The practical implication of the surprising lack of association between viability and outcome in these trials is unclear. Several study limitations with potentially confounding effects have been invoked to explain the seemingly contrary results. One important consideration must be the evolution and improved potency of medical therapy for ischemic heart disease since the publication of the original observational data. Thus, although the presence of viability is predictive of outcome, optimal medical therapy and coronary revascularization may be equally efficacious in the vast majority of patients.",
"   </p>",
"   <p>",
"    From a practical standpoint, it is reasonable to revascularize patients with LV systolic dysfunction and CAD with good coronary target vessels and relatively low surgical risk. For the patient at relatively high surgical risk (eg, an elderly patient with severe LV systolic dysfunction, renal dysfunction, and other co-morbidities), the demonstration of significant residual myocardial viability may make the risk-benefit ratio more favorable for surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/30/32226?source=see_link\">",
"       \"Patient information: Nuclear heart testing (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with stable symptoms of heart failure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angina in the setting of LV dysfunction, an exercise SPECT study with thallium-201 or Tc-99m sestamibi (with an accompanying",
"    <span class=\"nowrap\">",
"     redistribution/reinjection",
"    </span>",
"    or rest study) will provide comprehensive information regarding functional capacity (treadmill time and workload), the extent of stress-induced ischemia (read as the degree of stress defect reversibility), and the extent of myocardial viability (read as the isotope content within dysfunctional territories).",
"   </p>",
"   <p>",
"    The data related to ischemia and viability permit an estimation of the probability and magnitude of recovery of regional and global dysfunction after bypass surgery or angioplasty; they can thus play an important role in decision making regarding catheterization and revascularization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=see_link\">",
"     \"Diagnosis and management of ischemic cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with known severe coronary disease and known significant regional and global LV dysfunction, the extent of myocardial viability should be considered, even if angina is not present, since revascularization may be appropriate in some cases. Clinical studies have thus far failed to demonstrate superiority of one perfusion tracer (ie, thallium-201, Tc-99m sestamibi or Tc-99m tetrofosmin) over the others for viability assessment, and individual centers should use standard site protocols.",
"   </p>",
"   <p>",
"    When the presence and extent of preserved myocardial viability is the only question of concern, a resting perfusion scan should be performed first. The administration of sublingual",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    five minutes before tracer injection at rest may slightly improve sensitivity for viability detection. When the amount of resting tracer uptake clearly establishes the presence (or absence) of viability, stress testing is not generally required. However, in cases of \"indeterminate\" resting scans, the demonstration of perfusion defect reversibility on stress testing provides additional information indicative of viability. Stress testing is also necessary in patients who may have areas of ischemia as well as viability.",
"   </p>",
"   <p>",
"    From a practical standpoint, it is reasonable to revascularize patients with LV systolic dysfunction and CAD with good coronary target vessels and relatively low surgical risk. For the patient at relatively high surgical risk (eg, an elderly patient with severe LV systolic dysfunction, renal dysfunction, and other co-morbidities), the demonstration of significant residual myocardial viability may make the risk-benefit ratio more favorable for surgery.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/1\">",
"      Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation 1998; 97:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/2\">",
"      Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/3\">",
"      Cleland JG, Pennell DJ, Ray SG, et al. Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial. Lancet 2003; 362:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/4\">",
"      Schinkel AF, Bax JJ, Sozzi FB, et al. Prevalence of myocardial viability assessed by single photon emission computed tomography in patients with chronic ischaemic left ventricular dysfunction. Heart 2002; 88:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/5\">",
"      Auerbach MA, Sch&ouml;der H, Hoh C, et al. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation 1999; 99:2921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/6\">",
"      Rees G, Bristow JD, Kremkau EL, et al. Influence of aortocoronary bypass surgery on left ventricular performance. N Engl J Med 1971; 284:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/7\">",
"      Chatterjee K, Swan HJ, Parmley WW, et al. Influence of direct myocardial revascularization on left ventricular asynergy and function in patients with coronary heart disease. With and without previous myocardial infarction. Circulation 1973; 47:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/8\">",
"      Brundage BH, Massie BM, Botvinick EH. Improved regional ventricular function after successful surgical revascularization. J Am Coll Cardiol 1984; 3:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/9\">",
"      Bonow RO. Identification of viable myocardium. Circulation 1996; 94:2674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/10\">",
"      Ragosta M, Beller GA, Watson DD, et al. Quantitative planar rest-redistribution 201Tl imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation 1993; 87:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/11\">",
"      Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med 1986; 314:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/12\">",
"      Senior R, Kaul S, Raval U, Lahiri A. Impact of revascularization and myocardial viability determined by nitrate-enhanced Tc-99m sestamibi and Tl-201 imaging on mortality and functional outcome in ischemic cardiomyopathy. J Nucl Cardiol 2002; 9:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/13\">",
"      Bax JJ, Cornel JH, Visser FC, et al. Prediction of recovery of myocardial dysfunction after revascularization. Comparison of fluorine-18 fluorodeoxyglucose/thallium-201 SPECT, thallium-201 stress-reinjection SPECT and dobutamine echocardiography. J Am Coll Cardiol 1996; 28:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/14\">",
"      Weich HF, Strauss HW, Pitt B. The extraction of thallium-201 by the myocardium. Circulation 1977; 56:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/15\">",
"      Pohost GM, Zir LM, Moore RH, et al. Differentiation of transiently ischemic from infarcted myocardium by serial imaging after a single dose of thallium-201. Circulation 1977; 55:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/16\">",
"      Liu P, Kiess MC, Okada RD, et al. The persistent defect on exercise thallium imaging and its fate after myocardial revascularization: does it represent scar or ischemia? Am Heart J 1985; 110:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/17\">",
"      Rozanski A, Berman DS, Gray R, et al. Use of thallium-201 redistribution scintigraphy in the preoperative differentiation of reversible and nonreversible myocardial asynergy. Circulation 1981; 64:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/18\">",
"      Gibson RS, Watson DD, Taylor GJ, et al. Prospective assessment of regional myocardial perfusion before and after coronary revascularization surgery by quantitative thallium-201 scintigraphy. J Am Coll Cardiol 1983; 1:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/19\">",
"      Nelson CW, Wilson RA, Angello DA, Palac RT. Effect of thallium-201 blood levels on reversible myocardial defects. J Nucl Med 1989; 30:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/20\">",
"      Cloninger KG, DePuey EG, Garcia EV, et al. Incomplete redistribution in delayed thallium-201 single photon emission computed tomographic (SPECT) images: an overestimation of myocardial scarring. J Am Coll Cardiol 1988; 12:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/21\">",
"      Gutman J, Berman DS, Freeman M, et al. Time to completed redistribution of thallium-201 in exercise myocardial scintigraphy: relationship to the degree of coronary artery stenosis. Am Heart J 1983; 106:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/22\">",
"      Yang LD, Berman DS, Kiat H, et al. The frequency of late reversibility in SPECT thallium-201 stress-redistribution studies. J Am Coll Cardiol 1990; 15:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/23\">",
"      Kiat H, Berman DS, Maddahi J, et al. Late reversibility of tomographic myocardial thallium-201 defects: an accurate marker of myocardial viability. J Am Coll Cardiol 1988; 12:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/24\">",
"      Perrone-Filardi P, Pace L, Prastaro M, et al. Assessment of myocardial viability in patients with chronic coronary artery disease. Rest-4-hour-24-hour 201Tl tomography versus dobutamine echocardiography. Circulation 1996; 94:2712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/25\">",
"      Dilsizian V, Rocco TP, Freedman NM, et al. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990; 323:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/26\">",
"      Ohtani H, Tamaki N, Yonekura Y, et al. Value of thallium-201 reinjection after delayed SPECT imaging for predicting reversible ischemia after coronary artery bypass grafting. Am J Cardiol 1990; 66:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/27\">",
"      Rocco TP, Dilsizian V, McKusick KA, et al. Comparison of thallium redistribution with rest \"reinjection\" imaging for the detection of viable myocardium. Am J Cardiol 1990; 66:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/28\">",
"      Inglese E, Brambilla M, Dondi M, et al. Assessment of myocardial viability after thallium-201 reinjection or rest-redistribution imaging: a multicenter study. The Italian Group of Nuclear Cardiology. J Nucl Med 1995; 36:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/29\">",
"      Tamaki N, Ohtani H, Yamashita K, et al. Metabolic activity in the areas of new fill-in after thallium-201 reinjection: comparison with positron emission tomography using fluorine-18-deoxyglucose. J Nucl Med 1991; 32:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/30\">",
"      Dilsizian V, Bonow RO. Differential uptake and apparent 201Tl washout after thallium reinjection. Options regarding early redistribution imaging before reinjection or late redistribution imaging after reinjection. Circulation 1992; 85:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/31\">",
"      Gewirtz H, Beller GA, Strauss HW, et al. Transient defects of resting thallium scans in patients with coronary artery disease. Circulation 1979; 59:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/32\">",
"      Berger BC, Watson DD, Burwell LR, et al. Redistribution of thallium at rest in patients with stable and unstable angina and the effect of coronary artery bypass surgery. Circulation 1979; 60:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/33\">",
"      Dilsizian V, Perrone-Filardi P, Arrighi JA, et al. Concordance and discordance between stress-redistribution-reinjection and rest-redistribution thallium imaging for assessing viable myocardium. Comparison with metabolic activity by positron emission tomography. Circulation 1993; 88:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/34\">",
"      Bonow RO, Dilsizian V, Cuocolo A, Bacharach SL. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging with 18F-fluorodeoxyglucose. Circulation 1991; 83:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/35\">",
"      Udelson JE, Coleman PS, Metherall J, et al. Predicting recovery of severe regional ventricular dysfunction. Comparison of resting scintigraphy with 201Tl and 99mTc-sestamibi. Circulation 1994; 89:2552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/36\">",
"      Basu S, Senior R, Raval U, Lahiri A. Superiority of nitrate-enhanced 201Tl over conventional redistribution 201Tl imaging for prognostic evaluation after myocardial infarction and thrombolysis. Circulation 1997; 96:2932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/37\">",
"      Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutyl isonitrile) technetium(I) in cultured chick myocardial cells. Mitochondrial and plasma membrane potential dependence. Circulation 1990; 82:1826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/38\">",
"      Okada RD, Glover D, Gaffney T, Williams S. Myocardial kinetics of technetium-99m-hexakis-2-methoxy-2-methylpropyl-isonitrile. Circulation 1988; 77:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/39\">",
"      Li QS, Solot G, Frank TL, et al. Myocardial redistribution of technetium-99m-methoxyisobutyl isonitrile (SESTAMIBI). J Nucl Med 1990; 31:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/40\">",
"      Taillefer R, Primeau M, Costi P, et al. Technetium-99m-sestamibi myocardial perfusion imaging in detection of coronary artery disease: comparison between initial (1-hour) and delayed (3-hour) postexercise images. J Nucl Med 1991; 32:1961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/41\">",
"      Sinusas AJ, Bergin JD, Edwards NC, et al. Redistribution of 99mTc-sestamibi and 201Tl in the presence of a severe coronary artery stenosis. Circulation 1994; 89:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/42\">",
"      Marzullo P, Parodi O, Reisenhofer B, et al. Value of rest thallium-201/technetium-99m sestamibi scans and dobutamine echocardiography for detecting myocardial viability. Am J Cardiol 1993; 71:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/43\">",
"      Altehoefer C, vom Dahl J, Biedermann M, et al. Significance of defect severity in technetium-99m-MIBI SPECT at rest to assess myocardial viability: comparison with fluorine-18-FDG PET. J Nucl Med 1994; 35:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/44\">",
"      Bisi G, Sciagr&agrave; R, Santoro GM, Fazzini PF. Rest technetium-99m sestamibi tomography in combination with short-term administration of nitrates: feasibility and reliability for prediction of postrevascularization outcome of asynergic territories. J Am Coll Cardiol 1994; 24:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/45\">",
"      Galli M, Marcassa C, Imparato A, et al. Effects of nitroglycerin by technetium-99m sestamibi tomoscintigraphy on resting regional myocardial hypoperfusion in stable patients with healed myocardial infarction. Am J Cardiol 1994; 74:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/46\">",
"      Sciagr&agrave; R, Pellegri M, Pupi A, et al. Prognostic implications of Tc-99m sestamibi viability imaging and subsequent therapeutic strategy in patients with chronic coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol 2000; 36:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/47\">",
"      Klocke FJ, Baird MG, Lorell BH, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC Committee to Revise the 1995 Guidelines for the Clinical Use of Cardiac Radionuclide Imaging). Circulation 2003; 108:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/48\">",
"      Flotats A, Carri&oacute; I, Estorch M, et al. Nitrate administration to enhance the detection of myocardial viability by technetium-99m tetrofosmin single-photon emission tomography. Eur J Nucl Med 1997; 24:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/49\">",
"      Giorgetti A, Marzullo P, Sambuceti G, et al. Baseline/post-nitrate Tc-99m tetrofosmin mismatch for the assessment of myocardial viability in patients with severe left ventricular dysfunction: comparison with baseline Tc-99m tetrofosmin scintigraphy/FDG PET imaging. J Nucl Cardiol 2004; 11:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/50\">",
"      Levine MG, McGill CC, Ahlberg AW, et al. Functional assessment with electrocardiographic gated single-photon emission computed tomography improves the ability of technetium-99m sestamibi myocardial perfusion imaging to predict myocardial viability in patients undergoing revascularization. Am J Cardiol 1999; 83:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/51\">",
"      Kitsiou AN, Srinivasan G, Quyyumi AA, et al. Stress-induced reversible and mild-to-moderate irreversible thallium defects: are they equally accurate for predicting recovery of regional left ventricular function after revascularization? Circulation 1998; 98:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/52\">",
"      Schelbert HR. Metabolic imaging to assess myocardial viability. J Nucl Med 1994; 35:8S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/53\">",
"      Lucignani G, Paolini G, Landoni C, et al. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med 1992; 19:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/54\">",
"      Tamaki N, Yonekura Y, Yamashita K, et al. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989; 64:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/55\">",
"      Marwick TH, MacIntyre WJ, Lafont A, et al. Metabolic responses of hibernating and infarcted myocardium to revascularization. A follow-up study of regional perfusion, function, and metabolism. Circulation 1992; 85:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/56\">",
"      Carrel T, Jenni R, Haubold-Reuter S, et al. Improvement of severely reduced left ventricular function after surgical revascularization in patients with preoperative myocardial infarction. Eur J Cardiothorac Surg 1992; 6:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/57\">",
"      Gropler RJ, Geltman EM, Sampathkumaran K, et al. Functional recovery after coronary revascularization for chronic coronary artery disease is dependent on maintenance of oxidative metabolism. J Am Coll Cardiol 1992; 20:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/58\">",
"      Tamaki N, Kawamoto M, Tadamura E, et al. Prediction of reversible ischemia after revascularization. Perfusion and metabolic studies with positron emission tomography. Circulation 1995; 91:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/59\">",
"      Di Carli MF, Asgarzadie F, Schelbert HR, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995; 92:3436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/60\">",
"      Gerber BL, Ordoubadi FF, Wijns W, et al. Positron emission tomography using(18)F-fluoro-deoxyglucose and euglycaemic hyperinsulinaemic glucose clamp: optimal criteria for the prediction of recovery of post-ischaemic left ventricular dysfunction. Results from the European Community Concerted Action Multicenter study on use of(18)F-fluoro-deoxyglucose Positron Emission Tomography for the Detection of Myocardial Viability. Eur Heart J 2001; 22:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/61\">",
"      Beanlands RS, Ruddy TD, deKemp RA, et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol 2002; 40:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/62\">",
"      Haas F, Haehnel CJ, Picker W, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol 1997; 30:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/63\">",
"      Lee KS, Marwick TH, Cook SA, et al. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization. Circulation 1994; 90:2687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/64\">",
"      Siebelink HM, Blanksma PK, Crijns HJ, et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J Am Coll Cardiol 2001; 37:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/65\">",
"      Marin-Neto JA, Dilsizian V, Arrighi JA, et al. Thallium scintigraphy compared with 18F-fluorodeoxyglucose positron emission tomography for assessing myocardial viability in patients with moderate versus severe left ventricular dysfunction. Am J Cardiol 1998; 82:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/66\">",
"      Rohatgi R, Epstein S, Henriquez J, et al. Utility of positron emission tomography in predicting cardiac events and survival in patients with coronary artery disease and severe left ventricular dysfunction. Am J Cardiol 2001; 87:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/67\">",
"      Kerrou K, Toussaint JF, Froissart M, Talbot JN. Myocardial viability assessment with FDG imaging: comparison of PET, SPECT, and gamma-camera coincidence detection. J Nucl Med 2000; 41:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/68\">",
"      Mabuchi M, Kubo N, Morita K, et al. Value and limitation of myocardial fluorodeoxyglucose single photon emission computed tomography using ultra-high energy collimators for assessing myocardial viability. Nucl Med Commun 2002; 23:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/69\">",
"      Fitzgerald J, Parker JA, Danias PG. F-18 fluoro deoxyglucose SPECT for assessment of myocardial viability. J Nucl Cardiol 2000; 7:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/70\">",
"      Bax JJ, Cornel JH, Visser FC, et al. Prediction of improvement of contractile function in patients with ischemic ventricular dysfunction after revascularization by fluorine-18 fluorodeoxyglucose single-photon emission computed tomography. J Am Coll Cardiol 1997; 30:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/71\">",
"      Sato H, Iwasaki T, Toyama T, et al. Prediction of functional recovery after revascularization in coronary artery disease using (18)F-FDG and (123)I-BMIPP SPECT. Chest 2000; 117:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/72\">",
"      Srinivasan G, Kitsiou AN, Bacharach SL, et al. [18F]fluorodeoxyglucose single photon emission computed tomography: can it replace PET and thallium SPECT for the assessment of myocardial viability? Circulation 1998; 97:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/73\">",
"      De Boer J, Slart RH, Blanksma PK, et al. Comparison of 99mTc-sestamibi-18F-fluorodeoxyglucose dual isotope simultaneous acquisition and rest-stress 99mTc-sestamibi single photon emission computed tomography for the assessment of myocardial viability. Nucl Med Commun 2003; 24:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/74\">",
"      Fukuchi K, Katafuchi T, Fukushima K, et al. Estimation of myocardial perfusion and viability using simultaneous 99mTc-tetrofosmin--FDG collimated SPECT. J Nucl Med 2000; 41:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/75\">",
"      Neely JR, Rovetto MJ, Oram JF. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis 1972; 15:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/76\">",
"      Goldstein RA, Klein MS, Welch MJ, Sobel BE. External assessment of myocardial metabolism with C-11 palmitate in vivo. J Nucl Med 1980; 21:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/77\">",
"      Sch&ouml;n HR, Schelbert HR, Robinson G, et al. C- 11 labeled palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron-computed tomography. I. Kinetics of C- 11 palmitic acid in normal myocardium. Am Heart J 1982; 103:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/78\">",
"      Reske SN, Biersack HJ, Lackner K, et al. Assessment of regional myocardial uptake and metabolism of omega-(p-123I-phenyl) pentadecanoic acid with serial single-photon emission tomography. Nuklearmedizin 1982; 21:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/79\">",
"      Yang JY, Ruiz M, Calnon DA, et al. Assessment of myocardial viability using 123I-labeled iodophenylpentadecanoic acid at sustained low flow or after acute infarction and reperfusion. J Nucl Med 1999; 40:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/80\">",
"      Caldwell JH, Martin GV, Link JM, et al. Iodophenylpentadecanoic acid-myocardial blood flow relationship during maximal exercise with coronary occlusion. J Nucl Med 1990; 31:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/81\">",
"      Murray G, Schad N, Ladd W, et al. Metabolic cardiac imaging in severe coronary disease: assessment of viability with iodine-123-iodophenylpentadecanoic acid and multicrystal gamma camera, and correlation with biopsy. J Nucl Med 1992; 33:1269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/82\">",
"      Hansen CL, Heo J, Oliner C, et al. Prediction of improvement in left ventricular function with iodine-123-IPPA after coronary revascularization. J Nucl Med 1995; 36:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/83\">",
"      Iskandrian AS, Powers J, Cave V, et al. Assessment of myocardial viability by dynamic tomographic iodine 123 iodophenylpentadecanoic acid imaging: comparison with rest-redistribution thallium 201 imaging. J Nucl Cardiol 1995; 2:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/84\">",
"      Verani MS, Taillefer R, Iskandrian AE, et al. 123I-IPPA SPECT for the prediction of enhanced left ventricular function after coronary bypass graft surgery. Multicenter IPPA Viability Trial Investigators. 123I-iodophenylpentadecanoic acid. J Nucl Med 2000; 41:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/85\">",
"      Tamaki N, Tadamura E, Kawamoto M, et al. Decreased uptake of iodinated branched fatty acid analog indicates metabolic alterations in ischemic myocardium. J Nucl Med 1995; 36:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/86\">",
"      Knapp FF Jr, Goodman MM, Callahan AP, Kirsch G. Radioiodinated 15-(p-iodophenyl)-3,3-dimethylpentadecanoic acid: a useful new agent to evaluate myocardial fatty acid uptake. J Nucl Med 1986; 27:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/87\">",
"      Tamaki N, Kawamoto M, Yonekura Y, et al. Regional metabolic abnormality in relation to perfusion and wall motion in patients with myocardial infarction: assessment with emission tomography using an iodinated branched fatty acid analog. J Nucl Med 1992; 33:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/88\">",
"      Hamb&yuml;e AS, Vaerenberg MM, Dobbeleir AA, et al. Abnormal BMIPP uptake in chronically dysfunctional myocardial segments: correlation with contractile response to low-dose dobutamine. J Nucl Med 1998; 39:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/89\">",
"      Kudoh T, Tadamura E, Tamaki N, et al. Iodinated free fatty acid and 201T1 uptake in chronically hypoperfused myocardium: histologic correlation study. J Nucl Med 2000; 41:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/90\">",
"      Franken PR, Dendale P, De Geeter F, et al. Prediction of functional outcome after myocardial infarction using BMIPP and sestamibi scintigraphy. J Nucl Med 1996; 37:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/91\">",
"      Ito T, Tanouchi J, Kato J, et al. Recovery of impaired left ventricular function in patients with acute myocardial infarction is predicted by the discordance in defect size on 123I-BMIPP and 201Tl SPET images. Eur J Nucl Med 1996; 23:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/92\">",
"      Hashimoto A, Nakata T, Tsuchihashi K, et al. Postischemic functional recovery and BMIPP uptake after primary percutaneous transluminal coronary angioplasty in acute myocardial infarction. Am J Cardiol 1996; 77:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/93\">",
"      Naruse H, Arii T, Kondo T, et al. Clinical usefulness of iodine 123-labeled fatty acid imaging in patients with acute myocardial infarction. J Nucl Cardiol 1998; 5:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/94\">",
"      Bax JJ, Poldermans D, Elhendy A, et al. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol 2001; 26:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/95\">",
"      Underwood SR, Bax JJ, vom Dahl J, et al. Imaging techniques for the assessment of myocardial hibernation. Report of a Study Group of the European Society of Cardiology. Eur Heart J 2004; 25:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/96\">",
"      Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/97\">",
"      Tarakji KG, Brunken R, McCarthy PM, et al. Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction. Circulation 2006; 113:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/98\">",
"      Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011; 364:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/33/23066/abstract/99\">",
"      Beanlands RS, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007; 50:2002.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1473 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-CEC8CE9A1B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_33_23066=[""].join("\n");
var outline_f22_33_23066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Thallium-201 radionuclide myocardial perfusion imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Stress-redistribution imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Late redistribution imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Thallium-201 reinjection protocols",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Rest-redistribution imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Quantitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Nitrate enhanced imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SPECT IMAGING WITH TC-99M LABELED RADIOTRACERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Comparison of thallium and technetium imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tc-99m sestamibi ECG-gated SPECT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Stress imaging versus rest only imaging for viability detection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      POSITRON EMISSION TOMOGRAPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      FDG-SPECT IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      FATTY ACID IMAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      COMPARISON WITH NON-NUCLEAR TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Clinical implications of viability assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1473\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1473|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/1/39952\" title=\"diagnostic image 1\">",
"      Tc99m sestamibi rest imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1473|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/24/10638\" title=\"figure 1\">",
"      Revasc hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/30/44526\" title=\"figure 2\">",
"      Techniques myocardial viability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1473|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/16/267\" title=\"table 1\">",
"      Thallium 201 protocols",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/10/25768?source=related_link\">",
"      Attenuation artifact in SPECT radionuclide myocardial perfusion imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35192?source=related_link\">",
"      Basic properties of myocardial perfusion agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/3/24633?source=related_link\">",
"      Diagnosis and management of ischemic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/18/15656?source=related_link\">",
"      Dobutamine stress echocardiography in the evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/8/15497?source=related_link\">",
"      Epidemiology and causes of heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/41/10905?source=related_link\">",
"      Evaluation of hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23335?source=related_link\">",
"      Pathophysiology of stunned or hibernating myocardium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/30/32226?source=related_link\">",
"      Patient information: Nuclear heart testing (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_33_23067="Local sx CNS tumor child";
var content_f22_33_23067=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51623&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Signs and symptoms of pediatric central nervous system tumors based on tumor location",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Tumor location",
"       </td>",
"       <td class=\"subtitle1\">",
"        Presenting signs/symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebral cortex",
"       </td>",
"       <td>",
"        Headache, seizures, hemiparesis, hyperreflexia, clonus, sensory loss, speech disturbances, memory deficits, personality changes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posterior foss",
"       </td>",
"       <td>",
"        Nausea and vomiting, headache, abnormal gait and coordination, papilledema, abnormal eye movements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brain stem",
"       </td>",
"       <td>",
"        Cranial nerve deficits, gait and coordination disturbances, nystagmus, focal motor weakness, signs of increased ICP including headache and papilledema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinal cord",
"       </td>",
"       <td>",
"        Radicular pain and/or weakness (symptoms correspond to level of lesion); loss of bowel/bladder control; gait abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Optic pathway",
"       </td>",
"       <td>",
"        Visual disturbances; proptosis; nystagmus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypothalamus",
"       </td>",
"       <td>",
"        Endocrine disturbances including diabetes insipidus and growth failure",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ICP: intracranial pressure.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_33_23067=[""].join("\n");
var outline_f22_33_23067=null;
var title_f22_33_23068="Recurrence risk NTDs";
var content_f22_33_23068=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F63266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F63266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recurrence risk of neural tube malformations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Affected relatives",
"       </td>",
"       <td class=\"subtitle1\">",
"        Risk of anencephaly and spina bifida (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        No siblings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neither parent",
"       </td>",
"       <td>",
"        0.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One parent",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Both parents",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        One sibling",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neither parent",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One parent",
"       </td>",
"       <td>",
"        12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Both parents",
"       </td>",
"       <td>",
"        38",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Two siblings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neither parent",
"       </td>",
"       <td>",
"        10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One parent",
"       </td>",
"       <td>",
"        20",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Both parents",
"       </td>",
"       <td>",
"        43",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        One sibling and one second-degree relative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neither parent",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One parent",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Both parents",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        One sibling and one third-degree relative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neither parent",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        One parent",
"       </td>",
"       <td>",
"        16",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Both parents",
"       </td>",
"       <td>",
"        42",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nussbaum, RL, McInnes, RR, Willard, HF, Genetics of disorders with complex inheritance. In: Thompson and Thompson Genetics in Medicine, 6th ed, Philadelphia (PA): WB Saunders 2001. p. 289. Copyright &copy; 2001 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_33_23068=[""].join("\n");
var outline_f22_33_23068=null;
var title_f22_33_23069="Practical guide CBT IEI";
var content_f22_33_23069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    A practical guide for treating symptoms of idiopathic environmental intolerance (IEI) with cognitive behavioral therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Explore beliefs",
"       </td>",
"       <td>",
"        Ask patients what they believe is causing their symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Define goals",
"       </td>",
"       <td>",
"        Define goals, eg, take responsibility for one's health or reduce avoidance behavior.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behavioral analysis",
"       </td>",
"       <td>",
"        Analyze behavior to determine antecedents and consequences (ABC: antecedent, behavior, consequence). Ask about thoughts, behaviors, emotions, and situations that precede, accompany, and follow the symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diary",
"       </td>",
"       <td>",
"        The patient should use a diary to record symptoms, rate their severity, describe the situation during which a symptom occurred, describe how they felt at the time, and what they were thinking at the time. These entries are reviewed during treatment sessions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family",
"       </td>",
"       <td>",
"        The spouse or parents should be invited to attend one or more treatment sessions so they understand the treatment approach. Family members should be directed to stop their responses and accommodations to symptoms that are performed out of concern but which ultimately serve to reinforce the illness.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Behavior first",
"       </td>",
"       <td>",
"        The focus of treatment is changing cognitions and behaviors. It is easier to first change behaviors, especially for those patients who are less psychiatrically minded or more resistant to psychiatric explanations of their illness.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reduce maladaptive behavior",
"       </td>",
"       <td>",
"        Behavioral change starts with reducing avoidance behavior and other maladaptive behavioral responses to symptoms. This can reduce the frequency and intensity of symptoms, reduce disability, and help facilitate cognitive changes. In addition, clinicians and patients need to decide which adaptive behaviors to increase. These should be clearly specified, realistically attainable, and of value to the patient.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Incremental change",
"       </td>",
"       <td>",
"        Behavioral change is approached in a gradual way, with graded increases in desired activities. The difference between current behavior and the desired goals is assessed, and then broken down into manageable steps.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Practice",
"       </td>",
"       <td>",
"        The clinician should warn the patient that each increase in previously avoided behavior could cause a transient increase in symptoms. The desired behavior is practiced daily until it is mastered, and then the next goal is undertaken.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Relaxation",
"       </td>",
"       <td>",
"        Teach relaxation techniques to increase the patient's ability to bear with symptoms, reduce stress, and develop pleasant bodily sensations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Social skills",
"       </td>",
"       <td>",
"        Provide social skills training.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Regulate emotions",
"       </td>",
"       <td>",
"        Teach patients how to regulate their emotions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cognitive change",
"       </td>",
"       <td>",
"        Cognitive change begins with identifying the patient's thoughts and beliefs about bodily sensations, symptoms, and IEI. The clinician then asks the patient to consider alternative explanations and interpretations of symptoms. Patients record their thoughts about symptoms and practice challenging them by producing and recording more benign explanations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychoeducation",
"       </td>",
"       <td>",
"        Provide psychoeducation about IEI.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Realistic health concept",
"       </td>",
"       <td>",
"        Help the patient develop a realistic health concept. Challenge faulty assumptions, such as the idea that one must be in perfect health in order to function, or that any bodily sensation is pathologic.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Restructure cognitions",
"       </td>",
"       <td>",
"        Aim to restructure cognitions to accept the role of psychiatric factors in IEI.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Demonstrate role of psychiatric factors",
"       </td>",
"       <td>",
"        Conduct exercises to demonstrate the role of psychiatric factors in health. Biofeedback experiments can help patients understand how their somatic preoccupation perpetuates their symptoms and disability. As an example, if the patient focuses on a normal bodily sensation such as the heartbeat, this will reveal an increase in its apparent intensity. The value of distraction as a method of symptom control can then be demonstrated. These experiments provide personal evidence the patient can use in reconsidering IEI as the explanation of their symptoms.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Well-being",
"       </td>",
"       <td>",
"        Address problems affecting well-being, such as difficulties in relationships and at work, cognitive misattributions, and emotional state.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      Bornschein, S, Forstl, H, Zilker, T. Idiopathic environmental intolerances (formerly multiple chemical sensitivity) psychiatric perspectives. J Intern Med 2001; 250:309.",
"      <br>",
"       Sharpe, M, Peveler, R, Mayou, R. The psychological treatment of patients with functional symptoms: a practical guide. J Psychosom Res 1992; 36:515.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_33_23069=[""].join("\n");
var outline_f22_33_23069=null;
var title_f22_33_23070="Unintentional injury deaths children";
var content_f22_33_23070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F83770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F83770&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Annual unintentional injury death rates (per 100,000 population) among persons aged &le;19 years, by age group - National Vital Statistics System, United States, 2000-2009",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 451px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention (CDC). Vital signs: unintentional injury deaths among persons aged 0-19 years - United States, 2000-2009. MMWR Morb Mortal Wkly Rep 2012; 61:270.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_33_23070=[""].join("\n");
var outline_f22_33_23070=null;
var title_f22_33_23071="Angle of Doppler beam";
var content_f22_33_23071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52145&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Angle of Doppler beam in relationship to direction of blood flow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 272px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEQAcUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAqL7TAHKmeLcOCN4yKlrgtZ8JeGF8Vfa9U0WxlOpk5mkiBPnAdD9Rz+BpMDulljb7siH6EU8EHoQa5uPwL4XjwY9DsV/3Y8VOvhDQFPy6Xbj6Aj+tGoG7QSB1NYh8KaGcZ02A4+v+NMPg/QCMHS4D9c/40agb2aK5seB/DgkZ/7LiyQBjc2PyzVTVPA+htbOYbMQkL1SR1/XNGoHX0Vy/gnWGuoZdMvWJv7IAFmPMsfRX9/Q+/1rqKE7gFFFFMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACszxFpa6vpj25OyVWEsT/3HU5B/p+NadFAENkHFrEJPv7Rn61NQKKACiiigApCARgjIpaKAPPvHFlPpN9a69pSZurUklB0kjP3kP1H64rt9MvoNS0+3vbRt8E6B1Psex96TVLdbmyljZQ2VOAa8s+H+o3mg+Obrw/KjyaVfFpYGGcQSgZI/3WA/Me5qdmB69RRRVAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUGiigCrZXPm+ZG/EsTFWB7+h/EVarH1YmwvYr9VzE+Ip8dueG/ofwrWjcOispyCM0gHUUU3dhsUwHUDmqOoalb2Kb7iVUQevU+wFcNrvjWWQyR2WbeIcbj99vcDt/Ok2kB1+v6/ZaPbO9w5eTHyxRjLMa8k8F/EO4m+Jy2Gs2FpBbX+Y7SZcl4pOyk9Du6fXFUb/U5bqQyO3Puc5rgfFNvLuW7tnaO5hkEkTpwVcHIP6Vm5agfX9Fc18O/E0fi3wjY6qm1Z3XZcRj/lnKvDD8+R7EV0tap3AKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAiu7eO6tpYJhmORSrD61z2g6oyTTafecXVs2xge47MPYjmumrnPFuhz3ttPe6K8dvriQlYJHXKOeoVx6e/bNJgaepalb2NqZ7qaOGP8AvSNtFcVqXjdrjdFpSYj5BuZRtX/gI6n+VeRaLr15q2pyr4peWfVLWQxmKcBVgYHkBOgP1rp7mdpMnOXI9OB/n0rNzuBNdapJKxaaSSeduPMbr+HYVkktLM2QCxGc0wxujuxcFD0AHIp8shXZjO49cVIFW4BbrgDGRjofesq9jM4eMgHuoz1961em1uCMmqs67GLgZGOhNICb4L+IT4U8cPpV4xXTdYYICT8sU4+6f+Bcr+VfTNfIWu2YuLQtGWWRfmVhwVPUEH1yK+h/hD4u/wCEv8IQXFwQNTtT9nvF77wPvfRhg/n6VpB9AO2ooorQAooooAKKKKACiiigAooooAKKKjuRI1vKIGCzFCEY9A2OD+dAElFePN8KvEs+nPean8UfFA18LvEltOILJH64MAGGUHPcZHYdKytG+Ll0P2cpPFeuXCQ62UnsbedYiVnugGEbbVGBnAJ6LkHp0oA92or57/Z2tvhtqV7p9/pF3can4/hsftOoXU7XW8O4Cy/fxG2C+3jJ7+9fQlABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeK/Hfwc8bDxhosTG5gAW/iQf6yMdJMeq9/b6Vyei6mt/Yxyh1yF6V9KSRpLG0ciq8bgqysMgg9QRXzR4t8ON4E8Ym1iDf2NfZltGPRP70ZPquRj2IrKatqBfZ/NB2nPt61UecK/wA2cg1Kz5TcoyCKrTEAhjgsOeakBSY9wYNk46+lRSsPLAZvmJz9aibduyuNw7dxUT7WIPIfqSTSAiuXJAiB565HpUfhDxNL4C8YRakSx0i7Cw30Y7LniQe69fpkUnl/OxUHJJBPr7VBqGlTT2DI8TlZFIDEHmjYD61gmjuII5oHWSKRQ6OpyGUjIIPpT68m/Zxvr1vCN1pV+5cabMEgLdRGwyFP0Oce2K9ZrdO6uAUUVFdErazFSQQhII+lMCWivnL4K+Cb/wAc/DjTPEGrfEHx/DeXTTB0ttaZYxslZBgMrHoo717b4K8Nf8IrpUtj/bWt6z5kxm+0axd/aJlyqjYGwML8ucepPrQB0FFFFABRRRQAUUVW1KzTUNOurKVnSO5ieFmjOGAYEEg+vNAHkvjXxLqPxD1S68EfD2cLaLmLW9eXmK1Q/ehiI4eUjjjp+ZXY+IWgWHhb4A+INF0eIxWFnpE0cak5J+UksT3JJJJ9SaydI+A2naNZLZ6P448fWFopLCC11ZYkBPUhVjA5rqrH4d20Pg3WfDd94g8R6ta6orpLcaleieeNWUKRGxXAHGcEHkmgDFtNfn8L/s16ZrVoqtdWfhq2kh3dA/2dApI7gEg474rkNR03xH8P9I8M+L5fGev6vPPd2serWN7OJLWRJiFbykx+7ILcdf6V6lrvgm3vfhZP4LtLiRLcaYunQTTEFhsQKjNgAHlVJwB3xivOZNH+InjC08OeGfFHhyy0rSdOuree/wBTTUEm+2LByBHGvzJuIH3v06UAe6UUV5LqWqaj4Z/aG063vL+8l0DxPYNFBBLMzQwXcWCdik4XKgdMZL0AetUV538e/Etz4a+G982lySR6vqLpp1gYm2v50pxlT1DBdxBHOQK7Dwvp0+k+G9M0+8u5726traOOa5nkaR5nCjc5ZuTk5NAGpRVDXNY07QNMm1HWr2CxsYsb5p3CqMnAGT3J4A71ynhT4t+BfFeqLp2heIbee+Y4SGSOSFpDzwvmKu48HgZoA7qiuJ8YfFTwV4O1AWHiLXoLW9wGMCRyTOgPI3CNW25HPOK6PQte0rX9JTVNG1C2vNPcEieJwVGOoPoR3B6UAadFebTfHL4bw6k1i/im1MyttLJDK0Wf+uoQoR75xXo0MiTQpLC6vE6hlZTkMDyCDQA+ivK/jrqN9MfCvhLS76Wwk8SaiLa4uYGKyrbIN0oQ9icqM/UdDXJeOPBumfB19B8WeB/tWnxR6hDaarbNdSSR3dvIdrMwdj8wOMYwOc9qAPoGiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK5v4geGIfFnhuewfalyv722lI/1co6H6HofY10lFDVwPlnTJpR51jqCPDeWzGKVD1VhwatPjAO078evau7+Nnhs20sfiiwT5V2x36KOq9Fk/DgH2x6VwXnrNCsgbg8isGraAQyLuJx169elNG1sHaQfU1YtbWadyqIWJ+YbazNc1zS/DRaO8kNxefw28RyQff0pAXLa1lUySSOscaknc3CrWL4l+J7WlhJpemP9sPQuwyqn2Ncz8Q73XZYbOS/kjh027iEsKWzZUjupPqO4rhQygfLlfb1oA+i/wBmnxU/9s3mn6lMDPefOGPG49h+H9a+lK/Pzw1rE2k6naX1uxWWFwwI9q+5PA2vw+JPDVnqELhi6Dfz0NaQfQDfqK8/49J/9xv5VLTZUEkbo2cMCDitAPmj4AfB/wAC+K/hVpGsa/of2vUZ3nEk32uePcFmdR8quAOABwK9a8Qavpfwr8LaRo/h3Rbm9mnlNppek28hLSucu2XckhRySxzjNbvw/wDCVh4G8K2nh/SZrqaztS5R7llaQ73LnJVVHVj2rn/ipomvT6l4Y8S+E7SDUdU0G4lf+z5phCLmKaPy3VXPCsBjBPHX6EA5LwVqut6v+0PJP4l8Ov4evk8KmMWrXkd0GX7WCHDpxg5Ix6g17fXkngvT/Geo/GGXxV4q8O2+i2TaCdPijivkuSj/AGhX2uRjLfeOQNuMc5r1ugD59+Juj+A7nxxqk2ufCzxxrmosyedqGnWtw9vMfLXBQrMoOBhTgDkGuds9B+GYu4DH8FviNG4ddrvZXOFOeCf9I6V9SUUAFeVf8Xv/AOqbf+T1eq0UAeVf8Xv/AOqbf+T1H/F7/wDqm3/k9XqteYeLPHniG58cT+Dvh5pen3mrWcCXF/e6nIy2toHwVUhPmZiDnjpkdecAEP8Axe//AKpt/wCT1H/F7/8Aqm3/AJPVv+A9U8bTalead450bTbd4YxLDqGlyu1vcZYgqFf5lIGOp59K7agDgPC3/C0/7etf+Er/AOEI/sX5vtH9m/avtH3Tt2b/AJfvbc57Z71k/tH6TcXHgBde0tf+Jt4buotWtmA5Ajb58+23LH/dr1Wob21hvrO4tLqMSW88bRSIejKwwR+RoA8TudVt/ib8Y/BUWnuJdF0XTh4gnxyPOlA8lCezLlW/P8Pcq4T4W/C/Q/htHqK6HNf3D3xj82W9kV3AQEKoKquAMmu7oA8V+NMUOofFr4WaXraq+gT3VzI8UgzHLcKg8pWB4PzEAA9dxHNeqanpOjXFzp1zqNpZ/aLSVfscsgCvG/IAQ9RnkYHX0qr428H6L410gad4htPtECuJY2VykkTjoyMOQf8AJrl/Dfwi0jR9cstWvdb8Ta7d2JzZ/wBr6iZltjgjKKAo6HHORQBg/s0QWtzofibU7pI5PEFxrV1HqMrjMoIYYQk87QOQOnJrG8H6VZ3Hjb41+G9PuI9O8NXEcMRkjIWO2nlgZZSo4A+YtkcfdArufEnwi0XV9eu9Z0/VPEHh7UL0D7XJol8bYXJ9XGCCfpjPXrmtfRPhz4Z0bwffeGrOxb+zL9XF5vlYy3BcYZnkzuJP1GO2KAPMYbjx18LvAq2GveFvD/iHwtpUYWWawn8qTyF/jeORcMwxk4HJI92r27w/fWmqaDpuoaYu2wu7aKe3XbtxGyBlGO3BHFeaw/AvQRElndeIPF15oikY0e41VjZ7QchdgAOPxr1W1ghtbaK3to0igiQRxxoMKigYAA7ACgDxL9o/RtN1TxN8NT4ihEuhPqklldKXZATMq7MspBAyh5yOlcp8c/hJ4G8M+HNKHhrRhaa3qOq21lbMLueVjub5sK7kHgdcdxX0H4v8M6V4u0G40fXrYXFlPgkZKsrA5DKw5DA9/wChIrkvC3wi0XQ9ftNZu9U1/Xr+yQpZvrN99oFqCMHyxtAHHrnFAHo1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUARXdvDd20tvcxrLBKpR0YZDKRgg14XrfgTUfDc93Jb2k1/pEQaaOSIgyInUqV6kj1HWveaDzUuNwPinxf4y1pnk06wibSbdeG3DErDH6cV57ISsm8uWdjlnPJJ+tfUH7QPw+W7tP7c0yJRNEMSIoxlf/rV8xXMLLJjB296yas7MDufB0kvirQX8JTywpKha5sHkGW8wDmIH/a/mK4a7tWtbmSOcFJoyVZD2IpLO5nsbuO4tZGjmjYOjjqpBrs/GFgNa0O38V2khmeZvL1BdoBjm9cD+E0gOHhkOTxj+Ve7/s3eNBpmrHRLubFtdHMe48K1eFg57Yxzx3q1o93LZXsVxAdksbh1OcYIoTtqB+h1FcT8KPF8XizwzbzMw+1RrtkXPPFdtW6dwCiiimAUUUUAFFFFABRRRQAV4Td6snwp+MnivWvEttdp4Y8SRW0seqRW7Sx28sS7DHJtBIyWJHHPy9ece7UUAcV4D+ImmeOtQvF8O2t/LpVtGGGpzW7xQzuWI2R7gCcY5zjHpXa0UUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEN3bx3dtJBMMxyDaa+PvjN4Mk8K+IJDAmLC4JeLjIXnla+x65P4l+EoPF/hm5snVVuQu6GTHIYdKmcboD4VlAU4HOO9dJ4A1ayg1U2OtBn0e9HlXChiAp6K+B3U81ma7p82mahPZ3cZSaFijA+tYwDLJxgEHgViBteKtEk0HXLqweRZRE3yyIcq6nlSPwrLQEYbuOma7eCS08T+CPIwq65pOTGFXLXMJ6jjqV/lXCSMY3AOTzigD1D4JeL5fDviSKOSQ/Zp2AYZIGa+yLaZLm3jmiOY5FDA+xr87re6MUoYcYxivrf4AeNxrui/2dduBdwcAk/e//X/jVwdtAPXqKKK1AKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPn/wDaM8BiWL/hI9NiJccXKr3/ANqvmib5XyBg+tfofqFnDf2U9pcoHhmUo6nuDXxN8U/CEvhLxRdWjofs7sZIW67lPSspqzuBy3hnVZ9A1601K3IDxNkj+8vcH2I4rY8eaXbC9XWNHilTR9Q/ewlxwrfxJ+ByK5d+CSRgAV23gy+/tXSLnwnchGF0wkspHbaIZvr6EcY+lQBw6KVbLDiuu8BeJJ/DevW15buypkBwOeM9fwrl7+1ns72S2uUZJomKOpHII7UxHPHXg8mgD9BvDmrw63pMN5Ayneo3KpztP+ea06+Y/wBnXx0bW8Gj6hN+5cbUZj09Py/kTX05W0XdAFFFFUAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVHLcQxECWWNCeQGYCpKytWtI55w0sCSYTGWUHHJoYF37baY/4+YP+/gpReWxHFzCf+BiuVk021Lk/Zos88bBilXT7YRYNtHzz9wcVNwOp+122cfaIc/74p/nxYz5seP8AeFch9gth/wAu8RJPHyDj61ItpDtH7uPA4+6OaLgdasiN911P0NHmpnG9c/WuReGFMhVXaecAYrOuYomI3Qg4HcZzRcDv/MTrvXH1o8xP76/nXzR8UviZo/hNnsbaKO71QD/UJ0TP94/0614ovxh8UKZG/wBCIdshWgzgego5gP0DDKejD86Ny5xkZ+tfn8fjN4n242aeP+2H/wBesi8+JPiO6cF7mJSD/BHtou+wH6Mbl9R+dG5cZyMfWvzrsPib4jtMBZoHA6CSLdVyT4s+JHULiyA/64//AF6OZ9gP0JyPUUZHrX53H4oeJCc+bbg+0NTj4s+JtoG60yP4vJ5/nRzPsB+hVGa/PdPiz4pVtyvbfTyf/r1bT4x+KEUfurEkDGfJP+NHMB9+0V+f8nxi8VOCcWSj2hP+NNPxb8VSAZktgfaI/wCNLmA/QKivgS3+LXi2JVCywcc/6o5/nVo/GLxcw2sLMnHUxEf1o5wPvGivg5/jL4sYDC2gwMcRH/GkX4xeLi7Em2z6GI/40c4H3lXnHxu8Gp4p8MtJBHm/tcvGQOSPSvliD4yeLVfd/ouMdDG3+NXbb4yeLpGb5bXPr5bf40nK6sByV9byQyPHIjKykgqR0qnDNLBLHLGSkiEMrDgg1sePrvU5oLfXbeRo4LwbZkA4jlHX8D1rirK51TULxLe182eeU7VSNcljUJXA9R8VRT+JNETxTH5Xnqy299EgwVYDiQ/73864VicnHQ13Gi2tl4S0iRvEviVVuL4G1uNKtVWV0U93OcAjrXnPiuwvNB1qexkm8yMYeGVfuyxnlWHsRQlcDa0zUZdOvIp4XKvGwYHNfbvwk8XweLfClvMsim6gURzLnnpwa/O9rqYjlzXefCfx3e+GdbMZuTHaXY8uRjk7D2b8KtJx1A/QugEHoQa+IPEXxQ8X6PqM1pLPDvjb5WCNhgehHPeuc/4XD4njLBJLfBOeIyOfzpqV+gH6BUV8Ap8Z/FwyTdRntyp/xqufjF4vDg/bE3Z/uH/GnzPsB+g1FfAD/Gjxk3S+Ue20/wCNRn4x+MBjbfbe/wAqkf1o5gP0Dor4Bg+NHjdT8uqyc+oJ/rT2+NXjpyf+Jo5JPXB/xo5gPvuivgZPjR474zqbkdvlbn9amX42ePV5Gptz22H/ABpcwH3nRXwcPjh4+RsnUSR7oSP50+T44ePWYlb0HjAOxv8AGjmA+7qK+DB8b/HwP/ITfOP+eZ/xpV+OXxABXGoZI45jJ/rT5gPvKivhO2+OXxCV97anvAOSrRcH9a7Dwz+0PrsVwF17TnuISRue2dlYfgeKXOgPryivNfBXjrTPF1t5mkajK0q8yW0jFZI/qtdQsk+0lZpfl6fOaq4HRUVgiaUqpaWTrjO4jmq9/qDWlrNcSXEixRIXZtx4AGaLgdNRXxNrPjvxWmu3GuWHiLUFhW4MiWvmkxhQeBjoRjqDX194K8QQeKfC2m6za4CXUQZlH8D9GX8CCKUZXA26KKKoAooooAKq3gbcCuM471aqOVN9AGRKpYZbgjv2qBVJ+UHr61euYxnABOO3pUEcILsUGAD3NSAxIfLO09etNdMkjAGejVeERIO8e/Wl8gkYY8HuBTAyZY8HgjcPXvXkvx48fL4L0EW9gynVrzKwA8+Wvdz/AEr2TUStrE8rsFjRdzE9ABya+Bfid4jk8YeO9S1HcWtVcxwKegQcD/GpYHJ3Ek1xcSXN27SzytuZ3OSxPc1GxOeRVkoMDOBnvUZj5znI96VwIRntSqAAPzp7rhsYoVC33ecfrTuAxGJpSTwOM1oafpsl3JsQgDufStiTw3shJ3gsB6VLaA5fBK9ec08kAd8VakspYpWRlwR2potm2hsc9xRcCsWZsFegFOyxAOetTCIYwOD04o8rjOfyouAiE4AJFPXcTzj1p8cR2HIHPrSiNiwyOPWkAisQck8+9S+YwOD096RUO4E8YqQR7mHBPOM0gEUt09akR2Ugc0scRBzyewqVYck7R07UAGSMgDA71Yt96vmNx64zTVtn4Jzg1PFbEtgAn6UgOy8GWzeIkm8OTIXW+XCtjIicch65jxPfDwdNdeH/AA+Sl1GTFeahtxJKe6oeqp9Otep+DfC+tQ+Dnm0KxnuNV1AcvEOYLfOOvYsR+Qrj/jN4R1K1srLV9SspLW+2CK6jYYJxwsn44xTXmB485LEkklj1J5rrrCKLxF4VuYHkY6xpaebBvf8A1tuPvIM9161yTLtIyan067ewv4LqIBmicNtbkNg9D7Vo1cCqPWlBxXReNbSx+3xajo7L9gv0EojX/lg/8UZ+h6e1c4Oaa1GepeGHtvGHh/7HdKG1rTkJiJ6zwjt7lf5VgXmnQLIAsOCDzXN6Hqdzo2p299ZuUmhYMpHf2r1vW7a31vTYPEGkhRbXAIliHWGX+Jf6is5Kwjg0tIBjMSg01rKBZQyouTg4NaL2rZxzn+VQrbAtyCCO9TcCqoVScRrnrgAVIrKFIKDnqMVM1s3KMMHsfWla2cKQwwcZBoAh3x5C7ePQCkVueQB6YGKf9mYJvAyOmaEgJDbwy+nr9aAHo7BcPtGT2605nbAxjcfXFCwcKeoxTgoIYANtXrxQAGXZGCYwwYdz0piTjIU5weQCeBUnkkKSerdvWoTasQp+bnnpQBMj4yFAz1A/pUzSYUkLz/KmJAQQcbcgnJqRYGYHAIxSAqGRnKrnaOvNNa9hil8t5gJD0HrU32Uk5K5A65pr2qNjMaMV745pgXNM1C90zUodT0uZra/gwySIcbvY+oPpX1l8LfG0PjTw+tzxDfQ/urmD+647j2PavklIyOMEE+tdd8Ltek8K+N7G4aRksb5hbXQH3efut+BpxdgPrxcNnpgjFeZfHfVJrHwLdiOQp9rkW3RAeW3Hn8MA16am0/7vUEV4b+0rcZl0KxBOGaS4Zc+gAH86uWwHhKsUikjAGckEZzwa+i/2QdZe58K6zo8r5NhdBox6K4/xX9a+epYcuWXvx0r1L9lC9bT/AIjazprk7L2z80D/AGkYHP5E1EHqB9ZUUUVuAUUUUAFI3SlpDycd6AKVwN/CEjPXB5FMUZb/AGegqV1AyTkDPFJFGoOc5pAWggx0HIwaSVBswB7U9egFNkOFOOuKYHlH7QusNovww1qSKVhcSxiBSOD85wf0zXw9Yxlbct3bmvrL9rm58v4e28Ab5pbtAcd8Amvmiysle0hZiuNo6VlJgYxhLPnBoaMjIP6d635bDCEoQT1xURswvUYqbgYyW7ttCA8nFXIdNlcEBRx/nFdLoWkG6uUCjCk5xXoVloVtBC26JTngqRilcDzzwvaKIJdy/Pkce1bcMPmq2V6dK2fEWktapBcWCeXuIVlAzmqcIuxEzi16Zy3TBpAYN9ZW7SxiYcgfn9apXFvp6EpCGJ6HaOK0LmKSaVdwYSZ5p0eizbSzQyqD0JQigDlHs280hgQO3FAsgGA4OPauvGjTIzM0EuAOd6HFO/seZGG63kK+uw07gcwLH5gUxjtT4NOy+HHvzXWRaTOqnNtLtHTKkCrdvpNwuQ1vKM9yh4NK4HIJpGTgKSOo7VPDpPzH5ckngCu5XQ59jM0UgwBnKkVYj0h2HyxSgLzkoRQBw8ejrnkHn2q5HpcaHDp75Azmu0j0dlVh5T56529vrWhaaNudf3Tthc/dPSgDgDpKuoYA7V5q7pegvPdwKiHDuq5+pr0KTQlKESQMARu4GM+9avhnSbZNVtJJ4mWJZVLE+nrTsB2ms3F9pdx4H0fSbX/iV3jzx3TJN9n8xo0/dxlwMjPzHjrtxXm1/JqHiG8vrLxAjPYGW502CV5PMLxLIdh34+faSRu74rs9e1jUZru4sopi2mpJhI3iV1PPXkevSs66e5uxAs7mRYF2RLtChB6AAcVTA+S/Eui3Gh6xd6fdrtkgcrz3HYj6isfZXv8A8dvDLXNjZ6/CjebGBBc4BP8Ausf1FeGS2svLGJ8eoBxTTA2/CN/bT2N7oGphvst5h4HUZMVwPukex6GucvLSexupba7jaKaJirow5UinNBKhDqrjHIODxXX+I45vEuhxa8tvtuLRUt79s8yHosmPoME+tO9mBxAH6V23w08Spot+9pqQMmk3uI50/uns49xXINbSgFvLbb64qRIZeG8tseu2h6ge7XvhlUn3RMskMg3RyAcMp6EVhy6JsOMfMOOOlbPwa8Rrqlmnh7VMiaME2crDOR1KE129xpq4w8RzyOnvWdgPKzpLbeEbrnOKY+lyxnJj+XHBxXqEmmLsdVXBHO3H86gjsPOXa8bEn2wMUWA8wXTGO8bSOTSHS2fcShI/WvTLjRBgmKMg9ORUaaC4UlUJJ6EDjNKwHna6YW7YA4wBSf2WwUAAkngmvSbfR9jlXjJ9DS/2MDOr+UduePl60WA85/spsgkHgcAc1ImlvjHlnkZr0dNCj5kWJsHknGaeNHGY9kJPuB2p2A86bST5aEjAKkjPsahWxZmOFAzz9K9aj0mIW6GSPJAOCBWWmliWX5ISSBj7tFgPNnsdpKhcH1xkU0aYSOmMnsK9KOgNvZgmSD3HFNh0AY8woRjqAM0rAedLpuThULZPFSX2ku9o6KOQu5TjGCORXpyeG3DK8cLtnqPap30TDI88Xy42kY6U7AerfD/U/wC1vBukX0hBaaBC2exAwf1FePfHdftPjqzQkERWWSD2y1eh/BdivglIGOfIuJoR9A5xXKePLF9Q+Il/tiLpFawgcepJq3rEDySXTScrj5hz61v/AAaV9N+OOgjHy3EE0RPr+7b/AArpz4fmbOYmVSu3JXrUfhjSZLX40eD3WBkiPnHdg9omqUtQPp+iiitwCiiigAqOR9hJIOAKkqjfXHlyeXnGVzk/WgCOe4XqFYknj2pFmABzxngeoqlNOXQ7WGevTvUP2n5SdwbGec8ZqbgaZucAr3AzioXum3bgQBWV9rMm5hjI+UVDdXQRODn29aLgfM/7VfjS21XUbbw5YsZXspPMuGXoHI4X3IzXn2n7RpsQkQq+1c57Yqvr8N0PiFq8+rwyRXD3DuBIMZyeCPXiori5KuccnOcms5O4GhwW9R1+lN/i5wT9KzvtPA55NBvP7xGcVFgOw8JahDaX6+YCFI2nPavSklQR7gVK9Cc14Ol9tIK4yCK1E8Qu0ZjLsF9jxmmB6R4l1ZLe1hNu6lw2SV5xiqumXl9qKhY2WNCPmdhmvPJtYLhIzgKOSDXVeGdWUWkiqQuTzg/rSA6KXSGiuFuo7oefHyvA6+tR33jTxDIslvPesRwMbV9fpVRtY3AZb5sYJrMk1G1N4TMOcDvgfjQBr3XjLXZojFPfSNGSMjavOPwqSTxtrN0hie+kdD1Xavb8K5y81HTGUrGX5wevH41kfalWTcMKufWgD0RvG+s3FuYpL2QpxxgY4/CrR8d6xLCUe7ZlPJBC/wCFebR6opBwflzzUg1IAZJ5HSncD05fHmrzpIslxmNhgjA/wq2nji/a28prk+WV2EbRnHp0ryxdSUKcOEyfu1PFfg8Zwee+KLsD0n/hNdRlPkyXOLdhsI2gnH1xWkPGl6tr5c04aPhcKq8/XivJzfr69Bn5fWpBf5wzOCQfvZ6UXA9al8eXsqeVJMiptweBjFRr46uwpWScGIjB+UdK8ofUEViC/JHJqN9V+T72QPU0XYHrM/ju4eEqkqlTx90AkU3/AITi6njMe/5WGCSFya8na/CjKtk4xge9SR3671JbaV60XYHsR8RS6rp09hLN+6njMJLAHBIwD0r5517xf4l0l59ImukVLfMJTyU6Djrj0rubPWCg+RgccgCuX+LtpHex2eu26/64eRcYHAdRwfxFNO71A5Y+PNfNl9l+1p5Gzy9vkp93GMZxU2leNr9b6P7e8dxaPEbaWJkCqyHjnA7dRXJOMHkEe1N4BrTlQHfeJdd8SaBcnS5L+OS1MSmB0iXbJEw+Ug49Kxj41102wtvtv7kJs2+WvTGPSrelJN4p8PyWDz77/S4mks48DMsWcuuevHUD61yHTIwQaSSA67TfHviGxSJbfUGRYgAuI1yAB9K9/wDAHjqbxP4fVkmVNRtkxcRbRlvRhXymDz15rd8MeIrzw9qsF/YyYkQ/MOzDup9qTQH1H/bt7EAvncdMbRUVvr95GxjjmCqM4UgcVz8Gr22uaRBq+msPLl4mj6mJ+4I9PeqUlyY5TIcENwpHXNRcDr/+EhvVCrHcYCg4GBzRB4kvkAhEuwHOAQOa4V799xVN2z68VOl2I3j3uAAMH60XA7RPEl7EmPOK8HjaDznmlTxFfxwYjuDhT0AH+FcpLdwkH59ygAgr3qtLqcezGWZiMlTx+FFwO0tfE+oCEKs2EydoAHPrzUlv4lu/L8uGdgRy2QOP0rhYtRhATbvjxklgc/hip4NTijACs3vyOaLgejQ61dJbQKk/GSckDnP4VU/ty+hUeVOEVSew5zXGtrQ3hMFQCDkd6edTj2JkkDPQGncDrE8Q3sB2idgAN33R1ptv4h1CM4S4JXJGBjjPtXKDVImc7mIA4Oe9RpqsUU7u+doOPYg0rgd3D4pu03J52Byc4qO5125ktWhllV4mOWXHNcet9FId0bJjrz/KrEt0kNq8zSKIlUs4z2xmncD0H4PK8fgyRzwZLydxg/7RrO1DX7+Dx3qtqblo4UhhZEUcDIOTXQfDiE2ngvTo2jId083af9r5ufzrgfFl0tv8Q77eQqzWcXvnBIqnsgOpi126VTGJ5NoPoDiqPh/WtQn+LfhmwjupBZvFdSSxcYbCHGfxNc3Fqyliqk5U46YB/GtP4VMuo/GSBwD/AKHpc0nPqzqv9aSd2B9D0UUVsAUUUUAFc14pu/s86gMQ3l5x+Jrpa8v+Kl61vrVvGHKg2wP0+Zuf0qZOyAdPqvZsAEdN2KhOqrk4fIHUCuAl1BmfcHDdQATyKZHqx80ojEHHU1nzAd9/aQaIcj29qpT6lIVGfmHQc1xx1dRlGmx2xio5NchwAGJwc0XA1vF+h6R4l07GrwhmU/u5U4dfoa+efGvhW98NSebJILjTy2EmHVfQMP617Nd64sqYJB5zjNcr40Ua54euLSDaJJQCpboCDnrSuB49CWlB2Ddzng1Gz/vAM4A7EVZfw/q9jEUe1kYZyDGQ1ZMkzpKUkUo6nBVhg/lTt2AvZABPT3qMy9OcZ64qtJKSBjHNNZyaLAXTOCuM89RVyy1Wa0fMZ4x0PQ1iE9xyfT0pQ+44Ip2A6l/EMz4G1VOOo7Gs+S+eQli5OevNZsZ456inAjJHIJH6VNgLqznOSxIx0zT2uSQFUkDFUM/KBnIFIWO0DNFgL6XL7W5PNSi5bjBAPqTWYG2nJ6fWnNMM9cCiwGp9pcvud/1qUXwj43ZweTWIsrNkAcUFmJ/wosBtvqpDA44zwBTH1dy4JAUZ6Vk7zjAo5JHXNFgNddRfB54prXrFiR35GazR056d6BuZsKeKLAa0OoSKowuD161Kt85Aywz7/wAqzBkL8xI9hT8cDLAsOxpWA27fU9gHYdMVt2s66xo95pUhBWdN0XtIvIP49K4uIM3Y9MVq6dIYJI5FAHl4xjpkUAcRKpSRkcEMpIOfWoiSQeK6HxvbfZ9beaIARXQE647Z6j881z/UYP51qnpcCxp13Pp95FdWsjRTRtlWQ4Nbfi/TraH7Hqelf8g2/Xeqk5Mcg++h+h5+hrnRwOtdD4PksruSfSNU2pDeLiGdj/qJR90+wPQ0PuBzo680oJBGKluI2t5pIXxuRipP0qIbdw5pgdT4E8WT+GdSDEebYy/LcQHo6/4jtXp+tJA9rBqGnzedp9wN0Uinp/sn0IrwbODgjNdd4H8XHRZHstQRrjSJyPNiHVD/AH19CKiUeoHWi7KBuT14yaRb3GGY7Tjn5utLrVoLTypreRZ7GYb4Zk5V1/ofaucuZyrEZwKzA6Eangsd2M+h6VGdSZiMMcn1rAWY8Z/Wo2nyOR83tQB0aagxUozZJOKnW8woI5GcE+tczDMMDD8jvVu3uMPhj8mf8mgDfku5QyHqT0INStfllUZ5HtWJNPvZTnoQaeJtyg8Aj36UAaxvTv4Y4x3PSoxqHG0MzHnmsozgsGHrx7VBJKdytwBQBvW18yTH5iQf0rR0xJNe1mx0eDcRcyjziOdsYOWP9K46e/SFSzkNjgccn6V618KdJm0W1l1a+VF1C8xsQjJijHQU0gPbLeVbaCNAQoVQoGOmK8V+MF29r41tJIzhJbQr+IbP9a9KGp7nRmYNxj1FeY/G2RZrTTL9F3NDOYmYdMMP8ap7AcuurSoA+/kE16h+zQJNS8b+J9UkyVgtIbQH3Zix/wDQRXhn2gJG7ynCrkla+n/2X9Gax+HbapMhWbWLl7nnr5Y+VP5E/jSgtQPX6KKK3AKKKKACvEPjjHdS+KbNbeG4kX7Gn+rjZhne/cCvb6KUldWA+RZrW/8AOf8A0e6wf+mLD+lVfst8X3C2vMAf88m/wr7EoqPZgfHv2W82bhaTt2P7tj/Skltp9xxZ3CbuxjY/0r7Doo9mB8dvaXgH/HrOT3/dn/CoGsrtiSsEwHcGNv8ACvsujFHs/MD4saC7CjFvNz/0zP8AhXJ+L/B91qbLdWkMq3I+8GjIDD8q+/8AA9BSbR6D8qFC3UD84IfA+tbQGRVbPQq3+FSHwPrClhhOP9lv8K/RoopPKr+VBjQ9UX8qfK+4H5zxeBNXY5zEAfUN/hUieA9XBJBg4HOQ3+FfomIox0jT8qURoOiL+VHK+4H52J4G1lht32+fcN/hUn/CCa4Dybbp6N/hX6H+Wn9xfyoKIeqr+VHI+4H55/8ACvtcQje9qN3Izu/wpp8C6yFyXtfp8359K/Q4oh6qv5UeWn9xfyo5GB+eUfgHWJSpE9oFP8RLY/lUbeAtYXH7y0wf4gT/AIV+iHlR/wBxfyo8qP8AuL+VHI+4H52L4F1gniS1wOMgnn9KcfA2s4DB7bk9ief0r9EfKj/55p+VHlR/3F/KjkfcD87f+EO1jBGbXJ9zR/whurgcyWg/4Ea/RHyIv+eUf/fIpDbwnrDH/wB8ilyPuB+eDeDtY2nE1keOSHOBSx+ENVUkrNYkAZPzkV+hv2W35/cRc/7ApPsdr/z7Q/8AfAo5GB+e6+FNVGcyWeP9800eGdZVgM2fPGdx4r9ChZ2wORbw5/3BTvs8GP8AUx/98ijkA/PhfDGsqRj7Jj/fNWovDWuqCf8AQjjkgua+/fs0H/PGP/vkUvkQ/wDPKP8A75FHIB+d3jHTrtdIhF6sf2m3kwBGcgowz+hH61xflSA/6th+Br9Q2tbdvvQRH6oKabC0PW1gP/bMVSjYD8wEtZmZVWJyWOBx1NKbaZT/AKmTg/3TX6fCytR0toP+/Yp32S2xj7PDj/cFFmB+cviBP7c0a11SK3kGoQIIL1FjIBA4WXpjnofcVypikAyUYD6V+ov2aABh5MWG4I2Dmom06yYYaztiPQxL/hQk0B+X/lS5yI2P4GlWCYnKxvx7Gv1AGn2Q6WluPpEv+FKLG0HS2g/79inZgfnP4S8QXOlJJYX9u91pU33ojnMbf30PY/zrqZPCGrXcSXFlPpc1rLzE/n8kehHY+1fd/wBhtP8An1g/79inLaW6j5beIfRBUuFwPgObwd4giJONPIUYyJ6ik8Ia6SCTpo/7eBxX6Am1gPWCI/8AABSfY7Yf8u8P/fApcgHwJH4Q15iSp03j/p4FOTwj4gJYBtNyO32gZr76+yW46QRf98Cj7Jb5z5EWfXYKOQD4KPg/xJsJWKxIUZJFwOKQeGdeDYP9nH3NwK+9/s0GCPJiwf8AYFN+x2v/AD7Q/wDfAo9mB8CyeHNeKAA6fgHAxcCmN4W8RhPkisnHoswJFffos7UdLaEf8AFOFtAM4hi56/IKPZgfEnhLwhBY3KXuuTJdXqcxxDmOM/Tua7w6lyVBGOMD1NfT4t4QciKMH/dFL5MWc+Wn/fIo5APmuO/8pclwB15rH8Qr/beiX1i+G3KTGw4+bqD+dfVphjIwY0I+goEUYHEaD8BRyeYHwN4H8KeIPGusLodtbuqtIFurjYcQoDySeg/rX3hounW+j6RZabZrttrSFIIx/sqAB/Kraoq52qBn0FLVRjYAoooqgCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The diagram illustrates a situation in which the interrogating or insonocating beam lies at an angle to the flow of blood. Ideally, the Doppler beam should be placed parallel to blood flow. When the beam does not lie parallel, it is possible to introduce a correction into the calculation of flow velocity by measuring the cosine of the angle of interrogation and introducing this value into the Doppler equation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_33_23071=[""].join("\n");
var outline_f22_33_23071=null;
